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Abstract 
 
Introduction: Prostate cancer (PCa) is one of the most frequently diagnosed male 
cancers worldwide. One treatment, androgen deprivation therapy (ADT), is commonly 
prescribed and has been shown to increase survival in appropriately selected patients. 
However, the treatment-induced hypogonadism is often accompanied with a myriad 
of adverse effects, including those that negatively impact muscle, fat and performance 
outcomes. Therefore, ADT-treated men may be living longer, but are at risk of both 
age- and treatment-related complications. The overall aim of this thesis was to quantify 
outcomes of muscle, fat and performance in men treated with ADT when compared to 
PCa (men diagnosed with PCa, not treated with ADT) and healthy controls (men not 
diagnosed with PCa), and assess the feasibility of implementing a multi-component 
exercise program combined with protein, calcium and vitamin D supplementation 
(Ex+ProCaD) compared to usual care in ADT-treated men.  
 
Methods: This thesis presents two studies that form part of a larger 52-week 
randomised controlled trial (RCT), which examined the efficacy of Ex+ProCaD 
compared to usual care in men treated with ADT for PCa. The first study presented 
was a nested cross-sectional study performed parallel to the baseline assessment of the 
RCT and examined differences in muscle, fat and performance outcomes between men 
treated with ADT when compared to PCa and healthy controls. The second study 
presented examined the feasibility of implementing the first 26 weeks of the RCT. 
 
Results: The cross-sectional study showed that height, weight, body mass index and 
diet were similar between the three groups, but ADT-treated men were four years older 
and tended to be less physically active (23-30%; P=0.054). After adjusting for age and 
physical activity, total body fat mass was 3.3-5.0 kg (P < 0.05) greater in men treated 
with ADT compared to PCa controls, but there was no difference in total body and 
regional lean mass. When adiposity was considered, ADT-treated men had 10-12% (P 
< 0.05) lower appendicular lean mass adjusted for body mass index and 5.6-6.4% (P 
< 0.05) lower forearm percent muscle cross-sectional area compared to controls. 
Absolute muscle strength was similar between groups, but when expressed relative to 
body weight, men treated with ADT had 13-21% (P < 0.05) lower muscle strength 
compared to controls. Whilst only two ADT-treated men had sarcopenia, these men 
had a higher proportion (P < 0.001) of pre-sarcopenia when appendicular lean mass 
vi 
was adjusted for body mass index (42%) compared to PCa (15%) and healthy (7%) 
controls. These differences were not observed when appendicular lean mass was 
adjusted for height alone. Men treated with ADT had 15-36% (P < 0.05) greater storage 
of fat within subcutaneous depots when compared to controls, whereas visceral and 
intermuscular fat was similar. The majority of subcutaneous fat depots (excluding 
android region) were shown to be positively associated with ADT duration (P < 0.05). 
Forearm muscle density was shown to negatively correlate with ADT duration (P < 
0.05). The RCT had a high participant retention rate (96%). Adherence was high for 
the supplement (mean, 92-93%) and modest for the exercise program (mean, 60%). A 
relatively high proportion (81%) of men in the intervention group reported an adverse 
event, although only 16% were confirmed to be related to the intervention and the vast 
majority (97%) were determined to be mild or moderate in terms of severity. Across 
the ten separate recruitment pathways considered, clinician referral (43%) and PCa 
support groups (29%) yielded the greatest proportion of enrolled participants. A total 
of 149 potential participants were screened, which resulted in 42 participants at the 
time of write up for this thesis. Among the first 28 participants to complete the 26-
week intervention, 21-50% were unable to complete at least one measure of muscle 
strength due to pre-existing comorbidities. Data from the initial 28 participants tended 
to show that when compared to usual care, Ex+ProCaD led to net improvements in 
lean mass (0.2-1.4 kg), fat mass (-0.1 to -0.9 kg), muscle strength (8.0-19%), functional 
muscle power (8.6%) and functional capacity (12-14%). 
 
Conclusions: The following key themes emerged from this thesis and may be used to 
guide clinical practice guidelines and future research: 1) Men treated with ADT for 
PCa had greater amounts of fat when compared to non-ADT counterparts; therefore, 
muscle-based outcomes should be considered relative to body size or adiposity in these 
men, 2) Current definitions of sarcopenia and sarcopenic obesity were limited in men 
treated with ADT for PCa; thus, the development of additional risk stratification tools 
specific to this clinical population group are warranted, 3) The greater amounts of fat 
observed in men treated with ADT for PCa tended to be stored in subcutaneous depots 
and supersede age-related plateaus/losses; hence, the long-term risk associated with 
this pattern of fat accumulation should be explored in these men, 4) The recruitment 
of men treated with ADT for PCa into a lifestyle intervention was challenging; 
therefore, future trials should consider including clinician referral and PCa support 
groups to ensure sample size targets are met in a timely manner, and 5) Men treated 
vii 
with ADT for PCa tended to respond positively to a multi-modal exercise training 
combined with multi-nutrient supplementation; thus, the incorporation of similar 
interventions into usual care for this susceptible population group should be considered 
pending results of the larger 52-week RCT. 
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  Chapter 1 
1.1 Introduction 
Prostate cancer (PCa) is one of the most frequently diagnosed male cancers in 
developed countries [1]. Similarly, PCa accounts for a substantial proportion of male 
cancer-related deaths worldwide [1]. However, advancements in diagnostics and 
treatment options have led to five-year relative survival rates approaching 100% 
internationally [2]. Therefore, men diagnosed with PCa are now living longer, but may 
be at risk of both age- and treatment-related complications.  
 
One treatment, androgen deprivation (hormone) therapy (ADT), is commonly 
prescribed to men with both metastatic [3] and non-metastatic PCa [4] and has been 
shown to increase survival in appropriately selected patients [5-9]. The aim of this 
treatment is to suppress androgens to castration levels in an attempt to slow the growth 
and spread of PCa [3, 10]. However, despite potential benefits to survival in 
appropriately selected men, the treatment-induced hypogonadism is often 
accompanied with a myriad of adverse effects [11-14], including those that negatively 
impact muscle (lean mass and muscle cross-sectional area [CSA] [15-21]), fat (fat mass 
and CSA [17-23]) and performance (muscle strength and functional capacity [the 
performance outcome of a muscle or muscle group, whether independent or inclusive 
of other domains of functional capacity [24]] [25-34]). Moreover, the interplay between 
these adverse effects may hinder muscle quality (the intricate muscular structural 
changes associated with muscle function [35]) [15]. However, the true extent to which 
muscle and performance may be compromised in this susceptible population group is 
unknown due to methodological inconsistencies and the lack of assessment of these 
components concurrently within the same sample [15-23, 25-34, 36-38].  
 
In addition to muscle, ADT-induced region-specific changes in fat are poorly 
understood [17-23], which limits the ability to assess the influence of these changes on 
cardiometabolic risk and other potential health complications. There is also a general 
lack of available data quantifying muscle quality (intermuscular fat infiltration) in men 
treated with ADT [15]. This limits the ability to determine why physical performance 
may alter at rates non-parallel to changes in muscle mass, size or strength within this 
population group; a phenomenon in healthy older adults commonly suggested to be 
partially due to the accumulation of intermuscular fat mass [39]. Understanding this 
relationship is of increased interest in men treated with ADT, due to the accelerated 
accumulation of fat associated with this treatment, and the further complications that 
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may occur when fat infiltration of muscle occurs [40]. Therefore, future research should 
ensure multiple components of muscle, fat and performance are quantified in men 
treated with ADT, due to the potential musculoskeletal, cardiometabolic and 
functional complications associated with these outcomes when compromised. 
Moreover, there is a need to ensure that valid and reliable assessment methods are 
utilised, and known confounding variables (e.g. age, disease status, physical activity 
and diet) are accounted for during analyses. 
 
Once appropriately quantified, there is also a need to assess the risk of further adverse 
events with ongoing treatment due to any potential alterations to muscle, fat and 
performance outcomes. Collectively, any such compromises may predispose these 
men to an increased risk of falls, fractures, cardiometabolic disease, functional 
impairment and mortality [41-49] and partially explain the substantial economic burden 
of PCa on the Australian healthcare system [50]. Although in their infancy, the 
application of pre-defined syndromes, such as sarcopenia [51-53] and sarcopenic obesity 
[54, 55], may assist in quantifying the risk of adverse health outcomes in these men; thus 
potentially allowing for those at the greatest risk to be identified and addressed. To 
date, no studies have applied composite definitions of sarcopenia (those including 
measures of both muscle and performance) or sarcopenic obesity in an attempt to 
quantify the consequences in men treated with ADT, and future research would benefit 
clinical practice via this investigation and stratification of risk.  
 
Given the potential ADT-induced negative alterations to muscle, fat and performance 
outcomes, as well as the possible risk of further adverse events, interventions are 
warranted within this susceptible population group. There is emerging evidence that 
lifestyle interventions, such as exercise training and to a lesser extent nutritional 
supplementation, may improve or maintain muscle, fat and performance outcomes in 
men treated with ADT, which may in turn reduce the likelihood of further clinical 
complications [14, 56-59]. To date, previously evaluated interventions have been limited 
to singular modalities (e.g. exercise training only) and due to the severity and breadth 
of ADT-induced adverse effects, including those beyond the scope of this thesis (e.g. 
compromised bone health, sexual dysfunction and psychological distress [60]), these 
men may benefit from a multifactorial approach that includes a combination of various 
modalities of exercise training in conjunction with nutritional supplementation. To 
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date, no studies have examined this type of approach and thus there is a need to assess 
the feasibility and efficacy of such interventions.  
 
1.2 Experimental design 
This thesis presents two studies that form part of a larger 52-week randomised 
controlled trial (RCT), the IMPACT study (Owen et al. 2017. Trials. 18(1), 451; 
Appendix A), which was designed to examine the efficacy of a multi-component 
exercise program combined with protein, calcium and vitamin D supplementation 
compared to usual care in men treated with ADT for PCa. The first study presented in 
this thesis includes data from a nested cross-sectional study performed parallel to the 
baseline assessment of the RCT which examined differences in muscle, fat and 
performance outcomes between men treated with ADT, PCa controls (men diagnosed 
with PCa, not treated with ADT) and healthy controls (men not diagnosed with PCa). 
The second study presented includes data from the first 26 weeks of the RCT in terms 
of the feasibility of conducting the trial. 
 
1.3 Overall aims  
The overall aim of this thesis was to quantify outcomes of muscle, fat and performance 
in men treated with ADT when compared to PCa and healthy controls (Chapters 4 and 
5), and assess the feasibility of implementing a multi-component exercise program 
combined with protein, calcium and vitamin D supplementation compared to usual 
care in ADT-treated men (Chapter 6).  
 
1.4 Specific aims  
1. To compare lean mass (total body, appendicular, arm and leg; dual-energy x-
ray absorptiometry [DXA]) and muscle CSA (forearm [66% radius] and lower 
leg [66% tibia]); peripheral quantitative computer tomography [pQCT]) in men 
treated with ADT to PCa and healthy controls (Chapter 4). 
2. To compare fat mass (total body, arm, leg, android, gynoid, abdominal visceral 
and abdominal subcutaneous; DXA) and CSA (forearm [66% radius] and 
lower leg [66% tibia]; pQCT) in men treated with ADT to PCa and healthy 
controls (Chapter 4 and Chapter 5). 
3. To compare muscle strength (handgrip strength and three-repetition maximum 
leg press, chest press and seated row), functional muscle power (30-second sit-
to-stand) and functional capacity (timed up-and-go, four-square step test, four 
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metre walk and Berg balance scale) in men treated with ADT to PCa and 
healthy controls (Chapter 4). 
4. To compare the prevalence of pre-sarcopenia, sarcopenia, obesity and 
sarcopenic obesity in men treated with ADT to PCa and healthy controls 
(Chapter 4). 
5. To compare muscle density (forearm [66% radius] and lower leg [66% tibia]; 
pQCT) as a marker of intermuscular fat in men treated with ADT to PCa and 
healthy controls (Chapter 5). 
6. To assess the influence of duration of ADT use on lean mass, muscle CSA, fat 
mass and CSA, muscle density, muscle strength, functional muscle power and 
functional capacity in men treated with ADT (Chapter 4 and Chapter 5).   
7. To assess the feasibility (recruitment, attrition, adherence, data collection and 
safety) of a multi-component exercise program combined with protein, calcium 
and vitamin D supplementation when compared to usual care in men treated 
with ADT (Chapter 6). 
 
1.5 Specific hypotheses  
1. Lean mass and muscle CSA would be lower in men treated with ADT when 
compared to PCa and healthy controls (Chapter 4). 
2. Fat mass and CSA would be greater in men treated with ADT when compared 
to PCa and healthy controls (Chapter 4 and Chapter 5). 
3. Muscle strength, functional muscle power and functional capacity would be 
lower in men treated with ADT when compared to PCa and healthy controls 
(Chapter 4). 
4. Pre-sarcopenia, sarcopenia, obesity and sarcopenic obesity would have a 
greater prevalence in men treated with ADT when compared to PCa and 
healthy controls (Chapter 4). 
5. Muscle density (as a marker of intermuscular fat mass) would be lower in men 
treated with ADT when compared to PCa and healthy controls (Chapter 5). 
6. Duration of ADT use would positively correlate with fat mass and CSA, and 
negatively correlate with lean mass, muscle CSA, muscle density, muscle 
strength, functional muscle power and functional capacity in men treated with 
ADT (Chapter 4 and Chapter 5). 
7. The multi-component exercise program combined with protein, calcium and 
vitamin D supplementation when compared to usual care in men treated with 
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ADT would be feasible in terms of recruitment, attrition, adherence, data 
collection and safety (Chapter 6). 
 
1.6 Significance 
Given the impact of PCa as a significant global and Australian public health issue, and 
the continued use of ADT for managing this disease, understanding the severity of 
treatment-induced adverse effects on muscle, fat and performance outcomes is 
warranted. This is of further clinical importance given the potential musculoskeletal, 
cardiometabolic and functional consequences associated with these potential changes 
and the need to quantify risk in this susceptible population group. Furthermore, as men 
diagnosed with PCa are now living longer, there is increased importance on enhancing 
the quality of years lived, which may benefit from the quantification of risk factors 
and subsequent management via intervention. These interventions are imperative to 
reduce the burden of disease at the individual level, as well as at the public healthcare 
system level from an economical perspective. Therefore, the findings of this thesis will 
assist in the clinical management of treatment-induced adverse effects on muscle, fat 
and performance outcomes in men treated with ADT, by quantifying these adverse 
effects, evaluating means of risk stratification and presenting an evidence-based 
intervention within this clinical population group.  
 
1.7 Organisation of the thesis 
The thesis is organised around the specific research aims noted above. In Chapter 2, a 
review of the current literature relevant to the specific aims of the thesis is presented. 
Chapter 2 also integrates two recent review journal articles where the PhD candidate 
was the lead author (Owen et al. 2015. Topics in Geriatric Rehabilitation. 31(4), 246-
250; Owen et al. 2017. Prostate Cancer and Prostatic Diseases. 20(2), 137-145; 
Appendix B and Appendix C, respectively). In Chapter 3, the general methods 
implemented in the cross-sectional study and RCT are presented. Chapter 3 also 
integrates a recently accepted protocol journal article where the PhD candidate was the 
lead author (Appendix A). In Chapter 4, results from the cross-sectional study 
regarding total body lean and fat mass, muscle strength and functional capacity are 
presented. In Chapter 5, results from the cross-sectional study regarding regional fat 
mass and CSA are presented. In Chapter 6, feasibility outcomes of the RCT are 
presented. In Chapter 7, a general discussion relevant to the specific aims of the thesis 
and outcomes of the cross-sectional study and RCT is presented. 
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2.1 Overview 
This chapter will introduce the concept of prostate cancer (PCa) as both a significant 
global and Australian public health issue. One treatment for PCa, androgen deprivation 
therapy (ADT), and the commonly reported treatment-induced adverse health effects 
known to impact muscle, fat and performance outcomes, will then be discussed. This 
will be followed with a specific emphasis on quantifying the risk associated with these 
outcomes both individually and collectively using the concepts of sarcopenia and 
sarcopenic obesity. Finally, potential interventions to manage these adverse effects in 
men treated with ADT will be discussed. Two review journal articles emanating from 
the literature review in which the PhD candidate was the lead author will be 
incorporated within this chapter. The first focused on the specific role of exercise 
training in men with PCa (Appendix A), and the second discussed lifestyle guidelines, 
with a specific emphasis on exercise training and nutritional supplementation, for 
managing the adverse effects of ADT on muscle and fat outcomes (Appendix B). 
 
2.2 The prostate gland and prostate cancer 
The prostate gland is an accessory organ of the male reproductive system, located 
below the bladder and vas deferens [61]. The primary function of the prostate is to 
secrete an alkaline fluid that forms part of seminal fluid and facilitates male fertility 
[61]. PCa refers to a malignant tumour of prostatic cell origin [61]. Although potentially 
aggressive, PCa tends to progress slowly and may lead to symptoms similar to those 
associated with benign prostatic hyperplasia, such as impaired genitourinary function 
[61].  
 
2.3 Prostate cancer epidemiology 
Worldwide, PCa was the second most frequently diagnosed male cancer in 2012, 
estimated to account for greater than 1.1 million diagnoses; which was 15% of 
worldwide male cancer incidence [1]. Moreover, approximately 758,700 cases were 
estimated to occur in developed countries, and PCa was deemed the most commonly 
diagnosed male cancer across these regions [1]. Although incidence rates vary by more 
than 25-fold throughout different regions of the world, Australia and New Zealand 
have the greatest age-standardised PCa incidence [1], which has been attributed to the 
increased availability and use of prostate-specific antigen (PSA; an enzyme associated 
with prostate gland enlargement and inflammation [61]) testing [62]. In 2014, it was 
estimated that 17,050 new cases of PCa were diagnosed in Australia, accounting for 
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approximately 25% of total male cancer incidence [63]. Furthermore, the most recently 
reported 5-year prevalence for PCa in Australia was 86,207 cases, accounting for 
approximately 42% of active male cancer [63]. Therefore, PCa has both the greatest 
incidence and prevalence of any male cancer in Australia. 
 
Globally, PCa accounted for the fourth most common cause of death from any male 
cancer in 2012, totalling 307,500 deaths; which was approximately 6.6% of worldwide 
male cancer-related deaths [1]. Moreover, in developed countries such as Australia, 
PCa was estimated to cause 3,390 male cancer-related deaths in 2014 [63]. This 
represents approximately 13% of male cancer-related deaths in Australia and ranks 
second only to lung cancer [63]. Furthermore, in 2011, PCa accounted for 4.4% of all 
male deaths in Australia, with an additional 1,803 deaths attributed to PCa as a 
contributing cause of death [50]. In 2011-12, PCa also accounted for 51,328 
hospitalisations in Australia; 11% of all cancer-related admissions [50]. In addition, the 
most recent estimates from the Australian Institute of Health and Welfare [50] 
concluded that PCa costs the Australian health-care system $349 million per year.  
 
The five-year relative survival rate of PCa is now over 90% internationally, with 
developed countries such as the United States of America and Australia having 
reported 99% [2] and 93% respectively [63]. Specifically, Australia observed an increase 
in five-year relative survival rate from 59% in 1986 to 90% in 2007 (Figure 2.1). 
Hence, men diagnosed with PCa are now living longer, but may be at risk of age-
related and treatment-related health issues. 
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Figure 2.1. Five-year relative survival rates of prostate cancer in Australia from 1986 
to 2007 (adapted from Australian Institute of Health and Welfare [50]). 
 
2.4 Prostate cancer screening, diagnosis and treatment 
PCa screening practices vary globally in terms of availability, utilisation and 
interpretation [62]. The most common forms include monitoring PSA levels over time 
and digital rectal examination [64]. Although these tests are informative and have been 
shown to correlate with PCa risk, they are not diagnostic, and suspicious outcomes 
will require transrectal ultrasound guided biopsies to acquire tissue for 
histopathological examination [64]. Once histologically confirmed, numerous treatment 
options, both passive and active, become available based on PCa stage and grade [64, 
65]. The most commonly utilised treatments for localised PCa include active 
surveillance, radical prostatectomy (surgery) and radiotherapy [64]. ADT and 
chemotherapy are often reserved for advanced PCa [65]. The following section focuses 
on the therapeutic role and potential adverse effects of ADT for the treatment of PCa. 
 
2.5 Androgen deprivation therapy 
The aim of ADT is to reduce the activity and/or concentration of androgens, such as 
testosterone, to castration levels; which limits the growth and spread of PCa [3, 65]. This 
is most commonly attained pharmacologically, but may also be achieved via surgical 
orchiectomy [3, 65]. Despite the significantly lower cost of an orchiectomy, men are 
more often treated pharmacologically due to the reversible nature of the hypogonadism 
(impaired function of the testes [61]; clinically diagnosed with repeated fasting early-
morning measures of testosterone < 8.0 nmol/L [66]) [67]. Pharmacological ADT is 
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achieved via gonadotropin-releasing hormone (GnRH) agonists and antagonists, anti-
androgens or a combination of GnRH agonists and anti-androgens, known as 
combined androgen blockage [65]. Various modalities of ADT, including those 
administered neoadjuvant or adjuvant with other treatments, improve survival in 
appropriately selected men with PCa [5-9]. However, due to various assessments of 
survival, modalities of treatment and follow-up durations, an exact figure that 
represents the increased overall survival due to ADT does not exist. In contrast, the 
evidence that ADT prolonged survival in men with localised PCa remains limited and 
therefore debated [68-70]. Despite these findings, the use of ADT is commonly 
prescribed to men with both metastatic [3] and non-metastatic PCa [4]. In 2008-09, it 
was estimated that 23,500 Australian men received ADT via GnRH agonists [56]. Upon 
repeating this analysis for 2014-15, approximately 25,500 men were receiving ADT 
via GnRH agonists [71]. Thus, ADT remains the most common cause of severe male 
hypogonadism in Australia. 
 
2.6  Adverse effects of androgen deprivation therapy 
Despite potential benefits to overall survival in appropriately selected men, the 
hypogonadism induced via ADT has been associated with numerous adverse effects 
[11-14]. In healthy eugonadal men (fasting early-morning measures of testosterone > 12 
nmol/L [66]), androgens, such as testosterone, assist in various metabolic processes 
which include maintaining musculoskeletal health, reducing cardiometabolic risk and 
improving aspects of health-related quality of life, including sexual function and 
cognition [72]. Therefore, men with ADT-induced hypogonadism may experience 
declines in the aforementioned aspects of health [11-14]. Given that these men are often 
of older age (mean age of diagnosis in Australia, 68 years [63]), have experienced the 
diagnosis of PCa and likely undergone additional non-hormonal treatment (e.g. 
prostatectomy or radiotherapy for curative intent upon diagnosis [64]), the compounded 
impact of these factors on the adverse effects of ADT should be considered [73-75].  
 
The following sections focus on the age-related, PCa-related and ADT-related changes 
on the interconnected components of muscle, fat and performance, and the commonly 
utilised clinical measures used to quantify these measures. In addition to the definitions 
outlined in Chapter 1, the following definitions are used throughout the thesis: 
• Lean mass: an areal assessment of tissue used as a measure of regional or total 
body muscle mass [76]. 
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• Muscle cross-sectional area (CSA): a volumetric assessment of a slice of tissue 
used as a measure of regional muscle mass [77]. 
• Muscle density: a volumetric assessment of a slice of tissue used as a measure 
of intermuscular fat mass (any storage of lipids in adipocytes between muscle 
fibres, also referred to as intramuscular fat, or muscle groups located beneath 
the fascia of a muscle [40]; excluding intramyocellular lipids, which are stored 
within the muscle cells themselves and are not always harmful to the cell [78]) 
and therefore muscle quality (e.g. a decrease in muscle density suggests an 
increase in intermuscular fat mass) [77].  
• Muscle strength: the ability of a muscle or muscle group to exert maximal force 
externally [24]. 
• Muscle power: the ability of a muscle or muscle group to exert force externally 
as quickly as possible [24]. 
• Functional capacity: the ability to perform activities of daily living (ADL) [79]. 
• Subcutaneous fat mass: the fat mass located beneath the skin within the 
hypodermis region [77]. 
• Visceral fat mass: the fat mass located within the abdominal cavity, between 
various organs (also known as intra-abdominal fat mass) [77]. 
 
2.6.1 Quantifying the risk associated with changes in muscle, fat and 
performance 
Collectively, negative alterations to muscle, fat and performance may lead to 
additional complications beyond those associated with each individual factor, and thus 
an assessment of accumulated risk is warranted. Two potential concepts that may assist 
in quantifying accumulative risk are sarcopenia and sarcopenic obesity. The following 
sections will discuss these concepts and their components with regards to changes 
associated with ageing, PCa diagnosis and non-hormonal treatment and ADT. 
  
Sarcopenia 
Sarcopenia was initially described by Rosenberg [80] as the loss of lean mass associated 
with the ageing process. Since then, sarcopenia has been deemed a syndrome (with 
varying stages; Table 2.1) and evolved to include a decline of lean mass, muscle 
strength and functional capacity commonly associated with the ageing process [40, 53]. 
The cut-off points for lean mass, muscle strength and functional capacity for 
diagnosing sarcopenia in men are currently debated; with various groups having 
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proposed and adopted different criteria (Table 2.2) [51-53, 81-87]. To date, these 
definitions of sarcopenia are limited in that they do not include a measure of muscle 
density as a marker of muscle quality and future research would benefit from this 
investigation. Nonetheless, various definitions of sarcopenia have been associated with 
adverse health outcomes such as increased risk of falls [81, 88, 89], fractures [48, 88, 90], 
functional impairment [88, 91-94] and mortality [88, 91, 95, 96]; however, the true extent of 
risk associated with the diagnosis of sarcopenia is unknown due to the lack of universal 
consensus regarding its definition.  
 
Table 2.1. Stages of sarcopenia. 
Stage Muscle mass Muscle strength Functional capacity 
Pre-sarcopenia ↓   
Sarcopenia ↓ ↓                   OR                   ↓ 
Severe Sarcopenia ↓ ↓                                           ↓ 
Adapted from Cruz-Jentoft et al. [53]. 
 
Table 2.2. Proposed cut-off points for diagnosing sarcopenia in men. 
Method Authors Lean mass Muscle strength Gait speed 
EWGSOP 
Baumgartner 
et al. [81] 
ALMI, 2 SD below healthy 
young men (≤ 7.26 kg/m2) 
- - 
Residual 
Newman et 
al. [82] 
Residual of ALM - ALMHFM, ≤ 
20th percentile (-2.29) 
- - 
Lowest 
quintile 
Delmonico 
et al. [83] 
ALMI, ≤ 20th percentile (≤ 7.25 
kg/m2) 
- - 
EWGSOP 
Cruz-Jentoft 
et al. [53] 
ALMI, 2 SD below healthy 
young men (≤ 7.26 kg/m2) 
Handgrip strength,  
< 30 kg 
Gait speed, 
< 0.8 m/s 
ESPEN-
SIG 
Muscaritoli 
et al. [85] 
%LM, 2 SD below healthy 
young men (≤ 37%) 
- 
Gait speed, 
< 0.8 m/s 
IWGS 
Fielding et 
al. [52] 
ALMI, ≤ 20th percentile (≤ 7.23 
kg/m2) 
- 
Gait speed, 
< 1.0 m/s 
SCWD 
Morley et al. 
[86] 
ALMI, 2 SD below healthy 
ethnicity-matched young men 
(≤ 6.81 kg/m2) 
- 
Gait speed, 
< 1.0 m/s 
AWGS 
Chen et al. 
[87] 
ALMI, 2 SD below healthy 
young men (≤ 7.0 kg/m2) 
Handgrip strength,  
≤ 20th percentile (< 26 
kg) 
Gait speed, 
< 0.8 m/s 
FNIH 
Studenski et 
al. [51] 
ALMBMI, < 0.789 
Handgrip strength,  
< 26 kg 
Gait speed, 
< 0.8 m/s 
%LM, percent lean mass; ALM, appendicular lean mass; ALMBMI, appendicular lean mass adjusted for 
body mass index; ALMHFM, appendicular lean mass adjusted for height and fat mass [ALMHFM (kg) = -
22.48 + 24.14 x height (m) + 0.21 x total fat mass (kg)]; ALMI, appendicular lean mass index; SD, 
standard deviation; AWGS, Asian Working Group for Sarcopenia; ESPEN-SIG, European Society for 
Clinical Nutrition and Metabolism Special Interest Groups; EWGSOP, European Working Group on 
Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; IWGS, 
International Working Group on Sarcopenia; SCWD, Society on Sarcopenia, Cachexia and Wasting 
Disorders. 
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In an attempt to establish a universal consensus, studies have attempted to assess the 
validity of various definitions of sarcopenia and their ability to predict adverse health 
outcomes [88, 97]. Cawthon et al. [88] applied numerous definitions of sarcopenia in an 
attempt to predict recurrent falls (two or more self-reported falls within a year), hip 
fractures, functional limitation and mortality in healthy community-dwelling older 
men (n=5,934; age, ≥ 65 years) when compared to age as a predictor alone. The authors 
concluded that although associated with increased prediction of recurrent falls (odds 
ratio [OR], 1.09-2.23) and mortality (OR, 1.22-3.60), risk estimates commonly varied 
between definitions and did not improve upon age alone as a predictor when assessing 
the four outcomes of interest. As a result, it was suggested that the application of these 
current definitions would be limited within the clinical setting for healthy community-
dwelling men [88]. Furthermore, Bischoff-Ferrari et al. [97] assessed falls risk in 445 
community-dwelling older adults (mean age, 71 years) and concluded that the 
Baumgartner et al. [81] (OR, 1.54; 95% confidence interval [CI], 1.09-2.18) and 
European Working Group on Sarcopenia in Older People (EWGSOP [53]; OR, 1.82; 
95%CI, 1.24-2.69) definitions produced the highest predictive validity of falls among 
sarcopenic versus non-sarcopenic participants when compared to other proposed 
criteria that diagnosed sarcopenia (OR, 0.61-1.66, all non-significant). Of note, both 
of these definitions utilised the same cut-off points for lean mass, whilst the EWGSOP 
[53] definition slightly differed with the addition of compromised muscle strength or 
functional capacity required for diagnosis (Table 2.2). The findings of this study 
suggested that adjusting for height alone when measuring lean mass is pragmatic 
within healthy community-dwelling older adults [97]. Moreover, these findings 
demonstrated the improved predictability of falls when the additional measures of 
muscle strength or functional capacity were incorporated; thus, the use of lean mass 
alone is limited in predicting fall risk [97]. Opposing definitions have noted that 
adjusting appendicular lean mass (ALM) for height (ALMI) alone may underestimate 
sarcopenic status [82] and that adjusting ALM for body mass index (BMI; ALMBMI) is 
required, to account for the increased muscle mass associated with increased BMI and 
how this may impact functional capacity [51, 54]. However, this confounding 
relationship appeared to be more apparent in women than men, particularly when gait 
speed was assessed as a predictor of functional capacity, and thus adjusting ALM for 
height alone appeared to be acceptable when applying the definition of sarcopenia to 
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older men [51]; although whether this applies to men treated with ADT is currently 
unknown.  
  
Sarcopenic obesity 
Sarcopenic obesity refers to a syndrome in which sarcopenia and obesity are 
concurrently present and has gained attention due to the likely compromising effect of 
age-related adiposity on muscle health (Figure 2.2). The initial implementation defined 
sarcopenia as ALMI (ALM divided by height [m] squared) two standard deviation 
below the mean of healthy younger men (≤ 7.26 kg/m2) [81] and obesity as a total body 
percent fat mass > 27% [98]. While the authors used the term sarcopenia, definitions of 
compromised lean mass alone are defined as pre-sarcopenia within this thesis. 
Moreover, this definition is likely limited in its ability to predict risk, as consensus 
population measures of obesity in men, such as BMI (≥ 30 kg/m2 [99]) and total body 
percent fat mass (> 30% [100]), were not utilised. Of these two measures, a total body 
percent fat mass > 30% has been commonly suggested as a more appropriate indicator 
of obesity when compared to BMI [101]; thus, this cut-off should be utilised when 
available. Since the initial proposal of sarcopenic obesity, the cut-off points for both 
the sarcopenia and obesity components have been debated (Table 2.3). These 
definitions are limited by the aforementioned issues with current sarcopenia 
definitions, as well as the lack of inclusion of muscle strength and functional capacity 
outcomes, thus deeming these definitions of pre-sarcopenia and obesity concurrently 
[51-53, 85-87]. Additionally, these definitions do not consider the role of varying regions 
of fat mass, such as visceral fat mass which has been shown to be more deleterious to 
health outcomes than subcutaneous depots [102, 103], and all apply a global definition of 
obesity, rather than considering a central obesity approach, which has been shown to 
be more proinflammatory when compared to global obesity [104]. A previous study that 
applied the seven definitions of sarcopenic obesity from Table 2.3 to 4,984 older adults 
(49% men; mean age of men, 70 years) observed a 19-fold difference in the prevalence 
of sarcopenic obesity in men pending differing cut-offs (range, 4.4-84%) [105]; thus 
suggesting the need for further large-scale trials to determine a consensus criteria for 
sarcopenic obesity that is capable of valid and reliable predictions of morbidity and 
mortality.  
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Figure 2.2. Effects of ageing on muscle and fat (adapted from Zamboni et al. [54]). 
 
Table 2.3. Proposed cut-off points for diagnosing sarcopenic obesity in men. 
Authors Sarcopenia*/pre-sarcopenia# Obesity 
Baumgartner et al. [98] 
ALMI, 2 SD below healthy young 
men (≤ 7.26 kg/m2) 
Total body fat percentage, 
greater than median in older 
men (> 27%) 
Davison et al. [106] 
LMI, lower 2 quintiles in older men 
(< 9.12 kg/m2) 
Total body fat percentage, 
upper 2 quintiles in older men 
(> 37.16%) 
Bouchard et al. [107] 
ALMI, 2 SD below healthy young 
men (< 8.51 kg/m2) 
Total body fat percentage, 
established values (> 28%) [24] 
Kim et al. [108] A 
ALMI, 2 SD below healthy young 
men (< 7.40 kg/m2) 
Total body fat percentage, 
upper 2 quintiles in older men 
(> 20.2%) 
Kim et al. [108] B 
Total body lean mass percentage, 2 
SD below healthy young men (< 
35.7%) 
Total body fat percentage, 
upper 2 quintiles in older men 
(> 20.2%) 
Kim et al. [108] C 
ALMI, lower 2 quintiles in older 
men (< 8.81 kg/m2) 
Total body fat percentage, 
upper 2 quintiles in older men 
(> 20.2%) 
Levine et al. [109] 
ALM percentage, 2 SD below 
health young men (< 25.7%) 
Waist circumference, 
established values (> 102 cm) 
[110] 
* as defined by authors; # as defined in this thesis. ALMI, appendicular lean mass index; LMI, lean mass 
index; SD, standard deviation. 
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2.6.2 Measuring muscle, fat and performance 
Lean mass and muscle cross-sectional area 
Computed tomography (CT) and magnetic resonance imaging (MRI) are recognised 
as the gold standard for acquiring measures of muscle with high accuracy [40, 77, 111, 112]. 
However, these techniques are limited in the clinical and research setting due to the 
high costs of scan acquisition and data processing, complications with claustrophobic 
and severely obese individuals (BMI ≥ 40 kg/m2), and in the case of CT, high exposure 
to ionising radiation [76, 111]. Therefore, alternative measures, such as dual-energy x-
ray absorptiometry (DXA) and peripheral quantitative CT (pQCT), have been 
suggested for use in these settings [77, 113]. Rationale for the use of these methods 
include the relatively low cost, decreased reliance on highly trained personnel and 
accessibility to equipment in both the research and clinical setting [77, 112, 113]. 
Bioelectrical impedance analysis (BIA), both single and multi-frequency, is another 
tool that may be used to estimate lean mass within the clinical and research setting, 
specifically due to its high portability [112]. However, due to the lack of robust 
reliability data when compared to DXA and the notable influence of age, sex, race, 
health status and hydration on results, more robust measures such as DXA should be 
utilised when available [112].  
 
DXA assessments of muscle include areal total body and regional (arms, legs, trunk) 
lean mass (Figure 2.3) which can be used to calculate additional measures such as total 
body lean mass index (total body lean mass divided by height [m] squared), ALM (sum 
of arm and leg lean mass), ALMI (ALM divided by height [m] squared) and ALMBMI 
(ALM divided by BMI) [77]. These adjusted calculations allow for comparisons 
independent of body size and are currently used in various definitions of sarcopenia 
[76]. Measures of lean mass via DXA are highly correlated with measures from CT and 
MRI (r > 0.91, both [112]) in older adults and can be performed at high precision with 
coefficients of variation (CV) ranging from 0.4% to 1.1% [114]. However, one limitation 
of DXA is that it does not provide a measure of muscle quality [77]. Despite this, DXA 
is an appropriate assessment technique for total body and regional lean mass in the 
clinical and research setting, but may need to be paired with a tool capable of 
quantifying muscle quality, such as pQCT. 
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Figure 2.3. Example of dual-energy x-ray absorptiometry total body scan with regions 
of interest defined [76]. A, android; G, gynoid; HL, head left; HR, head right; LL, lower 
limb left; LR, lower limb right; TL, trunk left; TR, trunk right; UL, upper limb left; UR, 
upper limb right. 
Muscle measures obtained via pQCT include muscle CSA and muscle density (Figure 
2.4) [77]. Muscle density measured via standard CT has been shown to highly correlate 
with simulated intermuscular fat within a phantom device (R2=0.995; CV of 0.5%) 
[115]. Measures of muscle CSA via pQCT at the upper leg (50% femur) highly 
correlated with MRI results at the same site (r=0.78-0.92) [116]. Furthermore, high 
precision in measuring lower leg (tibia) and forearm (radius) muscle CSA and density 
via pQCT has been demonstrated with CV ranging from 2.1% to 5.3% and 0.7% to 
3.2% respectively [117]. Despite this, pQCT measures are limited to the slices at lower 
leg (tibia), upper leg (femur), forearm (radius) and upper arm (humerus) sites, and thus 
are unable to quantify total body or larger regions of muscle CSA. Of note, high-
resolution pQCT is also available, but more research utilising this tool is required 
before its ability to quantify muscle parameters can be  compared to current gold 
standards [77]. Therefore, pQCT is a suitable assessment technique to pair with DXA 
to overcome muscle quality limitations and obtain additional measures of regional 
muscle CSA in the clinical and research setting. 
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Figure 2.4. (A) Peripheral quantitative computed tomography scanner (XCT 2000, 
Stratec Medizintechnik GmbH, Pforzheim, Germany) positioned for lower leg (tibial) 
scan; (B) cross-sectional scan obtained at the lower leg (66% tibia) with muscle 
borders manually drawn [77]. 
 
Fat mass and cross-sectional area 
Similar to the acquisition of muscle outcomes, MRI and CT are the gold standard for 
the assessment of fat, yet due to the aforementioned limitations, may not be feasible in 
the clinical and research setting [40, 76]. Alternatively, DXA can measure total body and 
regional fat mass with high precision (CV of 0.9-4.4%) [118] and correlation compared 
to MRI (r=0.990) and CT (r=0.979) at the same sites [119]. Various DXA algorithms 
have also been developed to estimate additional regions of interest, including 
abdominal visceral fat mass and subcutaneous fat mass, with abdominal visceral fat 
mass estimates highly correlated to MRI visceral fat volume (r=0.90) and CT visceral 
fat CSA (r=0.83) in overweight older men (mean age, 62-66 years; mean BMI, 29.7-
32.3 kg/m2) [120]. Furthermore, these algorithms have been shown to predict abdominal 
visceral fat mass with high precision in obese adults (CV of 5.1%; mean age, 35 years; 
mean BMI, 35.1 kg/m2), with no difference observed when compared to phantom 
measures (CV of 4.8%; P=0.670). However, DXA has been shown to significantly 
underestimate mean total body fat mass when compared to MRI and CT (-4.67 kg and 
-5.23 kg, respectively) [119], which may be further confounded by previously reported 
limitations of total body assessments in obese participants [121] and inter- and intra-
manufacturer variations in DXA scanners and algorithms [122, 123]; thus highlighting the 
importance of using a singular DXA scanner when possible and strictly adhering to 
manufacturer guidelines when analysing scans (e.g. the use of the estimate function in 
severely obese participants [76]). Despite these limitations, DXA is a suitable tool for 
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the acquisition of total body and regional measures of fat mass in older men in the 
clinical and research setting.  
 
Fat outcomes obtained via pQCT include fat CSA and intermuscular fat CSA [77]. 
Whilst fat CSA can be obtained with high precision at the lower leg (tibia) and forearm 
(radius) sites (CV of 2.4-6.4%), intermuscular fat CSA measured with pQCT at the 
same sites has been shown to have a CV of 3.3-42% [117]; thus muscle density is a more 
appropriate measure of intermuscular fat. Measures of fat CSA obtained with pQCT 
have been shown to not differ from those obtained with MRI (P=0.97) [116] and 
therefore provide a more feasible method to quantify regional fat CSA within the 
clinical and research setting. 
  
Muscle strength and power 
Muscle strength is a routinely implemented assessment of muscle performance in older 
adults [24]. Isokinetic dynamometry, typically of the lower limbs, is considered the gold 
standard for assessing muscle strength [124]. However, due to the high costs and lack of 
portability, measures of hand-held dynamometry, specifically handgrip dynamometer 
strength, have been suggested to be more feasible in the clinical and research setting 
[112, 124] and therefore has been incorporated into various definitions of sarcopenia [51, 
53, 87]. Furthermore, in comparison to other standard muscle strength testing, such as 
the one-repetition maximum (1-RM) protocols, hand-held dynamometry quantified 
muscle strength has been associated with decreased physical demand for participants, 
and reduced risk of accumulated fatigue in older adults [24, 125]. However, 1-RM 
protocols and protocols that use equations to calculate 1-RM outcomes, such as various 
three-repetition maximum (3-RM) protocols, remain commonly utilised within the 
research setting in older adults capable of completing these without the 
aforementioned concerns [24]. Currently, the Jamar hand dynamometer (Lafayette 
Instrument Company, Indiana, United States of America) is considered the gold 
standard hand-held measurement tool due to having the most extensive normative data 
[126] and results shown to highly correlate with isokinetic dynamometry lower limb 
strength in older adults (r=0.91; mean age, 83 years [127]). Furthermore, the Jamar hand 
dynamometer has a CV of 6.3% when used within clinical populations similar to men 
treated with ADT, such as those with advanced lung and gastrointestinal cancer [128]. 
However, despite the prevalent use of handheld dynamometry in the research setting, 
there is at present a lack of standardised protocol for assessing handgrip strength, and 
 20 
  Chapter 2 
thus drawing comparisons between studies must be performed with caution at times 
[126]. Efforts have therefore been made in an attempt to standardise this measure, and 
future trials should consider adopting this protocol to ensure reproducibility and 
comparison between trials [126]. Thus, handgrip dynamometer strength assessment is a 
suitable measure of muscle strength in older men and allows for the prediction of risk 
associated with sarcopenia [53], particularly in those with known comorbidities that 
may affect a true measurements of muscle strength obtained via 1-RM or 3-RM 
protocols.  
 
Although not included in definitions of sarcopenia, muscle power is another measure 
of muscle performance that may be used to predict risk of adverse health outcomes 
[129]. The current gold standard for quantifying muscle power in older adults is debated 
and previously implemented measures include varying jump-based protocols, 
dynamometers, stair climb tests and the Wingate cycle test [129]; some of which may 
be contraindicated in older adults [24].  
 
One measure proposed to be suitable for estimating lower-limb muscle power in older 
adults is the 30-second sit-to-stand test [130], which has been shown to be reliable 
(intraclass correlation coefficient [ICC], 0.84). The quantification of muscle power via 
the 30-second sit-to-stand test, as opposed to muscle strength outcomes, showed good 
correlation with the Nottingham power rig (r=0.6 [131]); however, its use may be limited 
to an overall measure of functional capacity due to elements of muscle strength and 
endurance concurrently demonstrated during the test.  
  
Functional capacity 
Functional capacity is a clinically relevant and meaningful outcome in older adults, as 
it can be reflective of ADLs by combining aspects of muscle performance, 
sensorimotor and cognitive process [132]. There are numerous tools for assessing 
functional capacity depending on the domain to be assessed (e.g. balance, mobility, 
range of motion, dexterity), which vary in task, duration, physical demand and 
feasibility; most of which aim to emulate ADLs [24, 112]. Valid and reliable measures in 
older adults (age, ≥ 60 years) include those such as the timed-up-and-go (falls risk, 
sensitivity=87%, specificity=87%; interrater ICC=0.98-0.99 [133]), four-square step 
test (falls risk, sensitivity=89%, specificity=85%; interrater and test-retest ICC of 0.99 
and 0.98, respectively [134]) and Berg balance scale (falls risk, r=0.46-0.62 when 
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compared to caregiver global rating [135]; interrater and test-retest ICC of 0.98 and 0.97, 
respectively [136]). Whilst there is no consensus on what is considered the gold standard 
for assessing functional capacity overall, a previous systematic review that examined 
the various tools in community-dwelling older adults (≥ 60 years) concluded that gait 
speed assessment was a valid (r=0.74-0.93) tool for assessing mobility limitation and 
ADL disability in the clinical setting due to the simplicity of administration (when 
performed over short distances; e.g. four metres) [112]. Moreover, short distance gait 
speed (i.e. four metres) has been shown to have similar reliability (ICC=0.96-0.97 [137]) 
in healthy older adults when compared to distances ranging two metres to one 
kilometre (ICC=0.94 [112]). Therefore, these measures of functional capacity are 
feasible within the clinical and research setting, with short-distance gait speed also 
providing risk assessment as part of the criteria for sarcopenia [53]. 
 
2.6.3 The effects of ageing on muscle, fat and performance in men 
Lean mass and muscle cross-sectional area 
In healthy men, the ageing process is commonly accompanied by annual decreases in 
total body lean mass ranging from approximately 0.5-1.0% beyond the age of 40-45 
years [132, 138, 139], with this rate shown to accelerate after the fifth decade of life [139]. 
Despite lean mass varying substantially on an individual level at any given age, most 
men aged greater than 70 years can expect to possess approximately 80% of the total 
body lean mass present when aged 20-30 years [132]. The decline in lean mass 
associated with ageing may not be uniform across differing muscles and regions, as an 
MRI-based study that examined 268 men (age range, 18-88 years) observed a more 
than two-fold decrement in lower limb lean mass when compared to that of the upper 
limb [139]. These results have been replicated in CT-based [140] and DXA-based [141] 
studies; thus, ageing likely influences lean mass distribution in men.   
 
Fat mass and cross-sectional area 
During the ageing process, total body fat mass and total body percent fat mass 
commonly increased in men until the seventh decade, after which it typically remained 
stable or decreased slightly throughout the remainder of life [142]. Similar age-related 
observations have been made in other total body measures of fat, including BMI and 
total body fat mass index (total body fat mass divided by height [m] squared) [139]. In 
a cohort of 929 older men (mean age, 74 years), total body fat mass measured via DXA 
increased approximately 0.5 kg over a three year follow-up; which equated to a 0.7% 
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increase per year [143]. Furthermore, these changes corresponded with an approximate 
0.8% increase in total body percent fat mass [143]. Similarly, a sample of 53 older men 
(mean age, 61 years) followed for 9.4 years demonstrated a 0.7% yearly increase in 
total body fat mass and 0.6% yearly increase in total body percent fat mass [144]. Of 
note, this study may have been limited when compared to the former [143] due to the 
use of hydrodensitometry (rather than DXA) and smaller sample size, but is 
strengthened by the duration of follow-up. Interestingly, despite the difference in mean 
age of participants, similar changes in fat mass were observed. Collectively, these 
studies highlighted the increases in fat mass often reported in older men. However, 
these two specific measures should both be interpreted with caution whenever reported 
as they do not account for height, lean mass and potential age-related changes in lean 
mass. Furthermore, neither of these measures quantified the location of fat and its 
accumulation, which may play a role in quantification of risk. 
 
To date, longitudinal age-related changes in the distribution of fat accumulation in men 
are limited. A recent DXA-based cross-sectional analysis of 1,133 men (age range, 20-
87 years; mean age, 63 years) reported that when compared to men aged 20-30 years, 
men aged ≥ 80 years had a 23% greater gynoid fat mass index (gynoid fat mass divided 
by height [m] squared) [145]. Moreover, age-predicted central fat mass index (central 
fat mass divided by height [m] squared), android fat mass index (android fat mass 
divided by height [m] squared) and visceral fat mass by the age of 70 years were 83%, 
82% and 181% greater, respectively, when compared to 20-30 year old men [145]. 
Subcutaneous fat mass index (subcutaneous fat mass divided by height [m] squared) 
was also shown to increase with age, with men aged 50 years and 85 years 
demonstrating greater values of 42% and 61%, respectively, when compared to men 
aged 20-30 years [145]. Breakpoint ages in the accumulation of fat mass were also 
observed for various regions, including central fat mass (70 years), android fat mass 
(73 years), subcutaneous fat mass (50 years) and visceral fat mass (68 years). Of note, 
the measures reported in this study were strengthened by height adjustment, a common 
confounding variable in studies that have examined body composition. In addition, a 
sample of 869 older men (mean age, 79 years) followed for five years were reported 
to decrease CT-derived abdominal visceral, abdominal subcutaneous and thigh fat by 
0.5%, 1.4% and 0.3% per year respectively [146]. Thus supporting the notion that fat 
slightly decreases during the seventh decade of life and beyond [142]. In summary, these 
data suggest that fat accumulation occurs at multiple regions of the body as men age 
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up until approximately the seventh decade. Furthermore, there appears to be greater 
accumulation at centralised sites and the accumulation of subcutaneous fat notably 
plateaus earlier. However, given the novelty of these studies, further investigation is 
warranted before definitive conclusion may be drawn regarding the age-related 
distribution of fat accumulation in men.  
 
The ageing process is also associated with increased intermuscular fat [40, 147], however, 
various methodological flaws in previous studies, such as small sample sizes and lack 
of control for known covariates, limit the ability to draw conclusions on the true rate 
of intermuscular fat accumulation and whether the ageing process alone plays a 
causative role. One cross-sectional analysis reported that age was associated with an 
approximately 0.2% yearly increase in intermuscular fat mass in 111 men (age range, 
19-84 years) [148]. In addition to the cross-sectional nature of these observations, the 
age range and lack of control for known covariates, including diet, physical activity 
and health status, should be noted when interpreting these results. To date, the largest 
longitudinal study followed 869 men (mean age, 79 years) for five years and reported 
that mid-thigh intermuscular fat CSA increased 9.7% per year [146]. Of note, these 
results were strengthened by being controlled for known confounding variables such 
as age, race, sex, smoking status, alcohol consumption and physical activity. A 
similarly sized longitudinal trial, which also accounted for numerous covariates such 
as race, health status and physical activity levels, followed 813 men (mean age, 74 
years) over a five-year period and observed an increase in mid-thigh intermuscular fat 
CSA of 9.7% per year [84]. Interestingly, despite the older age at baseline in both 
longitudinal samples, sizeable and consistent increases in intermuscular fat CSA were 
observed; thus contrasting the plateau/slight decrease in other measures of fat 
commonly observed in men beyond the seventh decade.  
 
Muscle strength and power 
As men age, various aspects of performance decline, beyond what can solely be 
attributed to losses in lean mass [132]. There is evidence that the rate of decline in muscle 
strength is at least two-fold greater than the decline in lean mass [39]. Therefore, other 
processes must be involved, such as increased intermuscular fat (see ‘Fat mass and 
cross-sectional area’ subheading within this section), mitochondrial dysfunction (e.g. 
age-related declines in mitochondrial mass, activity of tricarboxylic acid cycle 
enzymes, oxygen consumption and adenosine triphosphate synthesis [149]) and motor 
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neuron loss (e.g. age-related reduction in motor units [150]) [53]. Reid et al. [151] examined 
these processes and attempted to quantify the physiological mechanisms responsible 
for a similar three year decrement in lower-limb muscle performance between healthy 
older adults (-8.5%; n=26; mean age, 74 years) and mobility limited older adults (-
8.8%; n=22; mean age, 77 years). In healthy older adults, losses in lower limb muscle 
power were associated with decreased neuromuscular activation, but no change in 
muscle strength and lean muscle CSA [151]. Conversely, decrements in mobility limited 
older adults were associated with decreased muscle strength and lean muscle CSA, 
rather than changes in neuromuscular activation [151]. Therefore, the assessment of 
performance is warranted when investigating age-related differences in lean mass to 
avoid the underestimation of risk that may occur when using muscle imaging outcomes 
alone.  
 
Over a three year follow-up, a cohort of 929 older men (mean age, 74 years) were 
observed to lose 3.4% (Caucasian) to 4.1% (African-American) lower-limb muscle 
strength per year [143]. Furthermore, these decrements were three times greater than the 
loss of lean mass observed during the study [143]; which again demonstrated greater 
losses in muscle strength when compared to losses in lean mass in older adults. 
However, this study did not examine additional factors of muscle quality or 
neuromuscular activation, thus causality within this cohort remains elusive. 
Goodpaster et al. [143] also observed that despite the ability of some older men to 
maintain or improve lean mass, muscle strength decrements were still apparent. Given 
these findings, interventions aimed at improving muscle strength and subsequent 
function in older adults should consider approaches beyond preserving or increasing 
lean mass alone. Similarly, handgrip strength, a measure of upper body muscle 
strength, in a cohort of 38 men (mean age, 75 years) was observed to decrease 
approximately 4.0% per year (3.8% when adjusting for fluctuation in weight) [152]. 
These measures were accompanied by absolute (3.7% to 8.9%) and weight-adjusted 
(3.5% to 8.8%) decrements in muscle strength during elbow flexion, knee extension, 
trunk extension and trunk flexion in the same study [152]. Whilst limited by a modest 
sample size, these declining trends were also shown in a larger study, albeit cross-
sectional in nature [153]. In a sample of 2,442 older men (mean age, 66 years), right-
hand handgrip strength decreased 8.9% per decade from the sixth decade onwards; 
which equated to approximately 0.9% per year, and 0.7% to 1.0% per year when 
accounting for multiple comorbidities [153]. Of note, there is some evidence that yearly 
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decrements in handgrip strength may remain consistent in older men [154]. Daly et al. 
[154] reported no difference in the magnitude of grip strength loss per year, with men 
aged 50-60 (n=41), 60-70 (n=49) and ≥ 70 (n=52) years demonstrating declines of 
3.1%, 2.8% and 2.8% respectively. Beyond sample sizes alone, differences in the 
magnitude of change between these studies may be explained by various factors within 
study design, such as whether data was longitudinal or cross-sectional and the 
heterogeneity regarding participant demographics and health status. Regardless, 
evidence supports the notion that ageing is associated with a decline in muscle strength 
at various sites in men. 
 
Functional capacity 
Assessments of functional capacity may be more suitable for predicting risk in older 
men within the clinical and research setting, as these measurements are often easy to 
administer, require limited space and infrastructure and are less physically demanding 
than some assessments of muscle strength and power [24]. Given many tests of 
functional capacity incorporate aspects of gait (e.g. timed-up-and-go [133] and four-
square step test [134]) and commonly aim to predict similar outcomes (e.g. falls risk), 
assessments of gait speed have received substantial attention in the research setting, 
particular in those potentially at greater risk of adverse events, such as older men. In a 
sample of 2,349 older adults (mean age, 76 years; 48% male) followed for three years, 
gait speed decreased 0.017 m/s (1.5%) per year [155]. Further follow-up (four years) 
and analysis of the same trial provided similar data and demonstrated declines of 0.015 
m/s (1.3%) per year (n=2,306; mean age 75 years; 50% male) [156]. The authors also 
noted, albeit without supplying numerical data, declines were similar by sex, however, 
baseline gait speed of men was 0.10 m/s greater than that of women [156]. Whilst these 
follow-up results may have provided an underestimate of the true effect due to drop-
out and potential survivorship bias, they supported the contention that gait speed 
continued to decline rather than reach a plateau. These decrements were corroborated 
in a similar two-year study that examined older men specifically (n=1,513; mean age, 
72 years), in which gait speed decreased 0.019 m/s (1.7%) per year [157]. Furthermore, 
decrements in gait speed were observed to be larger as age increased, with reported 
decreases of 0.015 m/s (1.3%), 0.015 m/s (1.4%), 0.028 m/s (2.8%) and 0.038 m/s 
(3.9%) in men aged 65-69 (n=567), 70-74 (n=557), 75-79 (n=294) and ≥ 80 years 
(n=95), respectively [157]. Similar trends were detected in another study, in which gait 
speed decrements per year significantly differed between older men aged 50-60 (n=41; 
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+0.1%), 60-70 (n=49; -0.6%) and ≥ 70 (n=52; -1.7%) years [154]. Collectively, these 
studies demonstrated that gait speed declined with advancing age, with the magnitude 
of these decrements becoming larger as age increased.  
 
Sarcopenia and sarcopenic obesity 
The prevalence of sarcopenia varies by adopted definition and demographics in older 
men. A recent systematic review concluded that the overall estimated worldwide 
prevalence of sarcopenia in men was 10% (95%CI, 8.0-12%) [158]. When considering 
the EWGSOP definition [53], sarcopenia in cohorts of community-dwelling older men 
(mean age range, 67-86 years; sample size range, 66-568 older men) varies from 2.6% 
to 27% [95, 159-165]. Conversely, one study that applied this definition of sarcopenia to 
institution-dwelling older men (mean age, 84 years), albeit of limited sample size 
(n=31), reported a prevalence of 68%. Although conceivably justifiable due to the 
clinical characteristics that often predispose an individual to require institutional care 
(e.g. limited functional capacity or diminished cognitive function [166]), further 
research with larger samples is required to extrapolate whether this increased 
prevalence of sarcopenia is truly affecting institutional-dwelling older men. Several 
factors may be attributed for notable variation in prevalence, including lean mass 
measurement techniques, age, geographical location and sample size. Only two studies 
within community-dwelling older men utilised DXA for the assessment of lean mass 
(sarcopenia prevalence, 4.6-11% [160, 162]), whereas others relied on less reliable 
measures such as BIA (sarcopenia prevalence, 2.6-22%) and mid-upper arm 
circumference (sarcopenia prevalence, 26-27%) [95, 159, 161, 163-165]. Furthermore, the 
demographical heterogeneity amongst study cohorts may have contributed to the large 
range of prevalence. For example, when comparing a cohort of older men with a mean 
age of 67 years [162] to those with a mean age 74 years [160], DXA-based sarcopenia 
prevalence was 4.6% and 11%, respectively. Finally, a major limitation of these 
findings is the lack of a large-scale population-based trial in which many older men 
are assessed for sarcopenia with robust measures of muscle mass (e.g. DXA). 
Although financially burdensome, based on the limitations of research to date, these 
large-scale trials are warranted to assess the true prevalence of sarcopenia in older 
men. Therefore, the true prevalence of sarcopenia in community-dwelling older men 
is unknown, although based on the current literature utilising DXA-based measures, it 
is likely to be in the vicinity of 4.6-11%.  
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Similarly, the prevalence of sarcopenic obesity varies by definition and population 
group examined. The prevalence of sarcopenic obesity in older men based on a 
composite assessment of sarcopenia [53] and a total body percent fat mass [167] is 
unknown. However, studies utilising previously suggested definitions of sarcopenic 
obesity (although limited to a diagnosis of concurrent pre-sarcopenia and obesity as 
per definitions in this thesis; Table 2.1) have been conducted. Within a sample of 4,984 
older adults (49% men; mean age, 70 years), there was a 19-fold range of variation 
(prevalence range, 4.4% to 84 %) between the eight definitions of sarcopenic obesity 
applied [105]. Of note, none of these definitions adopted measures of muscle strength or 
functional capacity, and thus may have underestimated or overestimated the 
prevalence of the sarcopenia component of the definition. Moreover, various other 
studies have reported the prevalence of sarcopenic obesity using multiple definitions 
in older men (age range, ≥ 50 years; sample size range, 269-3,169 older men) to be 
4.0-19% [82, 98, 104, 107, 168]. Beyond the differences in definitions, variable population 
group demographics and sample sizes may have also impacted the prevalence of this 
syndrome. Until a standardised approach is available, the true prevalence of sarcopenic 
obesity in older men is unknown and its investigation is warranted due to the potential 
associated consequences beyond individual components, sarcopenia and obesity alone. 
 
2.6.4 The clinical implications of age-related changes on muscle, fat and 
performance in men 
Lean mass and muscle cross-sectional area 
Muscle is the largest secretory organ in the body and decrements in muscle health that 
impair myokine responses and/or resistance to its effects may lead to numerous 
adverse effects [169]. When considering losses in lean mass alone, men with a total body 
percent lean mass < 31% (< two standard deviation below sex-specific young adults 
aged 18-39) within a sample of 14,528 healthy adults (mean age, 45 years) 
demonstrated greater insulin resistance (homeostatic model assessment of insulin 
resistance [HOMA-IR] ratio, 1.39-2.13) and pre-diabetes status (OR, 1.43-1.46), 
regardless of obesity status, when compared to a reference group of those without low 
lean mass or obesity [45]. However, it should be noted that this study used BIA rather 
than DXA, CT or MRI to quantify lean mass, which has its known limitations [112]. 
Regardless, the loss of lean mass, even during the early years of accelerated loss (mean 
age, 45 years), may predispose men to metabolic disorders such as diabetes, although 
further evidence is required using more robust analyses of body composition. 
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Additionally, in a sample of 796 older men (mean age, 65 years), Szulc et al. [48] 
observed that those within the lowest quartile of ALMI (< 6.32 kg/m2) had decreased 
areal bone mineral density (BMD; aBMD) at the femoral neck (-5.1%) and distal 
radius (-6.2%) when compared to those within the highest quartile of ALMI (> 7.31 
kg/m2). Furthermore, men within the lowest quartile of ALMI also demonstrated lower 
external diameter (-4.2% to -6.7%), cortical thickness (-4.5% to -6.3%) and section 
modulus (-12.2% to -18.3%) of the femoral neck and distal radius when compared to 
those within the highest quartile of ALMI [48]; thus a loss of lean mass may be 
associated with increased fracture risk due to not only the loss of performance 
associated with decreased lean mass, but also the decreased size and bending strength 
of bone. A key limitation of this study however is the estimation of bone structure 
using DXA, an outcome not optimal via areal assessment and known to be more 
robustly assessed via volumetric CT-based methods [170]. Moreover, older men (mean 
age, 78 years) with lower ALMI (< two standard deviation below sex-specific 
population means, < 7.26 kg/m2) amongst a sample of 274 were shown to have greater 
self-reported mobility limitation across a range of ADLs (OR, 6.31) after adjusting for 
various confounding variables, such as age, smoking status and comorbidities, when 
compared to men with greater ALMI (> 7.26 kg/m2) [93]. Given the subjective nature 
of these data, future trials would benefit from the use of objective measures of 
functional capacity, such as short-distance gait speed, to assess these associations. 
 
Collectively, the compromised metabolic risk, skeletal health and performance 
declines associated with decreased lean mass may in part explain the marked increase 
in mortality amongst these older men. For example, in a sample of 3,659 older adults 
(mean age, 69 years) followed for a median duration of 13 years, those in the lowest 
quartile of ALMI (men, < 9.2kg/m2) had greater rates of mortality than those in the 
highest quartile of ALMI (men, > 10.8 kg/m2); 58% compared to 41%, respectively 
[46]. When adjusted for markers of cardiometabolic risk and demographical 
confounders, this relationship remained, as both the highest and second-highest (men, 
> 10.0 kg/m2) quartiles demonstrated reduced hazard ratios (HR) of 0.80 and 0.74 
respectively, when compared to the lowest quartile. Thus, compromised lean mass is 
an independent risk factor of mortality in healthy older men. 
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Fat mass and cross-sectional area 
Pending regional distribution, the accumulation of fat may pose differing health-
related risk in older men. Obesity, commonly measured at the population level with 
BMI rather than specific imaging-based outcomes, is a recognised risk factor for 
cardiometabolic morbidity and mortality in older men [55, 171]. Furthermore, obesity has 
positive associations with a myriad of detrimental conditions in older men, such as 
hypogonadism [172, 173] and various cancers [174]. However, there is a continually 
documented paradox in which global obesity, albeit counterintuitive, appears to be 
favourable against mortality in older men when compared to those with normal weight 
[175]. Collectively, these measures of global fat mass and their ability to predict adverse 
outcomes may be limited in that distribution of fat is not considered and when using 
BMI specifically, muscle mass, and its potential protective effect, is not taken into 
account. Fat accumulation in subcutaneous depots, such as those in the gluteofemoral 
region, appear to be negatively associated with cardiometabolic risk, whereas the 
accumulation within depots of the abdominal cavity (android region) is positively 
associated with chronic inflammation, cardiometabolic risk and functional impairment 
[40]. For example, in a sample of 1,549 men (mean age, 49 years), CT-based measures 
of abdominal subcutaneous and visceral fat volume were shown to be positively 
correlated with hypertension (OR, 1.5-1.9), impaired glucose metabolism (OR, 1.5-
1.8), diabetic status (OR, 1.6) and metabolic syndrome (OR, 2.5-4.2) [102]. Among 
these findings, the influence of visceral fat was shown to be greater than that of 
subcutaneous fat for all variables bar diabetic status (OR, both 1.6) [102]. Similar results 
were observed in 881 older men (mean age, 58 years), with increased abdominal 
subcutaneous and visceral fat volume shown to increase the risk of hypertension (OR, 
1.45-1.55), diabetic status (OR, 1.69-1.78) and metabolic syndrome (OR, 3.46-3.57) 
[103]. Moreover, visceral fat was shown to have a greater association with hypertension 
when compared to that of subcutaneous fat; whereas subcutaneous fat had a greater 
association with diabetic status and metabolic syndrome when compared to visceral 
fat [103]. In contrast, in a cohort of 869 older men (mean age, 79 years) followed for 12 
years, neither abdominal subcutaneous or visceral fat CSA assessed with CT was 
reported to be associated with mortality [146]. Similar results were observed in a cohort 
of 3,086 adults (51% men; mean age, 50 years) in which CT-derived subcutaneous and 
visceral fat volume did not increase the risk of all-cause mortality, despite visceral fat 
being independently associated with the increased risk of cardiovascular disease (HR, 
1.44) and cancer (HR, 1.43) [176]. Regardless, android fat accumulation, and the 
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subsequently increased visceral fat, is of increased concern in older men but further 
investigation into the role of varying fat distribution profiles and ageing on overall 
mortality is warranted.  
 
The age-related accumulation of fat within muscles may pose additional clinical 
implications. As increased intermuscular fat leads to decreased muscle density [77] and 
therefore compromised muscle quality, the accumulation of this form of ectopic fat 
may impact the ability of a muscle to perform and in part explain the non-parallel 
decrements of lean mass and muscle strength/power associated with ageing [40]. For 
example, in a cohort of 1,285 older men (mean age, 74 years), decreased mid-thigh 
muscle density was associated with decreased lower limb muscle strength (r=-0.26), 
independent of mid-thigh muscle CSA [177]. Similarly, lower limb functional 
performance, as assessed via a composite score combining gait speed and the ability 
to repeatedly rise from a chair, was shown to decrease (regression coefficient, -0.244 
to -0.292 Hounsfield units) per standard deviation (7 Hounsfield units) reduction in 
mid-thigh muscle density in a sample of 1,442 older men (mean age, 74 years) [178]. 
This model was strengthened by accounting for known confounding variables, such as 
age, total body fat, education, physical activity, health status and muscle CSA [178]. 
Although it is still unknown whether intermuscular fat is a marker or direct cause of 
impaired muscle performance, one potential mechanism to explain these relationships 
is decreased neural activation, with a previous study of 15 older adults (mean age, 71 
years) observing an inverse relationship between intermuscular fat CSA accumulation 
and quadriceps activation (r=-0.51) [179]. However, due to the small sample size and 
that this study only examined one muscle group, further investigation into whether this 
is a true relationship is required. Furthermore, investigation into other potential 
mechanisms is required before it can be determined whether direction causation exists 
between increased intermuscular fat and decreased muscle performance.  
 
From a metabolic perspective, those in a sample of 1,447 older men aged 70-79 years 
who had impaired glucose tolerance (n=235; mid-thigh intermuscular fat CSA, 10.3 
cm2) or type 2 diabetes (n=397; mid-thigh intermuscular fat CSA, 11.2 cm2) possessed 
greater amounts of mid-thigh intermuscular fat when compared to those with normal 
glucose tolerance (n=815; mid-thigh intermuscular fat CSA, 9.2 cm2) [180]. Thus 
suggesting that increased mid-thigh intermuscular fat may also be associated with 
systemic decrements in blood glucose regulation. Again, whether mid-thigh 
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intermuscular fat is a marker or has a direct physiological effect is unknown, with the 
most commonly suggested causative hypotheses of this association stemming from the 
potentially increased proinflammatory cytokines [40]. Finally, for each standard 
deviation decrement in mid-calf muscle density amongst a sample of 1,063 older men 
(mean age, 77 years), there was an increased risk of all-cause mortality (HR, 1.18) and 
cardiovascular mortality (HR, 1.34) [181]. This analysis was strengthened as it 
accounted for numerous confounding variables, such as age, race, physical activity, 
health status and DXA-derived fat mass [181]. Collectively, although this ectopic depot 
is of concern for both morbidity and mortality in older men, the lack of quantification 
beyond sites of the lower limb and commonality of relying on one site in each analysis, 
suggests that these results should be interpreted with caution. However, it appears that 
intermuscular fat may be associated with numerous clinical implications in older men 
and further research is required to assess whether this type of fat is a marker or cause 
of these adverse outcomes. 
 
Muscle strength and power 
Muscle strength has been suggested to be a better independent predictor of functional 
impairment when compared to lean mass alone [44, 49, 182]. In a sample of 1,612 men 
aged > 70 years, handgrip strength provided more accurate multivariable-adjusted 
prevalence ratios when compared to ALMI for self-reported functional limitation (1.30 
vs 1.19), performance-based functional limitation (1.80 vs 1.13) and physical 
disability (1.36 vs 1.15) [44]. Although unable to dismiss reverse causality (e.g. that 
functional impairment may have led to decreased muscle strength) due to the cross-
sectional design, these findings support the use of this simple to administer assessment 
for the quantification of functional limitation within the clinical and research setting. 
Similarly, in a sample of 1,286 older men (age range, 70-79 years), knee extensor 
muscle strength was shown to be an independent determinant (HR, 1.66) of mobility 
limitations over a 2.5 year follow-up and was suggested to mediate the relationship 
between mid-thigh muscle CSA and mobilisation limitations [49]. These longitudinal 
findings further support the use of muscle strength assessments for quantifying the risk 
of functional limitation within the clinical and research setting; however, the use of 
non-handheld dynamometry, such as that used to quantify knee extensor muscle 
strength in this study, may pose feasibility limitations in the research setting. Among 
a sample of 5,995 older men (mean age, 74 years), those within the lowest quartile of 
handgrip strength (cut-off point not reported; referent) were associated with greater 
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falls risk over a 4.5 year follow-up when compared to those within the three highest 
quartiles (relative risk [RR], 0.74-0.84) [42]. The increased risk of falls is of specific 
concern within this susceptible population group given that a 5.3 year longitudinal 
study of 5,902 older men aged ≥ 65 years demonstrated that those in the lowest quartile 
of handgrip strength (< 36 kg) and those with the inability to complete an assessment 
of handgrip strength also had a hip fracture HR of 1.63 and 4.50, respectively, when 
compared those in the highest quartile [41]. These studies highlight that older men with 
compromised muscle strength are not only at risk of functional impairment, but also 
the additional consequences that commonly accompany these impairments, such as 
falls and fractures. In addition to these consequences, a recent meta-analysis of 14 
studies examining handgrip strength in 53,476 community dwelling individuals of any 
age concluded that those in the lowest quartile of handgrip strength across all studies 
had an increased risk of mortality (HR, 1.67) when compared those in the highest 
quartile [43]. Furthermore, the authors reported that for each one kilogram decrease in 
handgrip strength all-cause mortality increased by 3.0% [43]. Thus there is evidence 
supporting the association between compromised muscle strength, particularly when 
assessed via handgrip dynamometry, and various forms of morbidity and mortality 
among older men. 
 
Functional capacity 
Measures of gait speed are often utilised to assess and quantify risk of incident 
disability, falls and fractures, hospitalisation and cognitive impairment [132]. In a 
sample of 5,995 healthy men (mean age, 74 years), those in the slowest quartile of 
narrow six metre usual pace gait speed were at greater risk of falling over a 4.5 year 
follow-up when compared to those in the two fastest quartiles (RR, 0.86-0.89) [42]. 
Although potentially limited by the self-reporting of falls, this study provided an 
additional functional capacity outcome that may be used within the research setting to 
quantify falls risk. A similar cohort of 5,902 healthy men aged ≥ 65 years, 
demonstrated those in the slowest quartile of narrow six metre usual pace gait speed 
(≥ 6.2 seconds) had a greater risk of hip fracture (HR, 3.70) when compared to those 
in the fastest quartile (< 4.5 seconds) [41]. Similarly, those unable to complete the 
assessment of gait speed also possessed a greater risk of hip fracture (HR, 3.53) when 
compared to the referent [41]. Thus, older men with compromised gait speed may be 
more likely to experience falls that result in injury, with this risk increased in those 
with severe mobility limitations. Furthermore, a recent meta-analysis that included 
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34,485 community-dwelling older adults (mean age, 74 years) across nine independent 
studies concluded that risk of mortality increased 12% for each 0.1 m/s decrease in 
walking speed [47]. Therefore, quantifying gait speed is an appropriate assessment tool 
for evaluating the risk of morbidity and mortality in older men. 
 
Sarcopenia and sarcopenic obesity 
Due to varying cut-off points and measures used to quantify sarcopenia, assessing 
accumulative risk may substantially differ among older adults depending on the 
definition adopted. For those including measures of lean mass only (defined as pre-
sarcopenia in this thesis; Table 2.1) [81-83], the aforementioned clinical outcomes 
associated with these changes are probable. However, these definitions likely 
underestimate the range and severity of adverse outcomes, due to neglecting 
performance decrements commonly accompanying the age-related loss of lean mass. 
Composite definitions of sarcopenia, such as that proposed by EWGSOP [53], may 
predispose those diagnosed to not only the aforementioned adverse outcomes of low 
lean mass, but also the previously discussed complications associated with low muscle 
strength and/or functional capacity. Furthermore, when these markers of sarcopenia 
are concurrently compromised, they may synergistically predispose older men to 
greater risk and create a cycle that results in the continual exacerbation of clinical 
outcomes [183]. For example, those diagnosed with sarcopenia in a sample of 5,934 
older men aged ≥ 65 years were at greater risk of recurrent falls (OR, 2.38), functional 
limitation (OR, 2.42) and mortality (OR, 1.83) over a 10-year follow-up period when 
compared to those not diagnosed with sarcopenia. Within the same study, the risk of 
these outcomes for those diagnosed with pre-sarcopenia via lean mass measures alone 
[81, 82], when compared to those not diagnosed with sarcopenia, was non-significant for 
recurrent falls, either non-significant or lower (OR, 1.30) for functional limitation and 
lower (OR, 1.22-1.25) for mortality. This provides rationale for the use of composite 
definitions of sarcopenia in older adults to avoid the underestimation of collective risk 
associated with this clinical syndrome state.  
 
A similar relationship may be seen with sarcopenic obesity, where obesity and 
sarcopenia coexist and therefore potentially increases the risk of adverse outcomes, 
such as cardiovascular disease and mortality, beyond that of either diagnosis alone [55]. 
A key limitation with many of the previously conducted studies is that muscle strength 
and functional capacity were not considered when defining the sarcopenia component 
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of sarcopenic obesity (defined as concurrent pre-sarcopenia and obesity in this thesis; 
Table 2.1); hence, the specific risk of falls, fractures, functional limitation and 
mortality is unknown in older men diagnosed with this syndrome. Although 
uncommonly investigated, a recent study used a composite definition of sarcopenia [53] 
and a total body percent fat mass of ≥ 30% to define sarcopenic obesity [101]. In this 
study 1,486 older men aged ≥ 70 years were followed for two years, and those 
diagnosed with sarcopenic obesity demonstrated a greater incidence rate ratio of falls 
(1.66) when compared to those without sarcopenia or obesity [101]. Furthermore,  
incidence rate ratios tended to be larger, although not statistically significant, when 
compared to sarcopenic non-obese older men (1.58) and non-sarcopenic obese older 
men (1.30) [101]. These findings support the notion that sarcopenic obesity, as defined 
by a composite definition of sarcopenia and total body percent fat mass definition of 
obesity, may predispose older men to a greater risk of falls when compared to either 
condition alone. However, further investigation is warranted to determine whether 
similar relationships exist for other known adverse outcomes, such as fractures, 
functional limitation and mortality.  
 
2.6.5 The effects of prostate cancer on muscle, fat and performance in older men 
As PCa is a disease of older men (mean age of diagnosis in Australia, 68 years [63]), 
age-related declines outlined in Section 2.6.2 are common in those diagnosed. 
Although PCa itself has no known direct physiological influence on muscle, fat or 
performance outcomes, both the diagnosis of PCa and adverse effects associated with 
treatment may indirectly negatively alter these outcomes. The following section 
discusses the adverse effects of PCa diagnosis and non-hormonal active treatments; 
including radical prostatectomy (surgery), radiotherapy and chemotherapy [64, 65].  
 
Prostate cancer diagnosis 
Following a diagnosis of PCa, a decrease in retrospective versus current self-reported 
physical activity was observed in a cohort of 59 older men (mean age, 65 years) by 72 
minutes per week, which corresponded with decrements in all recorded intensity 
categories (low, moderate and strenuous) [184]. Beyond potential self-report and recall 
bias, this association may be due to the psychological distress associated with the 
diagnosis of PCa; although when surveyed, only 31% of a similar cohort of 167 men 
admitted to experiencing significant levels of distress associated with their diagnosis 
[185]. Furthermore, among another sample of 150 older men (mean age, 65 years), 19%, 
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8%, 17% and 7% reported clinically significant uncertainty of treatment decision, 
depression, general anxiety and PCa-specific anxiety, respectively [186]. Of note, these 
findings may be an underestimate due to the discomfort men often report when 
admitting to these types of concerns or problems due to social norms and expectations 
regarding masculinity [184]. These suggestions are supported by the increased rates of 
suicide among men diagnosed with PCa when compared to healthy population means 
(1.4 times greater in total; 1.9 times greater in first three months following diagnosis), 
which is commonly attributed in part to psychological distress [187]. Inadequate 
physical activity is associated with decreased cardiorespiratory fitness and therefore 
potentially increases the risk of all-cause mortality [188]; however, this relationship has 
yet to be examined in this population group. Regardless, low levels of physical activity 
may partially explain why men diagnosed with earlier stage PCa are more likely to die 
from cardiovascular disease than from PCa [187, 189]; although further long-term studies 
are required before definitive conclusions may be drawn from this relationship.  
 
Non-hormonal active treatments  
Commonly reported treatment-induced adverse effects following prostatectomy and/or 
radiotherapy include bladder neck contracture, haematuria, incontinence, urethral 
stricture, diarrhoea, rectal bleeding and impotence [74]. Additionally, these treatments 
have been reported to increased perceptions of fatigue, with men who have undergone 
radiotherapy reporting greater levels of fatigue when compared to prostatectomy (33% 
vs 22%) [190]. Moreover, prostatectomies may result in general surgical complications 
(e.g. blood loss during surgery, incontinence and impotence) [74]. Finally, men treated 
with various chemotherapy agents also report further adverse effects such as 
gastrointestinal complications, fluid retention and more severe fatigue [73]. Of note, due 
to increased survival rates following treatment [2, 63], these adverse effects may 
contribute to long term comorbidities in these men. Comorbidities associated with 
these treatment-induced adverse effects may directly or indirectly limit physical 
activity in men diagnosed with PCa [191]; thus potentially negatively impact muscle, fat 
and performance outcomes.  
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2.6.6 The clinical implications of prostate cancer-related changes on muscle, fat 
and performance in older men 
Prostate cancer diagnosis 
Given the unlikelihood of having a direct physiological influence on muscle, fat and 
performance outcomes, robust studies examining the difference between older men 
and older men diagnosed with PCa and not actively treated are limited. Additionally, 
given the number of potential confounding variables, isolating the effects of PCa 
diagnosis alone on these outcomes, of which are likely psychological in nature, would 
be challenging and any result would likely need to be interpreted with caution. As 51-
77% of men diagnosed with PCa suitable for surgery and/or radiotherapy are likely to 
opt for immediate active treatment, quantifying treatment-induced adverse effects has 
received greater attention than that of diagnosis alone [2]. Regardless, the psychological 
burden of a PCa diagnosis should be considered in these men. 
 
Non-hormonal active treatments  
Despite the emphasis and attempt to quantify treatment-induced adverse effects, most 
studies have neglected to investigate changes to muscle, fat and performance outcomes 
[64, 74]. Furthermore, treatments such as chemotherapy are often used in conjunction 
with ADT, and thus adverse effects during therapy may be confounded by the 
hypogonadal state of these men. One study examining performance outcomes (six-
minute walk test, grip strength and timed-up-and-go) in both healthy and non-
hormonal treated men with PCa failed to report numerical outcomes regarding group 
descriptive statistics (e.g. mean and standard deviation) and results of between- or 
within-group statistical analyses [25]. Although the authors concluded that results did 
not reach minimum clinically important differences [25], it is unknown whether 
statistical differences were present between these two population groups.  
 
There are several reasons potentially explaining the lack of studies examining 
differences in muscle, fat and performance between healthy men and those treated with 
non-hormonal therapies for PCa. First, the robust quantification of muscle and fat 
requires access to expensive devices and appropriately trained individuals, which may 
not always be feasible. Second, men diagnosed with PCa are more likely to be 
concerned with adverse effects of rapid onset and hindrance (e.g. urinary incontinence 
and sexual dysfunction) [192], and thus quantifying and attempting to ameliorate these 
issues has been preferential within the research setting. Finally, the risk of publication 
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bias associated with statistically non-significant findings may be applicable if there is 
no true difference between these population groups for muscle, fat and performance 
outcomes [193]. In spite of these reasons, there is a need to appropriately assess and 
report whether differences in muscle, fat and performance exist between these two 
populations in order to determine whether interventions are required and to assist in 
the design and logistics of future studies in which men treated with ADT are compared 
to control groups. Currently, it is unknown where men diagnosed with PCa, not treated 
with ADT lie on the continuum towards possessing muscle, fat and performance 
measures of clinical concern (Figure 2.5). 
 
 
Figure 2.5. The potential range in which men diagnosed with prostate cancer, not 
treated with androgen deprivation therapy (ADT) lie on the continuum towards 
possessing muscle, fat and performance measures of clinical concern. 
 
2.6.7 The effects of androgen deprivation therapy on muscle, fat and 
performance in older men with prostate cancer 
Lean mass and muscle cross-sectional area 
Primarily due to the onset of hypogonadism, lean mass losses of 2.0-3.6% have been 
reported after a year of continuous ADT of varying modalities [18-21] (Table 2.4). In 
addition, findings from a study of 25 older men (mean age, 68 years) who commenced 
ADT reported that lean mass decreased by 1.4% in the first 12 weeks of treatment [38]. 
Although many of these studies lacked a control group and were non-randomised in 
design, the decrements in lean mass exceed those commonly observed in the healthy 
older men (0.5-1.0% per year [132, 138, 139]). Moreover, limited observations following 
the first 12 weeks of ADT suggested that these decrements may occur rapidly 
following the onset of hypogonadism [38]. While mediating factors contributing to the 
loss of lean mass with ADT are multifaceted, duration of treatment and patient age 
appear to be important. For instance, men treated with ADT demonstrated the greatest 
losses in lean mass (2.6-3.2%) during the initial 6-9 months of treatment [12, 18, 21]. 
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Specifically, one study observed a trend (P=0.06) in men treated with acute ADT (≤ 
six months; n=36), in which they had a greater decline in total body lean mass (3.7% 
vs 2.0%) when compared to those treated with chronic ADT (> six months; n=132) 
over a 36-month follow-up. This further strengthens the suggestion that these 
decrements rapidly follow the onset of hypogonadism. Furthermore, men aged ≥ 70 
years (n=127) treated with ADT over a 36-month period were shown to lose 
approximately three times (2.8% vs 0.9%) the amount of lean mass when compared to 
similar men aged < 70 years (n=41) [12]. Potential rationale for this observation include 
the aforementioned acceleration in age-related decreases in lean mass discussed in 
Section 2.6.2 (0.5-1.0% per year). Therefore, treatment duration and patient age should 
be considered as potential confounding variables when examining changes in lean 
mass within this clinical population group. Notably, after cessation of ADT and 
recovery of eugonadal testosterone levels, lean mass losses were not reversed over a 
two year follow-up in a cohort of 49 men (mean age, 73 years) [194]. Thus suggesting 
that the associated complications of ADT may be prolonged after the cessation of 
treatment and continual intervention may be required to offset these decrements.  
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Table 2.4. Non-randomised controlled trials examining the effects of continual 
androgen deprivation therapy (ADT) in men with prostate cancer on lean mass and fat 
mass. 
Authors N Average age (years) 
Change in lean mass 
(total body) 
Change in fat mass 
(total body or percent 
total body) 
Gonadotropin-releasing hormone agonist only 
26 weeks 
Boxer et al. [22] 30 72 -2.1% +9.5% 
Hamilton et al. [21] 26 71 -3.2% +12.0% 
48 weeks 
Smith et al. [17] 32 66 -2.7% +9.4% 
52 weeks 
Lee et al. [19] 65 66 -2.0% +6.6% 
Hamilton et al. [21] 26 71 -3.6% +14.1% 
Combined androgen blockade 
12 weeks 
Smith et al. [38] 25 68 -1.4% - 
36 weeks 
Galvão et al. [23] 72 74 -2.4% +13.8% 
52 weeks 
Smith et al. [20] 26 65 -3.6% +11.2% 
Pharmacological (any modality) 
24 weeks 
Smith et al. [36] 22 67 -2.7% - 
48 weeks 
Smith et al. [37] 79 71 -3.8% - 
52 weeks 
Greenspan et al. [18] 80 69-71 
Acute ADT: -3.5% 
Chronic ADT: NC 
Acute ADT: +10.4% 
Chronic ADT: NC 
N, number; NC, no change. Adapted from Owen et al. [195].  
 
To date, only three studies using CT have assessed muscle CSA and/or density in men 
treated with ADT (Table 2.5) [15-17], with multiple noteworthy methodological 
limitations apparent in each. First, none of these studies had a control group. Second, 
known confounding variables, such as physical activity and diet, were not assessed or 
accounted for during analysis. Together, these limitations suggest that the findings 
within these studies should be interpreted with caution, and thus the true effect of ADT 
alone on muscle CSA and density likely remains elusive. Moreover, one study [15] used 
varying CT scanners, protocols and patient positioning throughout the study, which 
further confounded results. Finally, one study [16] was only published as a conference 
abstract, and thus extensive detail of the protocol is currently unknown. No further 
results or details of the protocol have been published. Among the currently available 
studies, muscle CSA has been shown to decrease within the first year of ADT at 
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numerous muscle sites, including lumbar paraspinal (3.2%), quadriceps (15%), rectus 
femoris (17%) and sartorius (22%) [15-17]. Additionally, paraspinal muscle CSA 
decreased 5.5% within the first six months of treatment with enzalutamide (a second 
generation anti-androgen commonly prescribed once first generation ADT becomes 
ineffective at limiting PCa activity [196]) in men who had previously undergone ADT 
for an average of 44 months [16]. These observations suggest that decrements in muscle 
CSA associated with ADT may continue to increase over time, rather than plateau, 
and/or that different ADT pathways may influence muscle CSA differently. However, 
these suggestions are only speculative, and until multiple robustly designed studies are 
performed, the true effects of ADT on muscle CSA are unknown. Due to this, 
comparing differences in muscle CSA between healthy men and those treated with 
ADT remains limited. Beyond study design, the varying rates of muscle CSA decline 
observed within men treated with ADT may be partially explained by the use of 
different muscle sites, which differ anatomically, physiologically and functionally [197]. 
For example, paraspinal muscles are continually recruited to support and move the 
spine, whereas muscles of the lower limb are predominantly required during 
ambulation [197] and therefore more prone to atrophy in those less likely to be 
physically active, such as men diagnosed with PCa [184]. Collectively, due to the lack 
of research and a range of limitations among current studies [15-17], drawing conclusions 
on the true effect of ADT on muscle CSA is difficult. Therefore, research is required 
to examine changes in muscle CSA via CT measures at various sites, whilst also 
accounting for confounding variables, such as age, disease status and treatment 
modality. 
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 Table 2.5. Effects of androgen deprivation therapy (ADT) in men with prostate cancer on CT-derived muscle cross-sectional area (CSA). 
Authors N Average age (years) ADT details Duration Changes in muscle CSA Notable limitations 
Smith et al. [17] 32 66 
Commencing GnRH 
agonist 
48 weeks 
CSA: -3.2% (paraspinal, 
fourth lumbar vertebrae) 
No control group; not controlled for 
physical activity or diet 
Chang et al. [15] 39 73 
Commencing GnRH 
agonist 
14.6-20 
weeks 
CSA: -15.4 (quadriceps), 
 -16.6% (rectus femoris),  
-21.8% (sartorius) 
No control group; different CT 
scanners, protocols and patient 
positioning between baseline and 
follow-up; not controlled for physical 
or diet 
Ramalingam et al. [16] 
[Conference abstract] 39 74 
Previous ADT, median 
duration 43.5 months; 
commencing enzalutamide 
6 months 
CSA: -5.5% (paraspinal, 
third lumbar vertebrae) 
Limited detail of study protocol and 
outcomes; no control group; unknown 
if controlled for previous ADT use or 
other confounding variables 
CT, computed tomography; GnRH, gonadotropin-releasing hormone. 
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Fat mass and cross-sectional area 
Men treated with ADT were observed to experience a continuous increase in fat mass 
(Table 2.4), with the average annual gain exceeding 11% [198]. These annual gains 
contrast and exceed the plateau in fat mass accumulation commonly observed in older 
men [142]. Furthermore, following a two year period after cessation of ADT in a cohort 
of 72 men (mean age, 73 years), negative alterations to upper body, lower body and 
trunk fat mass remained [194]. Therefore, ADT-induced gains in fat mass may be of 
greater importance than those of ageing alone, given the prolonged nature of its 
presence and rate of accumulation. To date, limited studies have quantified if there are 
region-specific gains in fat mass during ADT [15, 17, 199], but of the limited research 
available, ADT has been associated with an 11-13% increase in abdominal 
subcutaneous fat mass [17, 199] and either an increase (22%) [199] or no change [17] in 
abdominal visceral fat mass after 48-52 weeks. Notable limitations of these studies 
include the small sample sizes (n=26-40 men) and lack of control groups [17, 199]. 
Furthermore, neither study controlled for confounding variables such as diet and 
physical activity. In addition, findings from a study of 39 men (median age, 73 years) 
commencing ADT reported increased fat infiltration of the rectus femoris, as assessed 
via CT-derived muscle density (-19%), after 15-20 weeks of treatment [15]. Similar to 
previous studies that have examined fat mass accumulation, this study also had a 
modest sample size (n=39) and lacked a control group. Moreover, variations in CT 
scanning protocol, including the use of multiple non-cross validated CT scanners 
suggests these results should be interpreted with caution. Given the lack of quantity 
and quality of research examining regional fat mass accumulation in men treated with 
ADT, there is a need for robustly designed longitudinal studies to determine the true 
effect of ADT on these outcomes. 
Muscle strength and power 
In addition to decrements in lean mass and muscle CSA, the potential subsequent loss 
of muscle performance, commonly assessed via measures of muscle strength and 
power, are of clinical importance in men treated with ADT. In line with definitions of 
sarcopenia, various studies have examined handgrip strength in men treated with ADT, 
with inconsistent findings demonstrated (Table 2.6) [25-30]. Cross-sectional analyses 
show that men treated with ADT possess either similar [26] or 29% less [27] handgrip 
strength when compared to age-matched healthy controls. Whereas 12-month 
longitudinal studies have reported decreases of 5.0% to 11% in men treated with ADT 
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when compared to PCa controls [25, 28, 29]. Whilst these decrements appear to be greater 
than that of healthy older men (approximately 4.0% per year), these studies had 
noteworthy methodological limitations and therefore these results should be 
interpreted with caution. Interestingly, the one longitudinal study that compared 
handgrip strength in men treated with ADT to healthy controls observed no difference, 
despite men treated with ADT having demonstrated significant decrements (5.0%) 
when compared to PCa controls. Common limitations among these studies include the 
lack of comparison to both healthy and PCa controls [26-30], with only one study to date 
including both within analyses [25]. Given the unknown degree in which men diagnosed 
and/or treated with non-hormonal therapies may experience indirect or direct 
decrements in handgrip strength (as discussed in Section 2.6.4; Figure 2.5), it is 
important that this population group is considered when attempting to quantify this 
outcome in men treated with ADT. The inclusion of both a healthy and PCa 
comparators would allow for the controlling of both age-related and PCa-related 
decreases; thus, increasing the likelihood of detecting the true effect of ADT on this 
outcome measure. Furthermore, each of these studies utilised a modest sample of men 
treated with ADT (n=20-87 men) and thus larger trials are warranted. Finally, 
inconsistent and poorly reported protocols regarding the collection of handgrip 
strength among these studies reduces the ability to compare observations. Hence, there 
is a need for future research to provide guidelines on standardising approaches when 
attempting to quantify handgrip strength in men treated with ADT [126]. 
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 Table 2.6. Effects of androgen deprivation therapy (ADT) in men with prostate cancer on handgrip dynamometer strength. 
Authors Study design Duration (months) N 
Average age 
(years) ADT details 
Changes or difference in 
handgrip dynamometer strength Notable limitations 
Stone et al. 
[30] 
Longitudinal 3 ADT=49 ADT=69 Commencing ADT No change 
Limited detail of protocol; 
no CON 
Joly et al. 
[26] 
Cross-sectional 0 
ADT=57 
HCON=51 
ADT=73 
HCON=72 
Any form of ADT, 
median 1.8 years 
No difference No PCON 
Soyupek et 
al. [27] 
Cross-sectional 0 
ADT=20 
HCON=20 
ADT=74 
HCON=73 
GnRH agonists > 12 
months 
-28.7%* No PCON 
Alibhai et 
al. [25] 
Longitudinal 12 
ADT=87 
PCON=86 
HCON=86 
ADT=70 
PCON=70 
HCON=68 
Commencing ADT -5.0%# 
Limited reporting of 
numerical results and 
statistical analyses 
Gonzalez 
et al. [28] 
Longitudinal 12 
ADT=62 
PCON=86 
ADT=68 
PCON=68 
Commencing ADT -5.3%# 
40% of sample did not 
complete assessment due to 
comorbidities; No HCON 
Cheung et 
al. [29] 
Longitudinal 12 
ADT=34 
PCON=29 
ADT=68 
PCON=71 
Commencing ADT 
Dominant hand, -8.4%# 
Non-dominant hand, -10.5%# 
No HCON 
# P < 0.05 compared to PCON; * P < 0.05 compared to HCON. CON, controls; GnRH, gonadotropin-releasing hormone; HCON, healthy controls; PCON, prostate cancer 
controls.  
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Beyond this measure, the muscle strength and power of men treated with ADT has 
been assessed in various studies [28, 33]. Within a sample of 118 men, those treated with 
ADT (mean age, 70 years) demonstrated lower muscle strength (8.7-19%, as assessed 
via 1-RM chest press, seated row and leg extension) and power (13%, as assessed via 
a chair rise task) when compared to age-matched healthy controls [33]. Of note, this 
study was cross-sectional in design, rather than longitudinal, and also did not contain 
a PCa control in addition to the healthy control. Multiple confounding variables were 
left unaccounted for within this study despite the valid and reliable assessments used 
for quantifying muscle strength and power. In a sample of 62 men (mean age, 68 years) 
commencing ADT, no baseline differences were observed in muscle power, as 
assessed via a chair rise task, when compared to age-matched PCa controls. 
Conversely, after 6- and 12-month follow-up, men treated with ADT demonstrated 
decreased muscle power when compared to PCa controls (25% and 30% at each time-
point, respectively) [28]. These findings suggest that decrements in muscle power may 
be largest in the first six months of ADT, similar to aforementioned observations in 
lean and fat mass. However, as almost 60% of men treated with ADT were precluded 
from one or more of these longitudinal assessments due to additional comorbidities, 
these results may have underestimated the true effect of ADT on muscle power over 
time. Given these issues and the likelihood of comorbidities among men treated with 
ADT, simplistic and easy to administer tests are required (e.g. handgrip strength).  
 
Functional capacity  
Limited studies have assessed short-distance gait speed in men treated with ADT, with 
measures commonly obtained as a component of the short physical performance 
battery (Table 2.7) [31-34]. Among cross-sectional analyses, differences have ranged 
from non-existent to 16% pending the duration of ADT (acute or chronic) and 
comparator group (PCa or healthy control). Most of these studies are limited in that 
they did not control for an extensive range of known confounding variables such as 
age, disease status, comorbidities, education and physical activity [200]. Moreover, only 
one longitudinal study has been conducted to date, in which men treated with acute 
ADT (< six months) at the commencement of the study decreased gait speed by 27% 
over a two year period when compared to healthy controls [34]. Conversely, men treated 
with chronic ADT (≥ six months) maintained gait speed throughout this follow-up [34]. 
This suggests that similar to other ADT-related adverse effects, greater negative 
alterations occur closer to the onset of ADT-induced hypogonadism. However, this 
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study is not without limitation, a modest sample size (acute ADT, n=12; chronic ADT, 
n=23; healthy controls, n=13), age differences between groups and the exclusion of 
men with low BMD warrants caution when reviewing these results. Given these 
limitations it is possible that these men do not represent the wider ADT population 
group.   
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 Table 2.7. Effects of androgen deprivation therapy (ADT) in older men with prostate cancer on gait speed. 
Authors Study design 
Duration 
(years) N 
Average age 
(years) ADT details 
Change or difference 
in gait speed Notable limitations 
Clay et al. [32] 
Cross-
sectional 
0 
Acute ADT=13 
Chronic ADT=42 
PCON=25 
HCON=13 
Acute ADT=74*# 
Chronic ADT=73*# 
PCON=65 
HCON=69 
Acute ADT, mean 
duration 3.7 months; 
Chronic ADT, mean 
duration 30.7 months 
Acute: no difference 
Chronic: -15.4%* 
Non-age matched 
Levy et al. [34] Longitudinal 2 
Acute ADT=12 
Chronic ADT=23 
HCON=13 
Acute ADT=71* 
Chronic ADT=74* 
HCON=67 
Acute ADT, mean 
duration 3.8 months; 
Chronic ADT, mean 
duration 24.6 months 
Acute: -26.5%* 
Chronic: no change 
Non-age matched; 
excluded men with 
limited function or 
low aBMD  
Galvão et al. [33] 
Cross-
sectional 
0 
ADT=48 
HCON=70 
ADT=70 
HCON=70 
GnRH agonist only or 
CAB (> 2 months) 
-6.3%* No PCON 
Bylow et al. [31] 
Cross-
sectional 
0 
ADT=63 
PCON=71 
ADT=72 
PCON=71 
ADT > 6 months, mean 
duration 41.7 months 
No difference No HCON 
# P < 0.05 compared to PCON; * P < 0.05 compared to HCON. aBMD, areal bone mineral density; acute, < 6 months; CAB, combined androgen blockade; Chronic, ≥ 6 months; 
GnRH, gonadotropin-releasing hormone; HCON, healthy controls; PCON, prostate cancer controls.
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Sarcopenia and sarcopenic obesity 
As discussed, individual components of composite definitions of sarcopenia (i.e. lean 
mass, handgrip strength and gait speed [51, 53]) have been reported in men treated with 
ADT in various cross-sectional and longitudinal studies (Table 2.4; Table 2.6; Table 
2.7). However, no studies have examined all three components in the same cohort and 
thus conclusions on the prevalence and population-specific outcomes of composite 
definitions of sarcopenia are limited. Furthermore, studies that have examined losses 
in lean mass or differences in lean mass when compared to other cohorts (e.g. PCa 
and/or healthy controls) have not applied previously proposed criteria for pre-
sarcopenia (low lean mass alone), therefore the prevalence of pre-sarcopenia is also 
limited. Individual components of sarcopenic obesity have also been reported in men 
treated with ADT, yet no studies have examined all components collectively (Table 
2.4; Table 2.6; Table 2.7). Thus there is a need to apply established definitions to 
quantify the likelihood of men treated with ADT possessing or developing sarcopenic 
obesity.  
2.6.8 The clinical implications of androgen deprivation therapy-related changes 
on muscle, fat and performance in older men with prostate cancer 
To date, the vast majority of studies that examined the adverse effects of ADT on 
muscle, fat and performance focussed on quantifying these changes, rather than the 
morbidity and/or mortality associated with changes in these outcomes. However, ADT 
use in general has been associated with an increased risk of falls [201] and subsequent 
fractures [202-204]. Similarly, ADT has been associated with increased cardiometabolic 
risk via compromised blood lipid profiles, decreased insulin sensitivity and increased 
arterial stiffness [59, 205, 206]; however, this elevated risk appears to be associated with 
cardiometabolic morbidity [207], but not mortality within these men [208]. ADT is also 
associated with increased fatigue, depressive symptoms and sexual dysfunction may 
in part explain the lower health-related quality of life commonly reported in men 
treated with ADT [209], which is of further concern given the susceptibility to suicide 
among these men [187]. Whilst each of these clinical implications notably contributes 
to the burden of disease associated with the treatment of PCa with ADT, the following 
sections will focus on outcomes that may in part be explained by ADT-related changes 
in muscle and fat and subsequent decrements in functional performance.  
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Changes in lean mass and muscle CSA associated with ADT may adversely affect 
functional performance and the ability to complete ADLs, as well as predispose men 
treated with ADT to falls and subsequent fractures [60]. In a cohort of 50 men treated 
with ADT (median age, 78 years), 24% of men demonstrated impairment during basic 
ADLs, whereas 42% showed impairment during higher functioning ADLs [201]. 
Overall, 15% of this cohort reported worsening ability to complete either basic or 
higher functional ADLs after a three month follow-up [201]. Moreover, 22% reported a 
recent fall within the previous three months, and 56% of these reporters experienced a 
fall within the subsequent three month period [201]. Finally, 12% of men who did not 
initially report a fall experienced a fall during the three month follow-up [201]. 
Subsequently, 6.0-14% of men treated with ADT experienced a skeletal fracture at any 
site resulting from a fall after 21-47 months [210-213]. While the accelerated loss of BMD 
demonstrated in men treated with ADT likely explains the increased fracture rates 
following a fall in this population group, the high incidence of falls in these men are 
likely to be partially explained by decrements in lean mass and muscle CSA. These 
potential links are of additional concern given that men classified as possessing a 
higher risk of skeletal complications after PCa diagnosis were more likely to be treated 
with ADT [214].  
 
Given the role of muscle as a secretory organ in the human body, changes in muscle 
mass or size may significantly influence myokine concentration and activity [169]. For 
example, compromised interleukin-6 concentration and activity is associated with 
reduced fat oxidation, increased inflammation and decreased insulin sensitivity [169]. 
Therefore, decrements in muscle mass and size during ADT may in part explain the 
increased prevalence of metabolic imbalances and subsequent disease in this 
population group. In men treated with ADT, insulin sensitivity assessed via an oral 
glucose tolerance test has been shown to decrease within the first 12 weeks of therapy 
[38, 215]. These studies also found that fasting plasma insulin increased 26-65% [38, 215]; 
thus further supporting the notion that glucose metabolism may be impaired in these 
men shortly after commencing treatment. Similarly, in a study of 26 men commencing 
ADT, HOMA-IR increased 12% after 52 weeks [199]; therefore there is some evidence 
that insulin resistance may remain elevated throughout therapy, however additional 
studies utilising this measure are required to confirm this observation and whether this 
is driven by changes in muscle mass and size.  
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Clinically, there are multiple consequences that may stem from ADT-related gains in 
total, regional and intramuscular fat mass [216]. For instance, potential increases in 
subcutaneous and visceral fat may contribute to the marked increase in 
cardiometabolic disorders in men treated with ADT [20, 56, 217]. These gains in fat mass 
and the subsequent increase in inflammatory cytokines may partially explain 
previously reported increments of 19-27% and 7.3% in serum triglycerides and low-
density lipoprotein (LDL) cholesterol after 48-62 weeks of ADT, respectively [17, 20]. 
In addition, increased fat infiltration within muscle impairs muscular function in non-
ADT treated older adults [40]; thus this phenomenon requires further investigation 
within this clinical population group.  
Despite the aforementioned clinical implications potentially associated with 
compromised muscle, fat and performance, the lack of studies that have examined the 
prevalence of sarcopenia and sarcopenic obesity in men treated with ADT limits the 
ability to draw conclusions on the accumulative risk associated with concurrently 
possessing compromised muscle, fat and performance. For example, since obesity is 
associated with an up-regulation of inflammatory cytokines [218], and chronic low grade 
systemic inflammation has been shown to contributed to age-related muscle wasting 
[219], it is possible that ADT-induced increases in fat mass and size may further 
exacerbate the loss in muscle mass and size in men with PCa undergoing this 
treatment. Thus, possessing a number of ADT-induced adverse effects may predispose 
these men to a greater risk of various clinical implications and further research is 
required to progress this understanding. 
2.7 Potential interventions to improve muscle, fat and performance in older 
men treated with androgen deprivation therapy for prostate cancer 
Current guidelines for managing the myriad of ADT-induced adverse effects generally 
involve monitoring known risk factors, pharmacotherapy and/or lifestyle 
interventions; however guidelines appear to vary by country, organisation and expert 
opinion [14, 56-59]. Moreover, these guidelines tend to focus on addressing decrements 
in bone health, rather than the adverse effects associated with ADT on muscle, fat and 
performance. The limited number of guidelines that address changes in body 
composition associated with ADT tend to have placed greater emphasis on weight 
management, and do not specifically focus on monitoring fat or lean mass and size via 
robust measures, such as DXA or pQCT [56, 59]. Whilst guidelines for managing 
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metabolic health during ADT briefly discussed the link between lean mass and insulin 
resistance, they did not recommend any interventions specifically intended to preserve 
or improve lean mass or muscle CSA [14, 56, 57, 59]. However, regular exercise training 
and/or physical activity are recommended, but greater emphasis is placed on weight 
management as an outcome, rather than lean mass or muscle CSA [14, 56, 57, 59]. Although 
guidelines are evidence-based, it remains uncertain as to whether they are routinely 
implemented and followed over time and if they are effective in ameliorating or 
attenuating many of the adverse effects of ADT.  
To date, only one set of guidelines [56], which focussed on bone and metabolic 
outcomes of ADT, has been implemented and evaluated [220]. In a two year prospective 
study, 236 men with PCa commencing ADT attended a clinic visit and received diet 
and lifestyle advice with overweight and obese men offered referral to a dietitian [220]. 
If required, men also received treatment for hypertension, hypercholesterolemia and 
osteoporosis as per standard management guidelines [56]. Men attending this clinic 
were assessed at 3-6 monthly intervals [220]. A summary of the assessment and 
management strategies used in this study are shown in Table 2.8. At the initial 
assessment, 87% of the men were overweight/obese, 61% had hypertension, 56% had 
hypercholesterolemia, 27% had prior cardiovascular disease, 11% had osteoporosis 
and 40% had osteopenia [220]. For the prospective study, 153 men had data available 
after 2-years of continuous ADT use [220]. The main findings from this study were a 
mean loss of 3.4% and 2.5% in lumbar spine (L1-4) and hip aBMD, respectively, over 
2-years, unless the men were treated with antiresorptive therapy (n=14), in which case
aBMD was maintained at both sites [220]. No measures of lean or fat mass or functional
capacity were assessed in this study, however, an increase in waist circumference of
2.7 cm was indicative of an increase in abdominal fat mass [220]. In contrast, reductions
were observed in blood pressure, total cholesterol and LDL-cholesterol with treatment
[220]. While it is important to acknowledge that this was an observational study, which
precludes inferences about causality, these findings provide some evidence that
adhering to the current management guidelines for men with PCa treated with ADT
may not mitigate some of the adverse effects associated with this treatment.
Furthermore, the lack of thoroughly assessed muscle, fat and performance outcomes
limits the ability to draw conclusions on whether or not guidelines can facilitate the
management for ADT-induced adverse effects on theses outcomes.
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Table 2.8. Clinical assessment and management guidelines for androgen deprivation 
therapy (ADT)-associated cardiometabolic and skeletal adverse effects.  
Cardiometabolic health 
• Metabolic risk assessment prior to ADT commencement: body mass index, 
waist circumference, blood pressure, fasting blood glucose, oral glucose 
tolerance test (if fasting glucose between 5.5-6.9 mmol/L) and fasting lipid 
profile. 
• Six-monthly to yearly metabolic assessment during the first 24 months of 
ADT. 
• Lifestyle intervention and/or dietician to prevent weight gain and worsening 
of insulin resistance. 
• Smoking cessation. 
• Blood pressure < 130/80 mmHg. 
• Lipid targets according to NCEP ATP III treatment guidelines 
• In men with diabetes, intensification of management as necessary to main 
HbA1c target 
Skeletal health 
• At commencement of ADT: assessment for history of minimal trauma 
fractures and risk factors for osteoporosis, aBMD measurement by DXA 
and, in men with osteopenia, postero-anterior as well as lateral 
thoracolumbar spine X-rays. 
• Yearly aBMD measurement during the first 24 months of ADT. 
• Advice regarding regular physical exercise, smoking cessation and alcohol 
consumption of ≤ 2 standard drinks per day at each visit. 
• Total daily calcium intake of 1,200–1,500 mg through diet, supplements, or 
both, unless there is a history of renal calculi. 
• Vitamin D supplementation as necessary to achieve a target serum 25-
hydroxyvitamin D level ≥ 75 nmol/L. 
• Commencement of treatment with a bisphosphonate in men with a minimal 
trauma fracture, an aBMD T-score of ≤ -2.5, or if 10-year absolute risk of a 
major osteoporotic fracture is > 20%. 
aBMD, areal bone mineral density; DXA, dual-energy x-ray absorptiometry; HbA1c, glycated 
haemoglobin; NCEP ATP III, national cholesterol education program adult treatment panel III. Adapted 
from Cheung et al. [220] on behalf of the Endocrine Society of Australia, the Australian and New Zealand 
Bone and Mineral Society and the Urological Society of Australia and New Zealand. 
 
2.7.1 The role of exercise training on muscle, fat and performance in older men 
treated with androgen deprivation therapy for prostate cancer 
In healthy older men, there is consistent and compelling evidence demonstrating that 
progressive resistance training (PRT) is safe and effective for improving lean mass and 
strength, with the greatest benefits typically observed with high-intensity training [24]. 
Exercise training has also been suggested to have an important role both pre- and post-
diagnosis of cancer [221], with emerging evidence that increased physical activity levels 
   53 
  Chapter 2 
may improve treatment-related outcomes and prevent cancer recurrence through the 
reduction and maintenance of body fatness [222]. Exercise training has been 
implemented and reviewed across a range of treatments in men diagnosed with PCa 
[60, 223]. Safety concerns regarding injury and increased PSA (a marker of PCa disease 
activity) following exercise training have been dismissed in various trials [224-229]. 
Moreover, no long-term testosterone increases have been observed following exercise 
training in men treated with ADT [226-229]. There is also emerging evidence that exercise 
training is safe and well tolerated in men with bone metastases of prostatic origin, 
which are commonly observed in men treated with ADT [230]. The effects of exercise 
training in men diagnosed and/or treated for PCa are displayed in Figure 2.6. 
 
 
Figure 2.6. The benefits of exercise training in men diagnosed and/or treated for 
prostate cancer (Owen et al. [231]). 
 
In addition to the benefits in men diagnosed with PCa, the effects of various modalities 
of exercise training, including aerobic, resistance and impact exercises, on muscle 
health in men treated with ADT has been assessed in multiple RCTs [225, 227-229, 232-244] 
(Table 6) and reviewed [60, 245]. Although the optimal training load and exercise 
programming variables for eliciting improvements in muscle, fat and performance are 
unknown, it appears that aerobic training, PRT and the combination of both over 
periods of 12-52 weeks may improve outcomes, such as total body lean mass (0.7 kg 
[227, 246]) and ALM (0.5 kg [227, 238]), total body (-0.6 kg [234]) and trunk fat mass (-0.2 to 
-0.5 kg [234, 246]), upper (4.0-26% [227, 232, 234, 238, 243]) and lower body muscle strength 
(17-37% [227, 232, 234, 238, 243]), upper (47% [227]) and lower body muscle endurance (69% 
[227]) and gait speed (6.4% [227]), when compared to usual care (Table 2.9). Moreover, 
emerging evidence supports the use of impact exercises that aim to provide a loading 
stimulus to bone in these men [242-244], predominantly to address accelerated decrement 
in BMD, but whether this modality is of increased benefit to muscle, fat and 
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performance outcomes when compared to aerobic or PRT is unknown. Given the 
growing rationale that various forms of exercise training are beneficial in this clinical 
population group and the increased attention of syndromes such as sarcopenia and 
sarcopenic obesity, future trials should incorporate measures and cut-off points 
included in these definitions to assess whether these interventions can reduce the 
burden of disease associated with these syndromes.  
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Table 2.9. Randomised controlled trials that have examined the effect of aerobic and/or resistance exercise training compared to a non-exercise 
control on total body and regional lean and fat mass, muscle strength and endurance and gait speed in men treated with androgen deprivation 
therapy (ADT) for prostate cancer (PCa). 
Authors N Age (years) ADT 
(months) 
Duration 
(weeks) 
Exercise prescription Results 
Segal et 
al. [228] 
INT, 82 
CON, 73 
INT, 68 
CON, 68 
INT, 12.5 
CON, 13.4 
12 Supervised, 3/week; PRT, 9ex, 
2sets, 8-12reps, 60-70%1RM 
↑Upper and lower body muscle endurance 
Segal et 
al. [229, 
232]
INT(PRT), 23 
INT(AT), 25 
CON, 26 
INT(PRT), 67 
INT(AT), 66 
CON, 65 
INT(PRT), 3.0 
INT(AT), 3.5 
CON, 3.7 
24 Supervised, 3/week; INT(PRT), 
10ex, 2sets, 8-12reps, 70-80%1RM; 
INT(AT), continuous, 15-45min, 
50-75%VO2peak
INT(PRT), ↑LM, ↓%FM, ↑Upper and lower body 
muscular strength  
INT(AT), ↔LM, ↔%FM, ↑Upper body muscle 
strength, ↔Lower body muscle strength 
Culos-
Reed et 
al. [225] 
INT, 53 
CON, 47 
INT, 67 
CON, 68 
Not reported 16 Supervised, 1/week, 60min; AT, 
walking; PRT, light intensity; 
Unsupervised, 3-5/week, as 
supervised 
↔Handgrip muscle strength 
Galvão 
et al. 
[227, 233, 
235, 236]
INT, 29 
CON, 28 
INT, 70 
CON, 70 
INT, 18.2 
CON, 10.1 
12 Supervised, 2/week; PRT, 10ex, 2-
4sets, 6-12-RM; AT, 15-20min, 65-
80%HRmax 
↑LM, ↑ALM, ↔FM, ↔%FM, ↔TrunkFM, ↑Upper 
and lower body muscle strength, ↑Upper and lower 
body muscle endurance, ↑Short-distance gait speed 
Winters-
Stone et 
al. [242-
244]
INT, 29 
CON, 22 
INT, 70 
CON, 71 
INT, 39.0 
CON, 18.5 
52 Supervised, 2/week; PRT, ex 
targeting hip and spine, 8-15RM or 
0-15%BW, 1-2sets, 8-14reps;
impact exercise (two-footed jump
only), 10-50reps, 0-10%BW
Unsupervised, 1/week; as
supervised
↔LM, ↔FM, ↔%FM ↑Upper and lower body 
muscle strength, ↔Short-distance gait speed 
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Cormie 
et al. 
[234] 
INT, 32 
CON, 31 
INT, 70 
CON, 67 
INT, 0.2 
CON, 0.2 
12 Supervised, 2/week; AT, 20-30min, 
various ex, 70-85%HRmax; PRT, 
8ex, 1-4sets, 6-12RM 
Unsupervised, AT, 150min/week, 
moderate intensity 
↔LM, ↑ALM, ↓FM, ↓%FM, ↓TrunkFM, ↑Upper and 
lower body muscle strength, ↔Short-distance gait 
speed 
Nilsen 
et al. 
[238-240] 
INT, 28 
CON, 30 
INT, 66 
CON, 66 
INT, 9.0 
CON, 9.0 
16 Supervised, 2/week; PRT, 9ex, 1-
3sets, 6-10reps 
Unsupervised, 1/week; as 
supervised 
↔LM, ↑ALM , ↔FM, ↔%FM, ↔TrunkFM, ↑Upper 
and lower body muscle strength 
Sajid et 
al. [241] 
INT(1), 8 
INT(2), 6 
CON, 5 
INT(1), 78 
INT(2), 76 
CON, 72 
INT(1), 67.4 
INT(2), 58.7 
CON, 60.0 
6 Unsupervised, 5/week; INT(1); AT, 
60-70%HRreserve, walking, 10,000 
steps; PRT, resistance band, 1-
4sets, 8-15reps; INT(2); as mode, 
intensity and duration of 
INT(1),Wii-Fit-based  
INT(1), ↔LM, ↔Upper body muscle strength, 
↔Handgrip muscle strength 
INT(2), ↔LM, ↔Upper body muscle strength, 
↔Handgrip muscle strength 
Wall et 
al. [246]* 
INT, 50 
CON, 47 
INT, 69 
CON, 69 
INT, 2.0 
CON, 2.0 
26 Supervised, 2/week; PRT, 6ex, 6-
12RM, 2-4sets, 1-2min rest; AT, 
various, 20-30min, 70-90%HRmax 
Unsupervised, AT, 150min/week 
↑LM, ↓FM, ↓%FM, ↓TrunkFM 
* secondary analysis, ↑ P < 0.05 compared to CON; ↓ P < 0.05 compared to CON; ↔ P > 0.05 compared to CON. %1RM, percentage of one-repetition maximum; %BW, 
percentage of body weight; %FM, total body percent fat mass; %HRmax, percentage of heart rate maximum; %HRreserve, percentage of heart rate reserve; %VO2max, 
percentage of max oxygen uptake; %VO2peak, percentage of peak oxygen uptake; ADT, androgen deprivation therapy; ALM, appendicular lean mass; AT, aerobic training; 
BW, body weight; CON, control; Ex, exercises; FM, total body fat mass; GRF, ground reaction force; INT, intervention; LM, total body lean mass; Min, minutes; Mo; month, 
PRT, progressive resistance training; Reps, repetitions; RM, repetition maximum. 
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2.7.2 The role of nutritional supplementation on muscle, fat and performance 
in older men treated with androgen deprivation therapy for prostate cancer 
Given the range of treatment-induced adverse effects in men undergoing ADT, 
investigation of lifestyle interventions, such as nutritional supplementation of vitamin 
D, calcium and protein, is warranted [195]. Notably, the rationale for calcium 
supplementation, and in part vitamin D, predominantly stems from the need to address 
decreases in areal and volumetric BMD in men treated with ADT [195], and is beyond 
the scope of this thesis. The following sections will focus on the safety and potential 
efficacy of supplementation with vitamin D, calcium and protein in ADT-treated men. 
 
In men treated with ADT, vitamin D supplementation, with variations from 400-2,000 
IU, is suggested per day [247]. The Institute Of Medicine recommends that individuals 
should not exceed the tolerance upper intake limits of 2,000 mg calcium and 4,000 IU 
vitamin D per day [248]. However, The Endocrine Society contends that the tolerance 
upper limit for vitamin D in men greater than the age of 50 years at risk of deficiency, 
such as those diagnosed with PCa [249, 250], is 10,000 IU [251]. Regardless, 
supplementation under the care of medical professionals has been suggested to 
minimise the risk of adverse outcomes and medical complications associated with 
nutritional supplementation [248, 251]. Although debated, potential adverse outcomes 
associated with excess intake of calcium may include hypercalcemia, hypercalciuria, 
vascular and soft tissue calcification, nephrolithiasis, PCa, impaired iron and zinc 
metabolism and constipation [248]. Whereas, potential adverse outcomes associated 
with excess intake of vitamin D may include hypercalcemia, hypercalciuria, falls and 
fractures, PCa and all-cause mortality [248]. A recent systematic review and meta-
analysis of prospective studies reported that although increased dairy or calcium intake 
was associated with an increased risk of PCa, no association was observed with 
supplemental or non-dairy calcium, which suggest that other components of dairy 
rather than fat and calcium may increase PCa risk [252]. In line with these mixed 
findings, supplementation at doses < 1,500 mg/d have been shown to either have no 
influence on PCa progression [253], reduce PCa risk [254] or decrease PSA velocity [255]. 
In addition, in men diagnosed with PCa, total milk/dairy intake after diagnosis was not 
associated with a greater risk of lethal PCa, with evidence of a decreased risk in those 
with a high intake of low fat dairy [256]. Moreover, previous studies that examined the 
effect of combined calcium and vitamin D supplementation in men treated with ADT 
(total n=1,175; 11 studies) [257-267] have reported adverse outcomes such as constipation 
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(n=99; 8.4%) and fragility bone fracture (n=1). Of note, due to the increased risk of 
fracture in this population group, it is unlikely this outcome was caused by 
supplementation of calcium and vitamin D. Additionally, in a cohort study of 1,476 
men diagnosed with PCa, vitamin D supplementation was not associated with 
increased PCa mortality; although vitamin D deficiency was associated with increased 
all-cause mortality in this population group [268]. With regard to protein 
supplementation, although yet to be examined in men treated with ADT, increased 
protein intake is commonly shown to be well tolerated and accompanied by no serious 
adverse events in older population groups [269, 270]. Furthermore, a diet high in protein 
(≥ 20% of calories) was shown to reduce the risk of all-cause and cancer-related 
mortality in a cohort of 3,342 adults aged 66 years or greater [271].   
No previous studies have examined the role of calcium or vitamin D supplementation 
compared to no supplement on muscle outcomes in men treated with ADT. In a study 
of 24 men supplemented with 500 mg calcium and 400 IU vitamin D for one year, lean 
mass declined 0.9% [259]; however a non-supplemented control was not provided. In 
healthy older population groups, there is some evidence to suggest calcium and 
vitamin D supplementation improved muscular function across a range of fitness 
assessments [272]. To date, no studies have examined the role of protein 
supplementation on muscular health in men treated with ADT. Although one study in 
healthy older adults reported that protein supplementation alone increased lean mass 
[273]. There is also evidence in older adults without PCa that higher protein intakes (> 
1.2 g/kg) can enhance weight loss, offset muscle loss, improve lipid profiles and 
insulin sensitivity [274]. While this is not a universal finding, this could be explained by 
the modest level of protein intake achieved in some studies and/or the type (quality) 
of protein consumed. Of note, emerging evidence suggests that greater protein intake 
may be required in older adults, when compared to younger individuals, to potentially 
slow the rate of muscle loss [275-277]. This is thought to be due to the anabolic resistance 
of ageing muscle to stimuli such as amino acids and resistance exercise training [275,
277]. Given these findings in older adults, future studies are required to evaluate the 
potential role of nutritional supplementation interventions on muscle outcomes in men 
treated with ADT as there are currently no guidelines with regard to dietary or 
supplemental protein intake. 
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Although yet to be evaluated in men treated with ADT, research in older population 
groups has suggested that supplementation of calcium and vitamin D or vitamin D 
alone decreased falls and fracture risk [272, 278-280]. A meta-analysis evaluating the 
effectiveness of vitamin D supplementation in reducing fracture risk in older adults 
concluded that 400 IU per day was not sufficient to lower risk; at least 700-800 IU per 
day was required to potentially reduce fracture risk [278]. With regards to protein 
supplementation, whether the skeletal benefits observed in older adults influenced 
long-term fracture risk is unknown [281]. There is also some evidence that calcium and 
vitamin D deficiency is associated with impaired glucose metabolism and type 2 
diabetes in general population groups [282]; thus nutritional supplementation may be a 
viable option to reduce type 2 diabetes incidence. It has also been suggested that 
protein supplementation in older population groups improved insulin sensitivity [273]. 
Future studies examining the role of nutritional supplementation in men treated with 
ADT should measure cardiometabolic risk factors known to be negatively altered by 
therapy.  
 
A survey of current practice of clinicians in the diagnosis and management of 
osteoporosis indicated that 50% of Canadian urologists and radiation oncologists 
recommended calcium supplementation to men commencing ADT [283]. Similarly, 
47% recommend vitamin D supplementation [283]. A similar survey has not been 
conducted within the Australian medical system. Therefore, despite various guidelines 
[247] and suggested benefits [56, 247, 253, 284-287], men treated with ADT are not commonly 
supplemented with calcium and vitamin D and deficiencies are highly prevalent [249, 
250].  
 
2.7.3 The role of combined exercise training and nutritional supplementation 
on muscle, fat and performance in older men treated with androgen deprivation 
therapy for prostate cancer 
Given the efficacy of the previously mentioned exercise training and emerging 
evidence supporting the use of nutritional supplementation to potentially counteract 
the range of treatment-induced adverse effects in men undergoing ADT, it is therefore 
plausible that the combination of these interventions may optimise benefit in these men 
[195]. Notably, calcium and vitamin D supplementation likely play a beneficial role 
when considering exercise training that elicits bone-related adaptations, however, this 
section will focus on the potential benefits predominantly on muscle. To date, no 
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studies have examined the combination of exercise training and nutritional 
supplementation in these men; however, one study is currently being conducted [288]. 
The study is examining the role of a six month exercise training program combined 
with nutritional supplementation (1,000 mg calcium and 800 IU vitamin D per day) on 
various aspects of health influenced by ADT [288]. No results have been published from 
this trial.  
 
Emerging evidence in older adults has provided rationale for the potential use of 
protein supplementation alongside PRT in clinical populations susceptible to 
decrements in muscle mass, size and performance, such as those treated with ADT 
[289]. Although yet to be examined within this population group, a recent meta-analysis 
of randomised controlled trials conducted in healthy older adults concluded that 
protein supplementation combined with PRT may elicit further gains in muscle mass 
and size than PRT alone [289]. However, the responses appeared to vary according to 
the type, amount, spread and/or change in protein intake, timing, pattern or distribution 
of intake and the potential influence of co-ingestion with other nutrients [290]. There is 
a growing body of evidence to suggest that high quality, rapidly digested, leucine rich 
protein sources (e.g. whey protein), when compared to other types of protein 
supplementation (e.g. casein and soy), can produce additive or synergistic benefits on 
post-exercise skeletal muscle protein synthesis and promote increases in muscle mass 
and size in older adults [291]. Similarly, recent findings suggests that 20-40 g of high 
quality protein may be required to elicit maximal gains in muscle mass and size in 
older adults [292]. Moreover, the timing of protein ingestion in relation to the exercise 
training session is also important with early (within 1-4 hours) post-PRT consumption 
of protein reported to be most effective for optimising muscle protein synthesis [292, 
293]. Therefore, examining the efficacy of similar interventions is warranted in men 
treated with ADT to potentially augment the benefits from exercise training. 
 
2.8 Summary 
Worldwide, PCa is the most prevalent male cancers and in Australia accounts for the 
highest male cancer incidence and second highest male cancer-related mortality rate. 
ADT continues to be prescribed to men with both metastatic and non-metastatic PCa. 
Despite increased survival in selected patients, adverse effects of ADT include 
negative alterations to muscle, fat and performance, which commonly exceed that of 
the ageing process. However, methodological flaws in previous studies have limited 
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the ability to quantity the true effect of ADT on these outcomes, and there is a need to 
adequately control for known confounding variables (e.g. age, disease status, physical 
activity and diet). Once appropriately quantified, there is a need to consider how these 
decrements may be ameliorated. Interventions utilising exercise training have been 
shown to improve muscle, fat and performance outcomes in men treated with ADT. In 
addition, studies in non-ADT population groups that assessed nutritional 
supplementation interventions have shown benefits to these outcomes from increased 
calcium, vitamin D and protein intake. Thus, combining these two interventions may 
be more beneficial than either alone on these outcomes in this susceptible population 
group. To date, no studies have examined the role of a combined exercise training and 
nutritional supplementation intervention in men treated with ADT when compared to 
usual care. The following chapter will discuss the general methodology of the two 
studies presented within this thesis.  
 
   62 
Chapter 3 
General methods 
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3.1 Overview 
This chapter details a cross-sectional study undertaken to assess the differences in 
muscle, fat and performance outcomes between men treated with androgen deprivation 
therapy (ADT) for prostate cancer (PCa), men diagnosed with PCa treated with non-
hormonal approaches (PCa controls), and healthy controls (Chapter 4 and Chapter 5). 
This chapter also details the methodology of a 26-week randomised controlled trial 
(RCT) that examined the feasibility and efficacy of a multi-component exercise 
program combined with protein, calcium and vitamin D supplementation 
(Ex+ProCaD) compared to usual care (Chapter 6) in ADT-treated men. A published 
protocol emanating from the RCT in which the PhD candidate was the lead author is 
incorporated within this chapter (Appendix A).  
The cross-sectional study presented in Chapter 4 aimed to compare total body lean and 
fat mass, regional lean mass and muscle cross-sectional area (CSA), muscle strength 
and functional capacity in men with PCa treated with ADT when compared to non-
ADT treated PCa controls and healthy controls. Secondary aims were to compare the 
prevalence of pre-sarcopenia, sarcopenia, obesity and sarcopenic obesity across the 
three cohorts, and assess the influence of ADT use duration on all outcome measures. 
The cross-sectional study presented in Chapter 5 aimed to compare total and regional 
fat mass, fat CSA and muscle density (as a measure of intermuscular fat) in men treated 
with ADT for PCa when compared to non-ADT treated PCa men and healthy controls. 
A secondary aim was to assess the influence of ADT use duration on these outcomes. 
The RCT presented in Chapter 6 initially aimed to examine the efficacy of Ex+ProCaD 
compared to usual care in men treated with ADT for PCa. However, the continued 
delays in the recruitment of this clinical population group resulted in an extended study 
timeline beyond the scope of this thesis. Therefore, the RCT presented aimed to 
examine the feasibility of conducting the first 26-week period of the study with regard 
to recruitment, attrition, adherence, data collection and safety. A secondary aim was 
to examine descriptive data from the first 28 men who completed the interventional 
period.  
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3.2 Cross-sectional study 
3.2.1 Study design 
This was a nested cross-sectional analysis performed in parallel to the baseline of the 
RCT. A flow diagram of the study protocol is outlined in Figure 3.1. Three groups of 
men were compared in this analysis; A) men diagnosed with PCa and treated with 
ADT (referred to as ‘men treated with ADT’; participants in the RCT), B) men 
diagnosed with PCa and not treated with ADT (referred to as ‘PCa controls’), and C) 
men not diagnosed with PCa (referred to as ‘healthy controls’). The study was 
approved by the human research ethics committees at Deakin University (HREC 2013-
184) and Alfred Health (Project No: 45l5/15) and registered with the Australian and
New Zealand Clinical Trials Registry (ACTRN12614000317695). In accordance with
ethics, all participants were provided with a plain language statement and consent form
(Appendix D).
Figure 3.1. Flow diagram of the nested cross-sectional analysis that examined 
the differences between men treated with androgen deprivation therapy (ADT), 
prostate cancer (PCa) controls and healthy controls. 
3.2.2 Participants 
Eligible participants were men aged 50-85 years who met only one of the following 
criteria; A) currently treated with ADT for histologically diagnosed PCa (men treated 
with ADT), B) men diagnosed with PCa treated with non-hormonal therapy (PCa 
Cross-sectional 
studyPre-allocation
Screening
Men treated 
with ADT
PCa controls
Healthy 
controls
65 
Chapter 3 
controls), and C) men not diagnosed with PCa (healthy controls). Two age-matched 
control groups were used instead of one to account for both the potential role of PCa 
diagnosis/non-hormonal treatment and natural ageing. Participants were excluded if 
they did not have the ability to complete surveys in the English language, had any 
disorder known to affect bone, calcium or vitamin D metabolism (other than 
hypogonadism), were currently receiving pharmacological intervention known to 
affect bone metabolism (other than ADT), had supplemented with protein, calcium (> 
600 mg/day) or vitamin D (> 1,000 IU/day) in the past three months, had undertaken 
progressive resistance training (PRT; > one session/week) or regular weight-bearing 
impact exercise (> 150 min/week) in the past three months, were current smokers, had 
a weight greater than 159 kg or had any absolute contraindications to exercise training 
(e.g. musculoskeletal, cardiovascular or neurological) according to the American 
College of Sports Medicine guidelines [24]. Specific to men treated with ADT, 
treatment must have been pharmacological (surgical orchiectomy excluded) and 
administered for greater than 12 weeks at enrolment. Additionally, ADT-treated men 
who had plans to travel for greater than six weeks continuously within the following 
52 weeks were excluded. These exclusion criteria were chosen based on factors that 
may have influenced main outcomes of the RCT. 
3.2.3 Recruitment and screening 
Participants were recruited via PCa support groups and advertisements in state/local 
newspapers within Melbourne and surrounding areas in Victoria, Australia. PCa 
support groups were initially contacted via email with information regarding the study, 
with brief presentation provided to groups interested. Men treated with ADT were also 
recruited via direct referral from clinicians across various hospitals, private practices 
and health networks. The direct referral process included mass mail outs to potential 
participants and face-to-face discussions during regular consultations with 
physicians/specialists. All potential participants were screened initially via telephone 
when they made initial contact with a member of the research team to determine their 
eligibility based on the inclusion/exclusion criteria. All eligible participants were 
required to provide informed consent before participating in the study and men treated 
with ADT were required to obtain medical approval from their physician. 
66 
Chapter 3 
3.2.4 Blinding 
Due to financial limitations, there was an inability to hire additional research staff to 
ensure that the researchers involved in the study were blinded to the group allocation. 
However, dual-energy x-ray absorptiometry (DXA) and peripheral quantitative 
computed tomography (pQCT) data were analysed blinded to group allocation.  
3.2.5 Measurements 
All measures were collected in each of the three groups examined. With the exception 
of blood samples, 24-hour food recalls and questionnaires, all data was collected at 
Deakin University. Blood samples were collected at an external commercial pathology 
clinic. The 24-hour food recalls were administered via telephone. Questionnaires were 
completed by participants at home prior to the testing sessions and checked by the 
research staff during these face-to-face testing sessions.  
Body composition 
Total and regional lean and fat mass (kg) and total body percent lean and fat mass (%) 
were assessed by DXA using software version 12.30.008 and enCore CoreScan 
software version 16 (Lunar iDXA, GE Lunar Corp., Madison WI, United States of 
America). Appendicular lean mass (ALM) was calculated as arm lean mass (kg) plus 
leg lean mass (kg) [77]. ALM index (ALMI) was calculated as ALM (kg) divided by 
height (m) squared [77]. ALM adjusted for body mass index (BMI; ALMBMI) was 
calculated as ALM (kg) divided by BMI (kg/m2) [294]. ALM adjusted for height and fat 
mass (ALMHFM) was calculated using an established regression equation method [82] 
adapted to the current study sample (ALMHFM = -38.51 + 34.31 x height [m] + 0.13 x 
total body fat mass [kg]). The short-term coefficient of variation (CV) for lean and fat 
mass repeated measures ranged from 1.0-1.7% within our laboratory.  
Muscle and subcutaneous fat CSA and muscle density (as a measure of intermuscular 
fat) at the proximal (66%) radius and tibia were assessed using pQCT (XCT 3000, 
Stratec Medizintechnik GmbH, Pforzheim, Germany). Percent muscle and fat CSA 
was calculated as muscle or fat CSA (cm2) divided by total limb CSA (cm2). 
Thresholds of -40 to +40 mg/cm3 hydroxyapatite density were used for estimating 
subcutaneous fat CSA. Muscle CSA was estimated by subtracting the total bone CSA 
and subcutaneous fat CSA from the total area of the 66% tibia or radius. The following 
CVs have been reported for muscle CSA (radius, 2.1-5.3%; tibia, 2.5-3.7%), muscle 
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density (radius, 1.4-3.2%; tibia 0.7-3.2%) and subcutaneous fat CSA (radius, 2.4-
3.2%; tibia, 6.0-6.3%) for repeated measures in a sample of postmenopausal women 
[117]. 
Muscle strength 
Muscle strength was obtained via chest press (Powerline Smith Machine PSM144X, 
Body-Solid Inc., Forest Park IL, United States of America), leg press (Omni Leg Press 
S-31-OPD, Synergy Fitness, Yatala, Australia) and seated row (Adjustable Tower 
Pulley System F3ATFS, Nautilus, Independence VA, United States of America) three-
repetition maximum (3-RM) protocols [24]. The 3-RM protocols assessed the maximum 
weight that could be lifted for three repetitions whilst maintaining correct form and 
technique and were selected rather than one-repetition maximum protocols to reduce 
participant exertion. Prior to attempting these protocols, participants completed a five 
minute aerobic warm-up. Thereafter, each participant performed a warm-up set of 
eight to 10 repetitions with a light load. The participant then completed six to eight 
repetitions at a heavier weight. The load was increased incrementally until only three 
repetitions could be completed. A two to three minute recovery period was provided 
between each set. Muscle strength per kilogram body weight was calculated as muscle 
strength (kg) divided by weight (kg). The 3-RM protocol has been shown to have a 
test-retest intraclass correlation coefficient (ICC) of 0.97 in a sample of untrained men 
[295] and strongly correlates with 1-RM results [296].
Maximal muscle (grip) strength was assessed using a digital handheld dynamometer 
(Jamar Plus Digital, Lafayette Instrument Company, Lafayette IN, United States of 
America) [126]. The participant was seated with their foreman resting on the arm of 
chair whilst maintaining a 90° angle at the elbow. Participants were asked to squeeze 
the dynamometer maximally. Six trials were completed (three with each hand 
alternating) with the single highest score recorded. A CV of 6.3% was reported for 
grip strength repeated measures with the same device in a sample of advanced lung 
and gastrointestinal cancer patients [128].  
Muscle power 
Muscle power was assessed using the 30 second sit-to-stand test [130]. Participants 
began in a seated position with their arms folded across their chest on a chair without 
arms. Participants were instructed to stand fully upright and then return to a seated 
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position as many times as possible in 30 seconds. This test was performed in triplicate, 
with the best result recorded. This test was observed to have a test-retest ICC of 0.84 
in a sample of community dwelling men aged 60 years and over [130]. 
Functional capacity 
Functional capacity was assessed using the timed-up-and-go with cognitive task, four-
square step test, Berg balance scale, four metre usual walk and 400 metre walk. The 
four-square step test and four metre usual walk were performed in triplicate, with the 
best result recorded. All other tests were performed once to avoid accumulative 
fatigue.    
The timed-up-and-go with cognitive task measured dynamic balance and dual-tasking 
[297]. Participants were seated in a chair (height, 45 cm) that was placed at the end of a 
three metre walkway. Once instructed to begin, the participant was instructed to stand 
up, walk at a regular pace for three metres, turn, walk back to the chair and sit down. 
During this task, the participant was provided with a mental arithmetic task (e.g. 
counting backwards from 100 by 3’s from a random number). A stopwatch was used 
to record the time taken (to the nearest millisecond) to complete this test. This test was 
observed to have an interrater ICC of 0.99 [133]. 
The four-square step test measured dynamic balance and stepping speed in four 
directions [134]. Participants were instructed to step forward, sideways, and backwards 
over four canes resting flat on the floor in a cross formation in a clockwise sequence 
and then back in an anticlockwise sequence. The participant was instructed to complete 
the test as fast as possible without touching the raised canes, and to face forward during 
the entire sequence. They were also instructed to ensure that both feet make contact 
with the floor in each square. The time (to the nearest millisecond) taken to complete 
the sequence was measured with a stopwatch. This test has been observed to have an 
interrater and test-retest ICC of 0.99 and 0.98 respectively in a sample of community 
dwelling adults aged 65 years and over [134].  
The Berg balance scale measured overall balance with both dynamic and static 
components [136]. The test rated participants on 14 different tasks on an ordinal scale 
ranging from zero (unable to perform the task) to four (performs the task 
independently). Assessments included variations of sitting, standing, reaching, 
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leaning, turning and stepping. The scores of the 14 tasks were summed to produce a 
total score ranging from 0-56 points. Higher scores indicated better performance. This 
test was observed to have an interrater and test-retest ICC of 0.98 and 0.97 respectively 
in a sample of adults aged 65 years and over [136].  
The four metre usual walk measured gait speed [137]. Participants were instructed to 
walk at a usual pace between two cones eight metres apart (two metre acceleration 
zone, four metre timed zone and two metre deceleration zone). Time was recorded 
when the participant’s front foot entered the timed zone and stopped when their front 
foot exited the timed zone. The time (to the nearest millisecond) to complete the timed 
zone was recorded with a stopwatch. This method had an ICC of 0.96 within our 
laboratory. 
The 400 metre walk test provided an estimate of mobility and cardiorespiratory fitness 
[298]. Participants were instructed to walk as fast as possible between two cones placed 
20 metres apart (turning when they approach each cone). The time (to the nearest 
millisecond) taken to complete 10 laps (400 metres) was recorded. This test was 
observed to have a test-retest ICC of 0.95 in a sample of middle-aged women [299]. 
Pre-sarcopenia, sarcopenia, obesity and sarcopenic obesity 
Pre-sarcopenia was defined as low ALM alone based on established criteria derived 
from previous studies (Table 3.1). Sarcopenia was defined as presenting with both low 
ALM and compromised muscle strength (handgrip strength) or functional capacity 
(gait speed) based on established definitions by the European Working Group on 
Sarcopenia in Older People (EWGSOP), Foundation for the National Institutes of 
Health (FNIH) and International Working Group on Sarcopenia (IWGS; Table 3.1). 
Severe sarcopenia was defined using the EWGSOP definition: low ALM, 
compromised muscle strength (handgrip strength) and functional capacity (gait speed), 
concurrently. Obesity was defined as BMI ≥ 30 kg/m2 [99] or total body percent fat mass 
≥ 30% [100], with the latter commonly deemed a more appropriate indicator of obesity 
when compared to BMI [101]. There are no consensus definitions for sarcopenic obesity, 
thus sarcopenic obesity was defined as concurrent sarcopenia (EWGSOP) and obesity 
(total body percent fat mass ≥ 30%) and pre-sarcopenic obesity was defined as 
concurrent pre-sarcopenia (ALMI ≤ 7.26 kg/m2 or ALMI ≤ 7.49 kg/m2) and obesity 
(total body percent fat mass ≥ 30%). Measures of ALMI were chosen over ALMBMI 
and ALMHFM due to the latter measures already incorporating an adiposity component. 
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Table 3.1. Definitions of pre-sarcopenia and sarcopenia and relevant cut-points for 
each criteria proposed for men. 
Method Lean mass Muscle strength and Gait Speed 
Pre-
sarcopenia 
IWGS [52] ALMI ≤ 7.23 kg/m2 - 
EWGSOP [53] ALMI ≤ 7.26 kg/m2 - 
IWGS/EWGSOP* ALMI ≤ 7.49 kg/m2 - 
Residual* [82] ALMHFM residual ≤ -1.63 -
FNIH [51] ALMBMI ≤ 0.789 kg/kg/m2  - 
Sarcopenia 
FNIH [51] ALMBMI ≤ 0.789 kg/kg/m2 Handgrip strength < 26 kg 
EWGSOP [53] ALMI ≤ 7.26 kg/m2 
Handgrip strength < 30 kg or gait 
speed < 0.8 m/s 
IWGS [52] ALMI ≤ 7.23 kg/m2 Gait speed < 1.0 m/s 
* adapted for current study sample. ALMBMI, Appendicular lean mass adjusted for body mass index;
ALMHFM, Appendicular lean mass adjusted for height and fat mass; ALMI, Appendicular lean mass
index; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the
National Institutes of Health; IWGS, International Working Group on Sarcopenia.
Anthropometry 
Height and body mass were assessed using a portable stadiometer and scales 
respectively. BMI was calculated as weight (kg) divided by height (m) squared. 
Habitual physical activity 
The Community Healthy Activities Model Program for Seniors physical activity 
questionnaire was used to assess participation in a comprehensive list of low, moderate 
and vigorous physical activities [300]. Participants documented the frequency and 
duration of their participation in a ‘typical week’ of the preceding four weeks.  
Diet 
Diet was assessed using a 24-hour food recall performed during a one on one interview 
via telephone following the face-to-face testing session. Prior to the phone interview, 
the participant completed a 24-hour food diary with instructions that were discussed 
at the testing session. These instructions included how to use household measures (e.g. 
measuring cups, plates, bowls and glasses) to help estimate food portion sizes.  In 
addition, a standard script was used during the phone interview to maximise the ability 
of participants to recall what was consumed. Dietary analysis was performed using 
Australia-specific dietary analysis software (FoodWorks, Xyris software, Highgate 
Hills, Australia). 
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Questionnaires 
A demographic, clinical and lifestyle questionnaire was used to obtain background 
information from participants (e.g. age, ethnicity, non-hormonal PCa treatment and 
ADT use details). Past and current medical conditions and use of prescription 
medication (type and dose) was also included in the questionnaire (Appendix E).  
3.2.6 Sample size calculation 
Sample size calculations were based on the limited research examining differences in 
total body lean mass [22, 237], handgrip strength [27], gait speed [32] and total body percent 
fat mass [237] in men treated with ADT when compared to PCa or healthy controls. The 
mean (assumed standard deviation, based on pooled weighted average [301]) differences 
in total body lean mass, handgrip strength, gait speed and total body percent fat mass 
were -4.0 kg (5.6 kg), -11.2 kg (5.9 kg), -0.18 m/s (0.60 m/s) and +5.4% (6.4%), 
respectively. To detect differences of these magnitudes in total body lean mass, 
handgrip strength, gait speed and total body percent fat mass, 35, 6, 25 and 23 men in 
each group provided 80% power (P < 0.05, two-tailed), respectively.  
3.2.7 Statistical analysis 
All analyses were performed using SPSS 24.0 (IBM Corp, Chicago IL, United States 
of America). Initially, all data were screened for outliers and descriptive statistics were 
computed to compare the three groups on known confounding variables of the primary 
outcomes. Equality of variances of all data were assessed using Levene’s test. 
Normality of distribution of all data were assessed using Shapiro-Wilk’s test. Data in 
violation of equality of variance or normal distribution underwent natural log (arm 
lean mass, ALMBMI, four-square step test, arm fat mass, leg fat mass, forearm fat CSA, 
forearm percent fat CSA, lower leg fat CSA, lower leg percent fat CSA, forearm 
muscle density and lower leg muscle density) or square root (total body fat mass, 
android fat mass, gynoid fat mass and abdominal visceral fat mass) transformation 
prior to all analyses, but all data presented were derived from raw values. Between-
group comparisons were assessed by analyses of covariance (ANCOVA), with age 
(years) and physical activity (energy expenditure; kilojoules/day) as covariates. The 
Kruskal-Wallis test was used for data that remained non-parametric following 
transformation (chest muscle strength relative to weight, back muscle strength relative 
to weight, timed-up-and-go, 30-second sit-to-stand, gait speed, abdominal 
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subcutaneous fat mass). Post-hoc analyses applied the Bonferroni correction, with the 
addition of Mann-Whitney tests following non-parametric analyses. In the men treated 
with ADT only, the strength and direction of associations between duration of ADT 
use and all outcomes were assessed by Spearman rank-order correlation coefficient. 
Continuous data were reported as mean ± standard deviation, whereas categorical 
variables were reported as frequency and percentage, unless stated otherwise. A 
significance level of P < 0.05 was adopted for all statistical tests.  
3.3 Randomised controlled trial [IMPACT study] 
3.3.1 Study design 
The study presented within this thesis examined the effects of a 26-week single-
blinded, two-arm RCT consisting of a supervised and structured multi-component 
exercise program in combination with a daily nutritional supplement on muscle, fat 
and performance outcomes (Figure 3.2). Notably, this study was part of a larger 52-
week RCT, however, ongoing recruitment issues and the subsequent extensions of 
study duration to ensure statistical power was attained for main outcomes (DXA and 
pQCT assessed bone health; see Appendix A) resulted in recruitment being extended 
until the intended sample size is achieved; thus, final data collection is beyond the 
timeframe of candidature. Additionally, within- and between-group statistics were not 
presented as: 1) trial results may change with follow-up of the complete cohort of 
participants; 2) the reporting of preliminary results may introduce biases that 
jeopardise the eventual outcomes; and 3) the lack of adequate statistical power may 
increase the probably of a type II error [302]. Men with PCa treated with ADT were 
randomised to either Ex+ProCaD or a usual care control group (who also received 
vitamin D). Men allocated to usual care did not receive a placebo drink as typical 
ingredients used to develop a placebo drink (e.g. maltodextrin as a food additive) have 
the potential to alter blood glucose levels and muscle mass. A factorial 2x2 trial was 
not conducted for several reasons: 1) the large sample size that would be required to 
detect an interaction, and 2) findings from previous research in older adults which 
indicates that the benefits of exercise training on musculoskeletal health require 
adequate nutrition (e.g. dietary calcium > 1000 mg/day) [303]. This study did not 
evaluate whether the combination of protein, calcium and vitamin D with exercise 
training was more effective than either of these treatments alone, but determined if 
combining the two approaches was effective for improving multiple health outcomes. 
This trial was undertaken within the Institute for Physical Activity and Nutrition at 
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Deakin University. The study was approved by the human research ethic committees 
at Deakin University (HREC 2013-184) and Alfred Health (Project No: 455/15) and 
was registered with the Australian and New Zealand Clinical Trials Registry 
(ACTRN12614000317695). In accordance with ethics, all participants were provided 
with a plain language statement and consent form (Appendix D). 
Figure 3.2. Prospective Consolidated Standards of Reporting Trials (CONSORT) 
diagram of the 26-week RCT presented within this thesis (adapted from Owen et al. 
[304]; Appendix A). 
3.3.2 Participants 
Eligible participants were men treated with ADT, as outlined in Section 3.2.2. 
3.3.3 Recruitment and screening 
Eligible participants were recruited and screened as outlined in Section 3.2.3. 
Assessed for eligibility 
Excluded 
• Failed telephone screening
• Not meeting inclusion criteria
26 week assessment 
Allocated to exercise training and 
nutritional supplementation 
26 week assessment 
Allocated to usual care 
control group 
Follow-Up 
Randomized 
Enrollment 
Analysis (intention-to-treat) 
Lost to follow-up / reasons 
 
Analysis (intention-to-treat) 
Lost to follow-up / reasons 
Analysis 
Analysis 
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3.3.4 Randomisation and blinding 
Randomisation was at the level of the individual participant following baseline testing, 
stratified by age (< 65 or ≥ 65 years) and BMI (< 30 or ≥ 30 kg/m2), using a computer-
generated random number sequence by an independent researcher not affiliated with 
the study. Furthermore, sealed opaque envelopes were utilised to ensure allocation 
concealment. Due to the nature of the intervention (i.e. exercise training and nutritional 
supplementation) and the inability to hire additional research staff due to financial 
limitations, neither the participants nor researchers involved in the study were blinded 
to the group allocation, with the exception of the DXA and pQCT scans which were 
assessed independently. 
3.3.5 Intervention group 
Multi-component exercise program 
The 26-week exercise program consisted of two gym-based sessions and one home-
based session per week. The two gym-based sessions were supervised by an 
Accredited Exercise Physiologist (tertiary trained exercise professional) in a 
community-based health and fitness facility. All intervention group participants were 
provided with a yearly membership at a community-based health and fitness centre 
and had the opportunity to complete their home-based sessions in this setting at their 
own discretion. 
The exercise training program was a multi-component program that followed key 
training principles of specificity and progressive overload and was individually 
tailored to the participant’s health and functional status. The program followed similar 
exercise prescription guidelines in terms of the structure, type and dose (frequency, 
sets, repetitions, intensity) of training to the previous ‘Osteo-cise: Strong Bones for 
Life’ community-based osteoporosis prevention exercise program in healthy older 
adults in which significant improvements were observed in musculoskeletal health and 
function (Table 3.2) [305-307]. To ensure progressive overload and promote a sense of 
achievement for the men, the 52-week program was divided into five mesocycles 
(training phases). The first mesocycle (four weeks; adoption phase) focussed on 
orientation to the exercise program, with an emphasis on correct technique. The four 
subsequent 12-weekly mesocycles focussed on progression through three 4-weekly 
microcycles (preparatory phase, challenge phase and consolidation phase). Each gym-
based session (approximately 60 minutes) consisted of a warm-up and cool-down and 
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a combination of aerobic training, PRT, weight-bearing impact activities and 
challenging balance/functional exercises. More specific details about each training 
component are provided below. Notably, the 26-week interventional period ended 
towards the end of the third mesocycle during the consolidation period.  
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Table 3.2. Structure of the exercise program and training doses for the 52-week randomised controlled trial. 
Phase Aerobic training Progressive resistance training Weight-bearing impact 
training 
Functional and core 
stabilisation training 
Microcycle Week Mesocycle Duration %HRMAX Sets Reps RPE1 Speed2 Rest Sets Reps Intensity3 Sets Duration/reps 
#1 1-4 Orientation 15-25 min 55-75% 2 12-15 3-4 Slow 1-2 min 3 10-20 Low 2 Balance exercises, 30-
60 seconds or until 
fatigue; Core 
stabilisation exercises, 
10-15 reps or up to 50
for abdominal based
exercises 
#2 
5-8 Preparatory 15-25 min 60-75% 2 10-15 3-4 Slow 1-2 min 3 10-20
Low to 
moderate 
2 
9-12 Challenge 15-25 min 60-75% 2 8-12 5-8 Rapid 2 min 3 10-20 2 
13-16 Consolidation 15-25 min 60-75% 2 8-12 5-8 Rapid 2 min 3 10-20 2 
#3 
17-20 Preparatory 15-25 min 60-75% 2 10-15 3-4 Slow 1-2 min 3 10-20
Moderate 
2 
21-24 Challenge 15-25 min 60-75% 2 8-12 5-8 Rapid 2 min 3 10-20 2 
25-26 Consolidation 15-25 min 60-75% 2 8-12 5-8 Rapid 2 min 3 10-20 2 
Initially adapted from Gianoudis et al. [305]. 1 RPE: Rating of perceived exertion (1-10); 2 Speed: slow (2-3 sec concentric and 2-3 sec eccentric contractions), rapid (rapid 
concentric and 2-3 sec eccentric contractions); 3 Intensity: low (ground reaction force [GRF] ~ 1-3 x body weight), moderate (GRF ~ 3-6 x body weight), high (GRF ~ 6-9 x 
body weight) (adapted from Owen et al. [304]; Appendix A) 
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Aerobic training 
For the aerobic exercise, participants were prescribed 15-25 minutes of continuous 
aerobic training at 55-75% of predicted heart rate maximum via modalities such as 
stationary cycling, treadmill walking or rowing. The type of aerobic exercise 
prescribed were based on each participant’s preference and functional capabilities. 
Progressive resistance training 
For PRT, participants were prescribed 5-6 targeted hip, spine and forearm resistance 
exercises using machine and free weights (two sets of 12–15 reps at moderate intensity 
[3-4 on the 10-point rating of perceived exertion (RPE) scale] for each exercise for the 
first 4-8 weeks, progressing to two sets of 8–12 reps at moderate to hard intensity [4-
6 on the RPE scale] thereafter; resistance was increased as tolerated to maintain 
intensity and ensure progressive overload). During the first mesocycle, five resistance 
exercises were available to choose from for each training session (leg press, bench 
press, one hip targeted, one spine targeted and one upper body exercise). New 
resistance exercises were introduced at the start of each subsequent mesocycle (three 
hip targeted, three spine targeted and one upper body targeted). Varying combination 
of the nine resistance exercises in each of these mesocycles were prescribed each 
session. After the initial eight weeks of training, participants were progressively taught 
to perform the concentric (lifting) phase of all lower body exercises at high velocity. 
This was designed to improve movement speed and muscle power. When possible, 
participants performed resistance exercises standing with the aim to also improve 
balance and physical function. 
Weight-bearing impact exercise 
For the weight-bearing impact-loading exercises, participants were prescribed three 
exercises (interspersed amongst the PRT exercises) consisting of three sets of 10-20 
repetitions that utilised body weight as the primary load. The program focused on 
lower limb exercises designed to load the hips. The exercises prescribed were based 
on a battery that was previously shown to be safe and effective for improving femoral 
neck and lumbar spine areal bone mineral density in older men [305]. This battery 
included a range of exercises from low to high intensity (magnitude of peak ground 
reaction forces) and difficulty (easy, moderate, hard) and is divided into three broad 
categories: stationary movements (e.g. marching on spot, mini-tuck jumps), 
forward/backwards movements (e.g. forward bench step-ups, drop jumps) and lateral 
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movements (e.g. side-to-side jumping). Training intensity was increased progressively 
by increasing the height of jumps, by adding additional weight, increasing the rate of 
impact loading or multi-directional movement patterns (e.g. diagonal loads). 
Challenging balance/functional exercise 
Challenging balance and functional exercises included a range of static and dynamic 
exercises, including fit ball exercises (e.g. sitting on fit-ball with knee extension), 
standing balance activities (e.g. single leg standing) and dynamic functional tasks (e.g. 
heel-to-toe walking). Participants were prescribed two exercises per session and asked 
to complete two sets of 30-60 seconds or for a given number of repetitions. To ensure 
progression, participants were prescribed a new exercise or advanced to a more 
challenging level (e.g. closing eyes, reducing base of support, confounding visual 
fixation, changing centre of mass or adding a second manual or cognitive task) once 
they have mastered the previous exercise (e.g. it is no longer challenging). 
Core stabilisation exercise 
Key muscle groups known to help maintain good posture, improve pelvic floor 
function and trunk stability (e.g. rotator cuff, scapular stabilisers, transverse 
abdominis, pelvic floor muscles) were targeted with these exercises, which are 
important for balance and muscular performance [308]. Participants were prescribed two 
exercises per session with light to moderate resistance in two sets of 10-15 repetitions. 
Of note, abdominal-based exercises were prescribed in two sets of up to 50 repetitions. 
Home-based exercise program 
The home-based exercise program consisted of similar types of exercise to the gym-
based sessions, but body weight and resistive tubing (provided to participants) were 
used for resistance exercises. This provided participants with knowledge and 
experience of ways to exercise relatively inexpensively in a home-based setting 
following the completion of the study. The home-based program was explained and 
demonstrated to the participants during the initial gym-based sessions and instructions 
were provided. Three resistance exercises, three weight-bearing impact-loading 
exercises and three functional exercises following the same training principles as gym-
based sessions were prescribed for each home-based session. The home-based 
program was progressed and new exercises were introduced once the previous 
exercises were no longer challenging for the participant.   
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Nutritional supplement 
The nutritional supplement consisted of a daily whey-protein, calcium and vitamin D 
enriched drink (powder) combined with a single vitamin D tablet. Participants were 
provided with a 26-week supply of powder in single use sachets and tablets. Each 
sachet was mixed with 150 ml of water and shaken vigorously in a ‘shake-and-take’ 
container (provided to participant). Each sachet of powder contained approximately 
25 g of whey protein concentrate 80% (WPC80; containing approximately 2.4 g of 
leucine), 1,200 mg calcium carbonate (approximately 480 mg elemental calcium) and 
1,000 IU vitamin D (Omniblend, Campbellfield, Australia). The vitamin D tablet 
contained 1,000 IU (Ostelin, Macquarie Park, Australia). On the non-training days, 
participants were asked to take one sachet every morning before breakfast. This was 
designed to try and ensure a more even protein intake throughout the day which has 
been reported to optimise muscle protein balance [309]. On exercise training days, 
participants were encouraged to consume the sachet within 1-2 hours of completing 
their exercise session as early post-exercise consumption of protein has been shown to 
promote an increase in muscle protein synthesis and muscle hypertrophy in older 
adults [293, 310].  
3.3.6 Usual care control group 
Participants allocated to usual care received ongoing care from their 
physician/specialist but did not receive additional education or access to exercise 
training or the protein, calcium and vitamin D enriched nutritional supplement powder 
sachet. Due to current practice guidelines [247] and a pilot study conducted in 31 men 
undergoing ADT for PCa in which 65% reported taking vitamin D supplementation 
(90% at least 1,000 IU/day), all men randomised to usual care received 1,000 IU 
vitamin D per day.  
3.3.7 Measurements 
All measures were collected at baseline and 26 weeks. All participants underwent all 
measures expect those specific to treatment allocation (i.e. compliance to the 
intervention). A summary of the outcome measures are shown in Table 3.3 and 
outlined in Section 3.2.5. Additional measurements specific to the RCT included 
prostate specific antigen, compliance and adverse events.   
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Table 3.3. Summary of data collection. 
Variable Data collection method 
Data collection points 
Baseline 26 weeks 
Outcome measures 
 Body composition DXA total body and regional lean and fat mass x x 
pQCT 66% radius and tibia subcutaneous fat and muscle cross-sectional area and muscle density x x 
 Muscle strength One-repetition maximum chest press, leg press and seated row x x 
Handgrip strength x x 
 Muscle power 30 second sit-to-stand x x 
 Functional capacity Timed-up-and-go with cognitive task x x 
Four-square step test x x 
Berg balance scale x x 
Four metre usual walk x x 
400 metre walk x x 
 Blood Overnight, fasted prostate specific antigen x x 
 Additional measures 
 Anthropometry Height, weight, body mass index x x 
 Habitual physical activity Community Healthy Activities Model Program for Seniors physical activity questionnaire x x 
 Diet 24-hour food recalls x x 
 Questionnaires Demographic questionnaire x - 
Clinical, medical and lifestyle questionnaire x x 
 Exercise program adherence Calculated from monthly calendars Collected every 4 weeks 
 Supplement compliance Calculated from supplement returned - x
 Adverse events Calculated from monthly calendars Collected every 4 weeks 
DXA, dual-energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography. 
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Prostate specific antigen 
Fasted, resting morning blood samples were collected at a commercial pathology clinic 
and sent to a central laboratory accredited by the National Association of Testing 
Authorities Royal College of Pathologists Australasia. Total prostate specific antigen 
(free and complexed) was assessed via immunoassay (Roche Diagnostics, Mannheim, 
Germany). 
Compliance 
Compliance with the exercise training program (i.e. attendance at each training 
session) and nutritional supplement (i.e. consumption) was assessed via attendance 
record and self-reported diaries, respectively. Diaries were monitored weekly and 
calendars were monitored monthly by the participant’s Accredited Exercise 
Physiologist and researchers. In addition to the calendars, compliance with the sachets 
and vitamin D tablets were checked by counting all returned at the 26 week testing 
session.   
Adverse events 
Any adverse events potentially associated or confirmed to be associated with the 
exercise program or protein, calcium and vitamin D supplementation was recorded by 
the exercise trainers at each exercise training sessions for the intervention group 
participants and monthly phone calls by the research staff to the control group 
participants. For this trial, an adverse event consisted of any health-related 
unfavourable or unintended medical occurrence (e.g. sign, symptom, syndrome or 
illness) that developed or worsens during the trial. All adverse events were assessed 
for seriousness, causality and expected outcome by the researchers and followed 
during the trial. Although there was no formal data monitoring committee, all data was 
reviewed at regular intervals throughout the study and researchers involved in 
recruitment, testing and implementing the trial updated the research team monthly 
about the study progress.  
Feasibility 
Feasibility outcomes are presented in Table 3.4. 
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Table 3.4. Feasibility outcomes examined in the randomised controlled trial. 
Outcome Measures 
Recruitment Enrolled participants compared to total screened potential participants 
Reasons for ineligibility or declined participation  
Enrolment timeline 
Efficacy of recruitment pathways 
Attrition Participants available for follow-up 
Reasons for loss to follow-up 
Adherence Supervised, home-based and total exercise training sessions completed 
Sachet supplement consumed  
Vitamin D tablet supplement consumed (both groups) 
Data collection Collected data compared to missing data 
Safety Number, severity and relatedness to the study of adverse events 
Prostate specific antigen 
3.3.8 Sample size calculation 
The larger 52-week RCT was statistically powered to observe changes in the primary 
outcomes (DXA and pQCT-derived measures of bone health), as well as various other 
outcomes known to be negatively influenced by ADT and potentially ameliorated by 
exercise training and nutritional supplementation interventions (Appendix A). Overall, 
it was estimated that a sample size of 51 men per group (102 in total) would be 
required, which accounted for a conservative 30% attrition rate.  
3.3.9 Statistical analysis 
All data were collated using STATA statistical software (STATA, College Station TX, 
United States of America). After data were screened for outliers, descriptive statistics 
were computed. Where possible, endpoint measures were obtained from any 
participant lost to follow-up and all randomised subjects that had completed 26-week 
follow-up by the time of data analysis for this chapter were included in descriptive 
statistics. Baseline measures and changes in outcome variables were computed as 
means ± standard deviation or 95% confidence intervals. Net differences were 
calculated by subtracting within-group changes for the control group from within-
group changes for the intervention group. 
3.4 Summary 
The studies presented in this thesis include a cross-sectional analysis between men 
treated with ADT, PCa controls and healthy controls and a 26-week RCT that 
examined the feasibility and efficacy of Ex+ProCaD compared to usual care in men 
treated with ADT for PCa. Notable strengths of these studies included the use of valid 
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and reliable measurement tools (e.g. DXA and Jamar handheld dynamometer), 
accounting for a range of potential confounding variables (e.g. physical activity, diet, 
ageing and PCa diagnosis) and the assessment of novel outcomes within this clinical 
population group (e.g. forearm and lower leg muscle and fat CSA via pQCT). The 
following chapters will present the results of the cross-sectional study (Chapter 4 and 
Chapter 5) and 26-week RCT (Chapter 6). 
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The effects of androgen deprivation therapy in men with prostate 
cancer on sarcopenia and its determinants and sarcopenic obesity: 
results from a cross-sectional study 
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4.1 Declaration statement 
Under the guidance of supervisors, the candidate developed the study concept and 
initiated the project, provided significant input into the development of the protocol, 
implemented the protocol and oversaw the collection of the data, analysed and 
interpreted all data presented.   
4.2 Overview 
This chapter presents the results from a cross-sectional study. The study examined 
whether there were any differences in total body lean and fat mass, regional lean mass 
and muscle cross-sectional area (CSA), muscle strength and functional capacity in men 
treated with androgen deprivation therapy (ADT) when compared to prostate cancer 
(PCa) and healthy controls. Moreover, this chapter presents between-group 
comparisons of the prevalence of pre-sarcopenia, sarcopenia, obesity and sarcopenic 
obesity, as well as within-group correlations between ADT use duration and muscle, 
fat and performance outcomes in men treated with ADT.  
4.3 Introduction 
PCa is one of the most commonly diagnosed male cancers both worldwide and in 
Australia [1, 2]. Besides the notable contribution to male cancer-related deaths [1], the 
diagnosis and treatment of PCa may predispose men to a range of adverse health 
outcomes. One specific treatment, ADT, is often accompanied by prospective 
decrements in lean mass and muscle CSA [15-21], increased fat mass [17-23] and reduced 
muscle strength and functional capacity [25-34]. While rates of compromise vary 
between trials, in part due to factors such as ADT duration and patient age, men treated 
with ADT tend to lose 2.0-3.6% lean mass and gain 11% fat mass per year [195]. 
Moreover, measures of muscle strength, such as via handgrip dynamometry, may 
decrease 5.0-11% per year in these men [25, 28, 29]. However, the true extent to which 
these outcomes may be compromised in these men in comparison to non-ADT treated 
individuals is unclear due largely to methodological inconsistencies in previous 
studies, including a lack of appropriate control group(s), differences in the 
measurements used to quantify muscle, fat and performance and the inability to 
account for different potential confounding variables such as diet and physical activity 
[15-23, 25-34, 36-38]. Similarly, region-specific alterations to lean mass and muscle CSA are 
poorly understood [17-23]; thus limiting the ability to quantify the risk of further 
complications associated with these changes (e.g. falls risk). Furthermore, since these 
86 
Chapter 4 
outcomes may be affected by other factors present in men treated with ADT, including 
increased age [63] and the diagnosis and non-hormonal treatment of PCa [74, 186], it is 
important to consider these known covariates by including appropriate control 
comparison groups when attempting to quantify the effects of ADT on body 
composition and performance. Once these individual factors are appropriately 
quantified, the application of known syndromes, such as sarcopenia, may allow for 
enhanced risk assessment in this susceptible population group. 
Sarcopenia was initially measured as the loss of muscle (lean) mass associated with 
ageing [80], but now includes measures of muscle strength and functional capacity, most 
commonly assessed via handgrip strength and gait speed, respectively [51, 53]. 
Subsequently, low muscle (lean) mass alone is now considered pre-sarcopenia. 
Worldwide, the prevalence of sarcopenia assessed using dual-energy x-ray 
absorptiometry (DXA) is approximately 8.0% in older men [158]. However, there is 
currently debate surrounding the clinical cut-offs for diagnosing sarcopenia, and thus 
there is no consensus definition. Notable definitions include those proposed by the 
European Working Group on Sarcopenia in Older People (EWGSOP; low 
appendicular lean mass [ALM] adjusted for height [ALMI] and low handgrip strength 
or slow gait speed) [53], Foundation for the National Institutes of Health (FNIH; low 
ALM adjusted for body mass index [BMI; ALMBMI] and low handgrip strength) [51] 
and International Working Group on Sarcopenia (IWGS; low ALMI and slow gait 
speed) [52]. Moreover, these conditions may be concurrent with obesity, thus deeming 
an individual to have sarcopenic obesity [54, 55]. While the definition of this syndrome 
remains in its infancy, its application may assist in quantifying the accumulative risks 
of ADT in this susceptible population group given the aforementioned concurrent 
effects on muscle and fat. To date, men diagnosed with these syndromes have been 
shown to be at greater risk of falls [81, 88, 89], fractures [48, 88, 90], functional impairment 
[88, 91-94] and mortality [88, 91, 95, 96]. Although, no studies have investigated the 
prevalence of sarcopenia or sarcopenic obesity in men with PCa treated with ADT. 
The aim of this study was to compare total body lean and fat mass, regional lean mass 
and muscle CSA, muscle strength and functional capacity in men with PCa treated 
with ADT when compared to non-ADT treated PCa controls and healthy controls. 
Secondary aims were to compare the prevalence of pre-sarcopenia, sarcopenia, obesity 
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and sarcopenic obesity across the three cohorts, and assess the influence of ADT use 
duration on all outcome measures.  
4.4 Methods 
Details on the methodology of this study are discussed in Chapter 3. Briefly, this was 
a cross-sectional study in which comparisons were made between 42 men treated with 
ADT for PCa, 54 men treated with non-hormonal therapies (men currently treated with 
active surveillance were eligible for inclusion in this group) for PCa (PCa controls) 
and 70 men not diagnosed with PCa (healthy controls). Men treated with ADT were 
recruited via clinician referral from Alfred Health (Melbourne, Australia) and six 
private practices (all within Victoria, Australia), as well as from 32 PCa support groups 
and advertisements in state/local newspapers. PCa and healthy controls were recruited 
from PCa support groups and advertisements in state/local newspapers. 
Height and weight were assessed using standard techniques. BMI was calculated as 
weight (kg) divided by height (m) squared. Habitual physical activity and diet were 
assessed by self-reported questionnaire and 24-hour food recall, respectively. 
Demographical, clinical and lifestyle information was assessed by questionnaire.  
Total body and regional lean mass and total body fat mass and percentage fat mass 
were assessed by DXA. ALM was calculated as arm lean mass (kg) plus leg lean mass 
(kg) [77]. ALMI was calculated as ALM (kg) divided by height (m) squared [77]. ALM 
adjusted for height and fat mass (ALMHFM) was calculated using an established 
regression equation method [82] adapted to the current study sample (ALMHFM = -38.51 
+ 34.31 x height [m] + 0.13 x total body fat mass [kg]). ALMBMI was calculated as
ALM (kg) divided by BMI (kg/m2) [294]. Muscle and limb CSA of the forearm (66%
radius) and lower leg (66% tibia) was assessed by peripheral quantitative computed
tomography (pQCT) [311, 312]. Percent muscle CSA was calculated as muscle CSA
(cm2) divided by total limb CSA (cm2). Muscle strength was assessed by various three-
repetition maximum (3-RM) protocols and handgrip dynamometry. Muscle strength
per kilogram body weight was calculated as muscle strength (kg) divided by weight
(kg). Functional capacity was assessed by a battery of common valid and reliable tests:
30-second sit-to-stand (a measure of lower limb muscle performance), timed-up-and-
go with a secondary cognitive task (a measure of dual-task gait speed), four-square
step test (a measure of dynamic mobility), Berg balance scale (a measure of static and
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dynamic balance), four metre usual walk (a measure of gait speed) and 400 metre walk 
(a measure of mobility limitations). Missing data among the three groups is presented 
in Table 4.1.  
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Table 4.1. Missing data in the three groups. 
Added after study 
began Unable to define ROI Movement artefact * 
Pre-existing 
comorbidities Total 
Measure ADT PC HC ADT PC HC ADT PC HC ADT PC HC ADT PC HC 
Dietary intake 8 0 0 - - - - - - - - - 8 0 0 
DXA total body scan - - - 1 0 0 - - - - - - 1 0 0 
pQCT forearm - - - 1 0 0 5 6 8 - - - 6 6 8 
pQCT lower leg - - - 0 0 0 2 4 2 - - - 2 4 2 
Handgrip muscle strength 6 0 0 - - - - - - 1 0 0 7 0 0 
Chest muscle strength - - - - - - - - - 9 15 18 9 15 18 
Leg muscle strength - - - - - - - - - 6 13 14 6 13 14 
Back muscle strength 6 0 0 - - - - - - 7 14 15 13 14 15 
30-second sit-to-stand - - - - - - - - - 0 0 1 0 0 1 
Gait speed 6 0 0 - - - - - - 0 0 0 6 0 0 
400 metre walk - - - - - - - - - 1 1 1 1 1 1 
Berg balance scale - - - - - - - - - 1 0 0 1 0 0 
Data are: number of participants with missing data. ADT, men treated with androgen deprivation for prostate cancer; DXA, dual energy x-ray absorptiometry; HC, healthy 
control; PC, prostate cancer control; pQCT, peripheral quantitative computed tomography; ROI, region of interest. * Excluded based on scores of four or five on the visual 
inspection rating scale of participant movement proposed by Blew et al. [311]. 
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Pre-sarcopenia was defined as low ALM alone based on established criteria derived 
from previous studies (Table 4.2). Sarcopenia was defined as presenting with both 
low ALM and compromised muscle strength (handgrip strength) or functional 
capacity (gait speed) based on established definitions by EWGSOP, FNIH and 
IWGS (Table 4.2). Severe sarcopenia was defined using the EWGSOP definition: 
low ALM, compromised muscle strength (handgrip strength) and functional capacity 
(gait speed), concurrently. Obesity was defined as BMI ≥ 30 kg/m2 [99] or total body 
percent fat mass ≥ 30% [100], with the latter commonly deemed a more appropriate 
indicator of obesity when compared to BMI [101]. There are no consensus definitions 
for sarcopenic obesity, thus sarcopenic obesity was defined as concurrent sarcopenia 
(EWGSOP) and obesity (total body percent fat mass ≥ 30%) and pre-sarcopenic 
obesity was defined as concurrent pre-sarcopenia (ALMI ≤ 7.26 kg/m2 or ALMI ≤ 
7.49 kg/m2) and obesity (total body percent fat mass ≥ 30%). Measures of ALMI 
were chosen over ALMBMI and ALMHFM due to the latter measures already 
incorporating an adiposity component.
Table 4.2. Definitions of pre-sarcopenia and sarcopenia and relevant cut-points for 
each criteria proposed for men in the study. 
Method Lean mass Muscle strength and Gait Speed 
Pre-
sarcopenia 
IWGS [52] ALMI ≤ 7.23 kg/m2 - 
EWGSOP [53] ALMI ≤ 7.26 kg/m2 - 
IWGS/EWGSOP* ALMI ≤ 7.49 kg/m2 - 
Residual* [82] ALMHFM residual ≤ -1.63 -
FNIH [51] ALMBMI ≤ 0.789 kg/kg/m2  - 
Sarcopenia 
FNIH [51] ALMBMI ≤ 0.789 kg/kg/m2 Handgrip strength < 26 kg 
EWGSOP [53] ALMI ≤ 7.26 kg/m2 
Handgrip strength < 30 kg or gait 
speed < 0.8 m/s 
IWGS [52] ALMI ≤ 7.23 kg/m2 Gait speed < 1.0 m/s 
* adapted for current study sample. ALMBMI, Appendicular lean mass adjusted for body mass index;
ALMHFM, Appendicular lean mass adjusted for height and fat mass; ALMI, Appendicular lean mass
index; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the
National Institutes of Health; IWGS, International Working Group on Sarcopenia.
Based on previous research, this study was powered (≥ 80%, P < 0.05, two-tailed) to 
detect the following between-group differences between men treated with ADT and 
healthy controls (hypothesised to demonstrate the largest differences between groups): 
total body lean mass (mean ± standard deviation; -4.0 kg ± 5.6 kg) [237], total body 
percent fat mass (5.4% ± 6.4%) [237], handgrip strength (-11.2 kg ± 5.9 kg) [27] and gait 
speed (-0.18 m/s ± 0.60 m/s) [32]. 
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All analyses were performed using SPSS 24.0 (IBM Corp, Chicago IL, United States 
of America). Initially, all data were screened for outliers and descriptive statistics were 
computed to compare the three groups on known confounding variables of the primary 
outcomes. Equality of variances of all data were assessed using Levene’s test. 
Normality of distribution of all data were assessed using Shapiro-Wilk’s test. Data in 
violation of equality of variance or normal distribution underwent natural log (arm 
lean mass, ALMBMI, four-square step test) or square root (total body fat mass) 
transformation prior to all analyses, but all data presented were derived from raw 
values. Between-group comparisons were assessed by analyses of covariance 
(ANCOVA), with age (years) and physical activity (energy expenditure; 
kilojoules/day) as covariates. The Kruskal-Wallis test was used for data that remained 
non-parametric following transformation (chest muscle strength relative to weight, 
back muscle strength relative to weight, timed-up-and-go, 30-second sit-to-stand, gait 
speed). Post-hoc analyses applied the Bonferroni correction, with the addition of 
Mann-Whitney tests following non-parametric analyses. In the men treated with ADT 
only, the strength and direction of associations between duration of ADT use and all 
outcomes were assessed by Spearman rank-order correlation coefficient. Continuous 
data were reported as mean ± standard deviation, whereas categorical variables were 
reported as frequency and percentage, unless stated otherwise. A significance level of 
P < 0.05 was adopted for all statistical tests.  
4.5 Results 
4.5.1 Participant characteristics 
Participant characteristics of the three groups are shown in Table 4.3. On average, men 
treated with ADT were approximately four years older than PCa and healthy controls 
(P=0.002). Men treated with ADT taking additional prescription medication were on 
average prescribed one more form of medication than PCa and healthy controls 
(P=0.024), despite no significant difference in the presence or total number of 
comorbidities. When compared to PCa controls only, men treated with ADT were 
more likely to have had advanced PCa and previously undergone radiotherapy or 
chemotherapy, but not prostatectomy. No other significant differences were observed 
between the groups, but men treated with ADT reported a 30% and 23% lower level 
of habitual physical activity (energy expenditure) compared to PCa and healthy 
controls, respectively (P=0.054).     
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Table 4.3. Participant characteristics of men with prostate cancer (PCa) treated with 
androgen deprivation therapy (ADT), PCa controls and healthy controls. 
Men 
treated 
with ADT 
PCa 
controls 
Healthy 
controls P-value
n 42 54 70 - 
Age (years) 73 ± 6 69 ± 7 69 ± 7 0.002 
Height (cm) 174.2 ± 6.7 176.3 ± 7.1 175.7 ± 6.5 0.324 
Weight (kg) 86.5 ± 18.0 82.8 ± 13.4 85.5 ± 12.6 0.413 
Body mass index (BMI; kg/m2) 28.4 ± 5.0 26.6 ± 3.9 27.6 ± 3.3 0.094 
Highest level of education, n (%) 
  Primary or some high school 4 (9.5) 3 (5.6) 8 (11.4) 
0.146 
  Completed high school 8 (19.0) 3 (5.6) 7 (10.0) 
  Technical/trade certificate 7 (16.7) 17 (31.5) 12 (17.1) 
  University or tertiary level 23 (54.8) 31 (57.4) 43 (61.4) 
Current work status, n (%) 
  Full-time 3 (7.1) 10 (18.5) 10 (14.3) 
0.426   Part-time 5 (11.9) 9 (16.7) 13 (18.6) 
  Retired 34 (81.0) 35 (64.8) 47 (67.1) 
Ethnicity, n (%) 
  Caucasian 40 (95.2) 53 (98.1) 65 (92.9) 
0.238   Asian 1 (2.4) 1 (1.9) 5 (7.1) 
  African 1 (2.4) 0 (0.0) 0 (0.0) 
Comorbidities*, n (%) 39 (92.9) 43 (79.6) 61 (87.1) 0.168 
  If yes, total (n) 3 ± 1 2 ± 1 2 ± 1 0.334 
Prescription medication, n (%) 33 (78.6) 36 (66.7) 45 (64.3) 0.267 
  If yes, total (n) 4 ± 2 3 ± 2 3 ± 2 0.024 
Energy expenditure (kJ/d) 2400 ±1481 3245 ± 
1940 
3016 ± 
1678 
0.054 
Time since PCa diagnosis 
(months) 91 ± 81 72 ± 58 - 0.177
a
Stage of PCa, n (%) 
  Localised/removed 15 (35.7) 46 (85.2) - 
< 0.001a  Advanced 24 (57.1) 6 (11.1) -
  Unknown 3 (7.1) 2 (3.7) - 
Duration of ADT (months) 34 ± 45 - - - 
Previous prostatectomy 20 (47.6) 37 (68.5) - 0.039a
Previous radiotherapy 30 (71.4) 12 (22.2) - < 0.001a
Previous chemotherapy 6 (14.3) 0 (0.0) - 0.004a
Current active surveillance - 8 (14.8) - - 
Data are: mean ± standard deviation unless stated otherwise. * comorbidities included 
asthma/respiratory problems, chronic bronchitis, muscle/ligament problems, back pain, 
angina/stroke/heart condition, diabetes, hypertension and hypercholesteromaemia; a men treated with 
ADT versus PCa controls only. 
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4.5.2 Dietary intake 
Dietary intakes for the three groups are reported in Table 4.4. No significant 
differences were observed between groups for any outcomes. Using current consensus 
criteria in terms of the recommended dietary protein intake for older adults [313], the 
proportion of men with a protein intake ≤ 1.2 g/kg/d was similar between men treated 
with ADT (48%), PCa controls (48%) and healthy controls (60%). Similarly, when a 
protein intake of ≤ 1.0 g/kg/d was considered, there were no differences between the 
groups (men treated with ADT, 31%; PCa controls, 33%; healthy controls, 27%).   
Table 4.4. Mean daily dietary intakes of men with prostate cancer (PCa) treated with 
androgen deprivation therapy (ADT), PCa controls and healthy controls. 
Men 
treated 
with ADT 
PCa 
controls 
Healthy 
controls 
P-value
n 34 54 70 - 
Energy (kJ/d) 
8661 ± 
1779 8211 ± 2196 8571 ± 2354 0.563 
Protein (g/d) 96 ± 26 102 ± 34 99 ± 31 0.750 
Protein (g/kg/d) 1.12 ± 0.31 1.26 ± 0.44 1.18 ± 0.38 0.256 
Protein (% of energy/d) 19 ± 5 21 ± 6 20 ± 4 0.069 
Carbohydrate (g/d) 227 ± 70 201 ± 68 218 ± 66 0.170 
Carbohydrate (% of energy/d) 43 ± 10 40 ± 10 42 ± 9 0.352 
Fat (g/d) 74 ± 32 75 ± 32 73 ± 29 0.881 
Fat (% of energy/d) 31 ± 10 33 ± 11 31 ± 7 0.250 
Saturated fat (g/d) 28 ± 12 26 ± 12 29 ± 13 0.388 
Saturated fat (% of energy/d) 12 ± 5 11 ± 4 12 ±4 0.397 
Calcium (mg/d) 846 ± 324 757 ± 361 879 ± 340 0.146 
Data are: mean ± standard deviation. 
4.5.3 Body composition  
Lean mass and muscle cross-sectional area 
There were no significant differences between the groups for total body or regional 
lean mass, ALMI, forearm or lower leg muscle CSA or lower leg percent muscle CSA 
(Table 4.5). In contrast, there was significant between-group differences for total body 
percent lean mass, ALMBMI and forearm percent muscle CSA (Table 4.5). Post-hoc 
analyses showed that men treated with ADT had 12% and 10% lower ALMBMI when 
compared to PCa (P=0.008) and healthy controls (P=0.018), respectively (Figure 4.1). 
Similarly, forearm percent muscle CSA was 6.4% and 5.6% lower in men treated with 
ADT compared to PCa (P < 0.001) and healthy controls (P < 0.001), respectively. Total 
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body percent lean mass was also 4.6% lower than PCa controls (P=0.006), but not 
healthy controls (P=0.099).  
Figure 4.1. Unadjusted mean percentage differences for appendicular lean 
mass (ALM) and ALM adjusted for body mass index (ALMBMI) between men with 
prostate cancer (PCa) treated with androgen deprivation therapy (ADT), PCa controls 
(PCON) and healthy controls (HCON); *, P < 0.05; #, P < 0.01. 
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Table 4.5. Mean total body and regional lean mass, muscle cross-sectional area and total body fat mass in men with prostate cancer (PCa) treated 
with androgen deprivation therapy (ADT), PCa controls and healthy controls, and the mean difference between the three groups. 
Unadjusted mean ± standard derivation Adjusted mean difference (95% CI) 
Men treated 
with ADT 
PCa 
controls 
Healthy 
controls 
P-value Men treated with ADT
vs PCa controls 
Men treated with ADT 
vs healthy controls 
PCa controls vs 
healthy controls 
Lean mass 
  Total body (kg) 52.5 ± 6.9 54.9 ± 6.2 55.5 ± 6.4 0.532 -0.3 (-3.5, 2.9) -1.2 (-4.2, 1.8) -1.0 (-3.6, 1.7)
  Total body (%) 62.4 ± 7.4 67.0 ± 6.0 65.5 ± 5.5 0.008 -4.2 (-7.4, -1.0) # -2.7 (-5.7, 0.3) 1.5 (-1.2, 4.2) 
  Arm (kg)a 6.0 ± 1.1 6.7 ± 0.9 6.8 ± 1.0 0.060 -0.2 (-0.7, 0.3) -0.3 (-0.8, 0.2) -0.2 (-0.6, 0.3)
  Leg (kg) 17.8 ± 2.7 18.7 ± 2.7 19.1 ± 2.6 0.365 0.0 (-1.3, 1.3) -0.6 (-1.8, 0.7) -0.6 (-1.7, 0.5)
  Appendicular (kg) 23.9 ± 3.8 25.3 ± 3.5 25.9 ± 3.5 0.276 -0.3 (-2.0, 1.5) -1.0 (-2.6, 0.7) -0.7 (-2.2, 0.7)
  ALMI (kg/m2) 7.86 ± 0.96 8.14 ± 0.84 8.36 ± 0.78 0.105 -0.02 (-0.45, 0.40) -0.29 (-0.68, 0.11) -0.26 (-0.61, 0.09)
  ALMBMIa 0.859 ± 0.127 0.966 ± 0.131 0.948 ± 0.118 0.006 -0.077 (-0.140, -0.014) # -0.063 (-0.124, -0.003) * 0.014 (-0.039, 0.067)
Muscle cross-sectional area 
  Forearm (cm2) 38.4 ± 5.8 41.4 ± 5.2 42.2 ± 6.0 0.073 -1.6 (-4.5, 1.4) -2.7 (-5.5, -0.1) -1.1 (-3.6, 1.4)
  Forearm (%) 67.1 ± 7.1 73.4 ± 4.5 72.7 ± 4.8 < 0.001 -6.1 (-9.1, -3.1) # -5.4 (-8.2, -2.5) # 0.8 (-1.7, 3.2) 
  Lower leg (cm2) 72.7 ± 12.7 73.5 ± 9.4 76.4 ± 12.1 0.180 3.1 (-2.6, 8.9) -0.5 (-5.8, 4.9) -3.6 (-8.4, 1.2)
  Lower leg (%) 73.5 ± 8.0 76.1 ±7.0 77.2 ± 6.3 0.097 -2.0 (-5.8, 1.8) -3.2 (-6.7, 0.3) -1.2 (-4.4, 2.0)
Fat mass 
  Total body (kg)b 29.4 ± 10.7 24.4 ± 8.5 26.1 ± 7.5 0.019 5.8 (1.1, 10.4) * 3.9 (-0.4, 8.2) -1.9 (-5.7, 2.0)
  Total body (%) 34.8 ± 7.8 30.0 ± 6.4 31.5 ± 5.4 0.006 4.5 (1.1, 7.9) # 3.1 (-0.1, 6.3) -1.4 (-4.2, 1.4)
Data are: unadjusted raw mean ± standard deviation and age- and physical activity-adjusted raw mean difference (95% confidence interval). * P < 0.05; # P < 0.01; a analysis 
used natural log transformed data; b analysis used square root transformed data. ALM, appendicular lean mass; ALMBMI, appendicular lean mass adjusted for body mass index; 
ALMHFM, residual of appendicular lean mass adjusted for height and fat mass; ALMI, appendicular lean mass index. 
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Fat mass 
There was a significant between-group difference for total body fat mass and total 
body percent fat mass (Table 4.5). Subsequent analyses revealed that men treated with 
ADT had 5.0 kg greater total body fat mass when compared to PCa controls (P=0.015), 
but not healthy controls (P=0.190), and 4.8% greater total body percent fat mass when 
compared to PCa controls (P=0.005), but not healthy controls (P=0.061).  
4.5.4 Muscle strength 
A between-group difference was observed for absolute leg (leg press) and back (seated 
row) muscle strength, but not chest (chest press) or handgrip (handheld dynamometer) 
muscle strength (Table 4.6). Further analyses revealed that men treated with ADT did 
not differ from either control group in leg or back muscle strength, but PCa controls 
had 7.6% less back muscle strength when compared to healthy controls (P=0.040; 
Figure 4.2). When muscle strength was expressed per kilogram body weight, all four 
measures of muscle strength differed between groups (P < 0.05, all). Compared to PCa 
controls, men treated with ADT had 15% and 13% lower weight-adjusted back 
(P=0.001) and chest muscle strength (P=0.006), respectively (Figure 4.2). Similarly, 
men treated with ADT had 21%, 18% and 13% lower weight-adjusted leg (P=0.046), 
back (P < 0.001) and chest muscle strength (P=0.003), respectively, when compared 
to healthy controls (Figure 4.2). Trends were also observed for weight-adjusted 
handgrip strength when men treated with ADT were compared to PCa (P=0.054) and 
healthy controls (P=0.051). Moreover, when muscle strength was expressed per 
kilogram lean mass, a between group difference was observed for back muscle strength 
only (P=0.003). Men treated with ADT had 12% lower muscle-adjusted back muscle 
strength compared to healthy controls (P=0.001), but not PCa controls (P=0.065). No 
other significant differences were observed between groups for muscle strength 
outcomes.  
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Table 4.6. Mean muscle strength and functional capacity outcomes in men with prostate cancer (PCa) treated with androgen deprivation therapy 
(ADT), PCa controls and healthy controls, and the mean differences between the three groups. 
Unadjusted mean ± standard derivation Adjusted mean difference (95% CI) 
Men treated 
with ADT 
PCa 
controls 
Healthy 
controls 
P-value Men treated with ADT
vs PCa controls 
Men treated with ADT 
vs healthy controls 
PCa controls vs 
healthy controls 
Muscle strength 
  Handgrip (kg) 38.0 ± 7.3 41.9 ± 6.6 43.3 ± 8.0 0.058 -1.8 (-5.6, 2.0) -3.5 (-7.1, 0.1) -1.7 (-4.7, 1.4)
  Handgrip/weight (kg/kg) 0.45 ± 0.12 0.52 ± 0.10 0.51 ± 0.09 0.034 -0.06 (-0.11, 0.00) -0.05 (-0.11, 0.00) 0.00 (-0.04, 0.05) 
 Chest (kg) 38.0 ± 10.0 40.3 ± 6.6 42.6 ± 11.2 0.172 1.6 (--3.7, 6.9) -1.9 (-6.7, 3.0) -3.5 (-8.0, 1.0)
  Chest/weight (kg/kg)b 0.45 ± 0.10 0.51 ± 0.11 0.51 ± 0.12 0.005 -0.05 (-0.11, 0.02) # -0.05 (-0.11, 0.01) # 0.00 (-0.06, 0.06) 
  Leg (kg) 131.4 ± 49.9 143.5 ± 41.5 160.2 ± 49.5 0.045 5.6 (-19.9, 31.1) -15.7 (-39.1, 7.6) -21.3 (-43.1, 0.4)
  Leg/weight (kg/kg) 1.53 ± 0.51 1.80 ± 0.48 1.88 ± 0.51 0.050 -0.15 (-0.43, 0.14) -0.27 (-0.53, 0.00) * -0.12 (-0.36, 0.12)
  Back (kg) 48.6 ± 12.5 52.1 ± 9.4 56.2 ±11.2 0.027 0.8 (-5.3, 7.0) -4.4 (-10.1, 1.3) -5.2 (-10.2, -0.2) *
  Back/weight (kg/kg)b 0.56 ± 0.11 0.65 ± 0.10 0.67 ± 0.10 < 0.001 -0.07 (-0.13, 0.00) # -0.09 (-0.15, -0.03) # -0.02 (-0.07, 0.03)
Functional capacity 
  Timed-up-and-go (sec)b 11.02 ± 4.02 11.61 ± 4.52 11.49 ± 4.97 0.517 -1.68 (-3.98, 0.62) -1.45 (-3.62, 0.71) 0.23 (-1.70, 2.15) 
  Four-square step test (sec)a 10.05 ± 2.21 9.04 ± 1.84 9.03 ± 2.05 0.281 0.53 (-0.47, 1.53) 0.58 (-0.36, 1.51) 0.05 (-0.79, 0.88) 
30-second sit-to-stand (n)b 13 ± 5 15 ± 4 15 ± 4 0.017 0 (-2, 2) -1 (-3, 1) # -1 (-3, 1)
  Gait speed (m/s)b 1.40 ± 0.18 1.48 ± 0.19 1.50 ± 0.22 0.039 -0.05 (-0.15, 0.06) * -0.07 (-0.17, 0.03) * -0.02 (-0.11, 0.06)
  400 metre walk (sec) 286 ± 38 275 ± 32 265 ± 42 0.142 0 (-19, 19) 11 (-6, 29) 11 (-4, 27) 
  Berg balance scale (n) 55 ± 2 55 ± 2 55 ± 1 0.460 0 (-1, 1) 0 (-1, 0) 0 (0, 1) 
Data are: unadjusted raw mean ± standard deviation and age- and physical activity-adjusted raw mean difference (95% confidence interval). * P < 0.05; # P < 0.01; a analysis 
used natural log transformed data; b Kruskal-Wallis test used for non-parametric data. 3-RM, three-repetition maximum. 
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Figure 4.2. Unadjusted mean percentage differences for handgrip, chest, leg and back 
muscle strength (black) and weight-adjusted handgrip, chest, leg and back muscle 
strength (white) between men with prostate cancer (PCa) treated with androgen 
deprivation therapy (ADT), PCa controls (PCON) and healthy controls (HCON); * P 
< 0.05; # P < 0.01. 
4.4.5 Functional capacity 
Gait speed and 30-second sit-to-stand were found to differ between groups (Table 4.6). 
Men treated with ADT had 14% lower 30-second sit-to-stand performance when 
compared to healthy controls (P=0.006), but not PCa controls (P=0.054), and 5.6% 
and 6.9% slower gait speed when compared to PCa (P=0.023) and healthy controls 
(P=0.021), respectively. No further significant between-group differences were 
observed for functional capacity outcomes.  
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4.5.5 Sarcopenia and obesity 
Pre-sarcopenia 
The prevalence of pre-sarcopenia differed between groups when assessed by ALMHFM 
residual (≤ -1.63) and ALMBMI (Table 4.7; Figure 4.3). Further statistical analysis 
showed that men treated with ADT had a greater prevalence of pre-sarcopenia as per 
FNIH (27-34%) and residual (7.2-10%) methods when compared to PCa and healthy 
controls. No other significant differences were observed for pre-sarcopenia prevalence 
between groups. 
Figure 4.3. Prevalence (percentage) of pre-sarcopenia (black) and non-sarcopenia 
(white) according to the different definitions in men with prostate cancer (PCa) treated 
with androgen deprivation therapy (ADT), PCa controls and healthy controls; * P < 
0.05 when compared to PCa controls; # P < 0.05 when compared to healthy controls; 
EWGSOP, European Working Group on Sarcopenia in Older People; FM%, total body 
percent fat mass; FNIH, Foundation for the National Institutes of Health; IWGS, 
International Working Group on Sarcopenia. 
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Table 4.7. Group prevalence and between-group differences in pre-sarcopenia, sarcopenia and obesity in men with prostate cancer (PCa) treated 
with androgen deprivation therapy (ADT), PCa controls and healthy controls. 
P-values
Men treated 
with ADT 
PCa 
controls 
Healthy 
controls P-value
Men treated 
with ADT vs 
PCa controls 
Men treated 
with ADT vs 
healthy controls 
PCa controls vs 
healthy controls 
Pre-sarcopenia, n (%) 
  ALMI, ≤ 7.26 kg/m2 (EWGSOP) 8 (19.5) 6 (11.1) 6 (8.6) 0.225 0.253 0.094 0.635 
  ALMI, ≤ 7.23 kg/m2 (IWGS) 8 (19.5) 6 (11.1) 6 (8.6) 0.225 0.253 0.094 0.635 
  ALMI, ≤ 7.49 kg/m2 (IWGS/EWGSOP*) 12 (29.3) 12 (22.2) 10 (14.3) 0.159 0.434 0.056 0.251 
  ALMBMI, < 0.789 (FNIH) 17 (41.5) 8 (14.8) 5 (7.1) < 0.001 0.003 < 0.001 0.167 
  ALMHFM, ≤ -1.63 (residual*) 15 (36.6) 9 (26.5) 10 (29.4) 0.013 0.027 0.007 0.715 
Sarcopenia, n (%) 
  EWGSOP 2 (5.9) 1 (1.9) 1 (1.4) 0.369 0.310 0.203 0.853 
  Handgrip strength < 30 kg 6 (17.1) 2 (3.7) 2 (2.9) 0.011 0.030 0.009 0.791 
  Gait speed < 0.8 m/s 1 (2.8) 0 (0.0) 0 (0.0) 0.177 0.218 0.161 - 
  IWGS 0 (0.0) 0 (0.0) 0 (0.0) - - - - 
  Gait speed < 1.0 m/s 1 (2.8) 0 (0.0) 0 (0.0) 0.177 0.218 0.161 - 
  FNIH 2 (5.7) 0 (0.0) 0 (0.0) 0.028 0.076 0.043 - 
  Handgrip strength < 26 kg 2 (5.7) 0 (0.0) 1 (1.4) 0.143 0.076 0.214 0.378 
Obesity, n (%) 
  BMI, ≥ 30 kg/m2 11 (26.2) 9 (16.7) 15 (21.4) 0.523 0.254 0.563 0.506 
  FM%, ≥ 30% 30 (73.2) 26 (48.1) 46 (65.7) 0.031 0.014 0.414 0.049 
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Pre-sarcopenia and obesity, n (%) 
  ALMI, ≤ 7.26 kg/m2 and FM%, ≥ 30% 6 (14.6) 1 (1.9) 3 (4.3) 0.025 0.018 0.054 0.447 
  ALMI, ≤ 7.49 kg/m2and FM%, ≥ 30% 7 (17.1) 5 (9.3) 7 (10.0) 0.434 0.256 0.279 0.890 
Data are: number of cases (percentage). * adapted for current study sample. ALMBMI, appendicular lean mass adjusted for body mass index; ALMHFM, residual of appendicular 
lean mass adjusted for height and fat mass; ALMI, appendicular lean mass index; BMI, body mass index; EWGSOP, European Working Group on Sarcopenia in Older People; 
FM%, total body percent fat mass; FNIH, Foundation for the National Institutes of Health; IWGS, International Working Group on Sarcopenia. 
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Muscle weakness and functional impairment 
The prevalence of muscle weakness, as defined by handgrip strength < 30 kg, differed 
between groups and specifically between men treated with ADT and PCa controls 
(17% vs 3.7%) and healthy controls (17% vs 2.9%). No significant differences were 
noted for muscle weakness defined as < 26 kg; with only three cases observed overall 
(n=2, men treated with ADT; n=1, healthy controls). Functional impairment 
prevalence, as defined by gait speed < 1.0 m/s or < 0.8 m/s, did not differ between 
groups (P=0.177, both), and was only detected for one participant overall regardless 
of the cut-off applied (n=1, men treated with ADT). 
Sarcopenia 
Overall two participants were classified having sarcopenia according to the FNIH 
definition, both of which were men treated with ADT (Table 4.7). When using the 
EWGSOP definition, two men treated with ADT, one PCa control and one healthy 
control were classified as having sarcopenia. When the IWGS definition of sarcopenia 
was applied, no cases were observed. Similarly, there were no cases of severe 
sarcopenia as per the EWGSOP definition.  
Obesity 
A between-group difference was observed for obesity as defined by total body percent 
fat mass ≥ 30% (Table 4.7), with a higher prevalence observed in men treated with 
ADT (73%) compared to PCa controls (48%), but not healthy controls (66%). Healthy 
controls also had a higher prevalence of obesity when compared to PCa controls. No 
significant between group differences were observed for obesity as defined by BMI. 
Sarcopenic obesity 
No men were classified as having sarcopenic obesity. However, concurrent pre-
sarcopenia (ALMI, ≤ 7.26 kg/m2) and obesity (total body percent fat mass, ≥ 30%) 
differed among groups. Subsequent analyses showed that men treated with ADT had 
a higher prevalence of concurrent pre-sarcopenic and obesity (14%) when compared 
to PCa controls (1.9%), but not healthy controls (4.3%). These differences were not 
observed when using the ALMI cut-off of ≤ 7.49 kg/m2 to define pre-sarcopenia. 
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4.5.6 Duration of androgen deprivation therapy use 
On average, men treated with ADT had undergone hormonal treatment for 34 months 
(standard deviation, 45 months). Duration of ADT use negatively correlated with 
forearm (rs=-0.43) and lower leg (rs=-0.38) percent muscle CSA (Table 4.8). On 
average, there were losses of approximately 0.1% of total limb muscle CSA per month 
of ADT use at both sites (Figure 4.4). No other variables were found to correlate 
significantly with duration of ADT use. 
Figure 4.4. Scatterplot of the relationship between duration of androgen deprivation 
therapy (ADT) and lower leg and forearm percent muscle cross-sectional area (CSA) 
in men treated with ADT. 
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Table 4.8. Spearman’s rho correlations (and P-values) between androgen deprivation 
therapy (ADT) use duration and body composition, muscle strength and functional 
capacity outcomes in men with prostate cancer treated with ADT. 
Measure ADT duration (month), Spearman’s rho correlations 
Lean mass 
  Total body (kg) 0.11 P=0.506 
  Total body (%) -0.24 P=0.138 
  Arm (kg) 0.06 P=0.728 
  Leg (kg) 0.11 P=0.499 
  Appendicular (kg) 0.10 P=0.536 
  ALMI (kg/m2) 0.20 P=0.208 
  ALMBMI (kg/kg/m2) -0.23 P=0.144 
Muscle cross-sectional area 
  Forearm (cm2) -0.08 P=0.654 
  Forearm (%) -0.43 P=0.005 
  Lower leg (cm2) -0.02 P=0.914 
  Lower leg (%) -0.38 P=0.022 
Fat mass 
  Total body (kg) 0.23 P=0.151 
  Total body (%) 0.23 P=0.147 
Muscle strength 
  Handgrip (kg) -0.01 P=0.947 
  Handgrip/weight (kg/kg) -0.14 P=0.389 
  Chest (kg) 0.24 P=0.172 
  Chest/weight (kg/kg) 0.28 P=0.875 
  Leg (kg) 0.03 P=0.849 
  Leg/weight (kg/kg) -0.02 P=0.892 
  Back (kg) 0.14 P=0.464 
  Back/weight (kg/kg) 0.04 P=0.845 
Functional capacity 
  Timed-up-and-go (sec) -0.24 P=0.132 
  Four-square step test (sec) -0.27 P=0.087 
30-second sit-to-stand (n) 0.09 P=0.550 
  Gait speed (m/s) 0.12 P=0.467 
  400 metre walk (sec) -0.01 P=0.925 
  Berg balance scale (n) -0.05 P=0.760 
ALMBMI, appendicular lean mass adjusted for body mass index; ALMI, appendicular lean mass index. 
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4.6 Discussion 
To our knowledge, this is the first study to evaluate the effects of ADT on the 
prevalence of sarcopenia or sarcopenic obesity and its components simultaneously 
within a sample of older men treated with ADT for PCa in comparison to men with 
PCa not receiving ADT and healthy controls. The main findings from this study were 
that absolute total body and regional lean mass and muscle CSA were no different 
between the three groups, but after adjusting for differences in adiposity, men treated 
with ADT had 10-12% lower ALM and 5.6-6.4% lower forearm muscle CSA 
compared to PCa and healthy controls. Similarly, absolute leg, back and chest muscle 
strength were comparable between the groups, but when expressed relative to body 
weight, men treated with ADT had 13-21% lower muscle strength relative to PCa and 
healthy controls. Gait speed was also impaired in men treated with ADT when the 
three groups were compared. Subsequently, there was a greater prevalence of pre-
sarcopenia and sarcopenia in men treated with ADT compared to both controls when 
definitions that consider adiposity-adjusted ALM were applied (i.e. ALMBMI and 
ALMHFM), but not those that adjust ALM for height alone (i.e. ALMI). Collectively, 
these findings suggest that it is important to account for adiposity when comparing 
muscle-based outcomes in men treated ADT to PCa controls and healthy controls.   
Effects of androgen deprivation therapy on total body and regional lean mass 
To our knowledge, only two previous studies have quantified differences in absolute 
total body lean mass between men treated with ADT and both healthy and PCa controls 
concurrently [314, 315]. Basaria et al. [314] observed no significant difference in absolute 
total body lean mass in 20 men (mean age, 70 years) treated with ADT when compared 
to age-matched healthy (n=18) and PCa controls (n=20). In contrast, absolute total 
body lean mass was 3.7 kg and 3.8 kg lower in 67 men treated with chronic ADT (> 
six months; mean age, 71 years) when compared to healthy (mean age, 63 years) and 
PCa controls (mean age, 67), respectively [315]. However, these findings should be 
interpreted with caution given the 4-8 year discrepancy in age between groups and the 
lack of control for this confounding variable in the analyses [315]. In our study, we 
observed that absolute total body lean mass was 2.4-3.0 kg lower in men treated with 
ADT compared to both controls, but these differences were not significant. 
Nevertheless, given that lower amounts of lean mass are associated with a myriad of 
adverse outcomes, including compromised cardiometabolic risk, an increased risk for 
osteoporosis and related fractures, mobility limitations and mortality [45, 46, 48, 93], these 
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differences are likely to be clinically meaningful. Indeed, losses of lean mass that 
classify patients as pre-sarcopenic or sarcopenic (using various established cut-offs) 
have been associated with poorer outcomes in cancer patients, such as those associated 
with mortality, disease progression, treatment-related complications and patient-
reported outcomes [316].  
A unique component of our study was that we investigated the effects of ADT on 
absolute regional lean mass (arm, leg and appendicular) in men treated with ADT and 
both PCa and healthy controls. Consistent with the findings for absolute total body 
lean mass, we found no significant differences in absolute arm, leg or ALM, although 
the latter was 1.4-2.0 kg lower in men treated with ADT when compared to both 
controls. These findings are partially supported by the only other known cross-
sectional study that examined differences in absolute regional lean mass between 48 
men treated with ADT (mean age, 70 years) and 70 age-matched healthy controls [33]. 
In this study, there were no differences between groups for either arm, leg or ALM, 
although ADT-treated men had a 0.8 kg lower ALM. [33] Of note, this study did not 
include a PCa control group, hence the diagnosis and/or non-hormonal treatment of 
PCa in these men may have influenced these findings. Moreover, robust measures of 
diet and physical activity were not controlled for in the analyses. Thus, it is possible 
that the approximate two-fold greater differences in absolute ALM we observed were 
more likely to reflect the true effects of ADT in these men when compared to controls. 
The lack of any significant differences between the three groups in our study may 
relate in part to the marked heterogeneity in terms of the duration of ADT use (3-169 
months) among treated men, with 31% of our sample treated for less than nine months. 
Previous research has indicated that duration of ADT appears to be important when 
considering lean mass, with losses of up to 2.6-3.2% of total body lean mass occurring 
within the initial 6-9 months of treatment  [195]. Given that around one-third of men in 
our study had not received ADT for this duration when assessed for this study, it is 
possible that we may have underestimated the true effects of chronic ADT (≥ six 
months) on total body and regional lean mass. However, it is worth noting that we 
observed no association between ADT duration and total body or regional lean mass 
in our study. This association has received limited attention when considering ADT 
duration as a continuous variable, however, when dichotomised, men treated with 
acute (< six months) ADT trended towards greater losses in lean mass (3.7% vs 2.0%) 
when compared to men undergoing chronic (≥ six months) ADT over a three year 
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period [12]. Additionally, a 52-week prospective study of 80 men observed that men 
treated with acute ADT (mean age, 69 years) demonstrated a loss of 3.5% total body 
lean mass, whereas men treated with chronic ADT (mean age, 71 years) showed no 
change [18]. Collectively these findings suggest that while the loss of absolute lean mass 
may be greater after the initial onset of hypogonadism, these losses may eventually 
decelerate or plateau. Identifying the time-point in which these decelerations or 
plateaus may occur could lead to advancements in clinical decision making with regard 
to the long term management of PCa with ADT.  
The accumulation of total body adiposity during ADT, compared to that of normal 
ageing, is well established in men with PCa [195]. For instance, previous cross-sectional 
studies have shown that total body fat mass is greater in men treated with ADT when 
compared to non-treated PCa men (mean difference, 3.9 kg [315]) and healthy controls 
(mean difference, 5.7-5.8 kg [315, 317]). Similarly, total body percent fat mass has been 
reported as 3.9-6.0% [32, 314, 315, 318] and 2.9-9.8% [32, 33, 314, 315, 317, 318] greater in ADT-
treated men when compared to PCa and healthy controls, respectively. In line with 
these findings, we found that men treated with ADT had greater total body fat mass 
compared to PCa control (5.0 kg and 4.8%) and tended to have greater fat mass than 
healthy controls (3.3 kg and 3.3%). Interestingly, in a sample of 1,129 healthy older 
men (mean age, 74 years), Koster et al. [319] observed that leg lean mass was 1.3 kg 
greater per standard deviation increment (7.0 kg) of total body fat mass, suggesting 
that men with greater adiposity have increased lean mass [319]. Consistent with these 
findings, there is evidence from one cross-sectional study that showed obese older men 
(mean BMI, 31.9 kg/m2; mean age, 66 years) have 18%, 26% and 14% higher absolute 
lean mass in the trunk, android and gynoid regions, respectively, than age-matched 
healthy weight men (mean BMI, 23.4 kg/m2) [320]. It has been suggested that the greater 
lean mass often observed in overweight/obese individuals may be explained by 
additional muscle contractile work required during normal locomotion and activities 
of daily living associated with carrying around the excessive fat [320]. In light of these 
findings, and the observation of greater amounts of fat mass in the ADT-treated men 
in our study compared to controls, there is a need to adjust muscle outcomes for 
adiposity and/or body size in this cohort of men to gain a greater understanding of the 
effects. 
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To date, there have been a number of methods proposed to adjust lean mass for 
adiposity and/or body size, including the FNIH method that adjusts ALM for BMI 
(ALMBMI) and the EWGSOP approach adjusting ALM for height alone (ALMI) [51, 53]. 
When ALM was adjusted for BMI in our study, we found that men treated with ADT 
had 10-12% lower ALMBMI than both controls. In contrast, no difference was observed 
between groups when adjusting ALM for height (ALMI). To our knowledge, only one 
other study in men treated with ADT adjusted ALM for height (ALMI) and observed 
that 30 ADT-treated men (mean age, 72 years) and 25 age-matched non-ADT 
hypogonadal controls had similar ALMI (mean, both 7.5 kg/m2). These findings in 
hypogonadal men (regardless of whether induced by ADT or not) were of a similar 
magnitude to the mean ALMI in our study (mean, 7.86 kg/m2). However, to our 
knowledge adiposity-based adjustments are yet to be applied in men treated with ADT 
when compared to controls, but some studies have considered adjustment for body size 
(e.g. total body percent lean mass). Clay et al. [32] reported that 42 men treated with 
chronic ADT (> six months; mean age, 73 years) had 4.4% and 4.5% lower total body 
percent lean mass compared to PCa and healthy controls, respectively. Similarly, a 
cohort of 29 chronic ADT-treated men (> six months; mean age, 73) were shown to 
have 3.9% and 5.4% less total body percent lean mass when compared to PCa and 
healthy controls, respectively [318]. When we expressed total body lean mass as a 
percentage of total body weight, we found that men treated with ADT had 4.6% less 
total body percent lean mass when compared to PCa controls, but not healthy controls. 
While adjustment for body size when expressed as total body percent lean mass tends 
to detect compromised muscle in men treated with ADT when compared to controls, 
our findings that ALMBMI in ADT-treated men differed to both groups, whereas total 
body percent lean mass only differed in comparison to PCa controls, supports the use 
of adiposity-based adjustments when considering these men and their susceptibility to 
treatment-induced increases in adiposity.  
 
Effects of androgen deprivation therapy on appendicular muscle cross-sectional area 
Another novel aspect of this cross sectional study was the assessment of forearm and 
lower leg muscle CSA assessed via pQCT, which is important as this technique can 
provide an accurate measure of muscle size [77]. However, consistent with the DXA 
absolute arm, leg and ALM findings, there were no significant differences between the 
three groups for absolute muscle CSA at either site. While no previous studies appear 
to have assessed the effects of ADT on pQCT-derived muscle CSA at these sites, 
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several prospective studies examining absolute muscle CSA at different sites (i.e. 
paraspinal, quadriceps, rectus femoris and sartorius) observed decrements of 3.2-5.5% 
in paraspinal muscles and 15-22% in muscles of the upper leg over 15-48 weeks of 
therapy [15-17]. Unfortunately these studies did not include control groups and neglected 
to account for known confounding variables, such as physical activity and diet [15-17]. 
While the lack of any significant differences in absolute muscle CSA (and lean mass) 
between ADT-treated men and controls in our study conflicts with our initial 
hypotheses, an interesting observation in our study was the forearm muscle CSA 
expressed as a percentage of total arm area was 6.1% and 5.4% smaller in the ADT 
men compared to PCa and healthy controls, respectively. This suggests that relative to 
body size, men treated with ADT have smaller forearm muscle size. However, lower 
limb muscle size does not appear to be compromised, which could be due to the fact 
that this is a weight-bearing (loaded) site [320], suggesting that ADT may have regional 
effects leading to greater losses at non weight-bearing sites. Moreover, regardless of 
the lack of difference between the three groups, we found that ADT duration was 
negatively correlated with both forearm and lower leg percent muscle CSA. Whilst 
these findings are difficult to explain given that we did not observe similar correlations 
for body size- and adiposity-adjusted lean mass outcomes, this may potentially be 
explained by the increased accuracy of quantifying muscle via pQCT when compared 
to DXA [77].  
Effects of androgen deprivation therapy on muscle strength 
With regard to muscle strength, previous research has shown that age-related losses in 
healthy older men are two-to-four fold greater than the losses in muscle mass [39], and 
that low muscle strength is a stronger predictor that muscle mass for poor physical 
performance, functional limitations and physical disability [182]. This suggests that 
muscle strength may be a clinically more relevant measure to assess than muscle mass. 
In our study, we found that absolute handgrip strength and muscle strength of the legs, 
back and chest was lowest in the ADT men, but there were no significant differences 
between the three groups. Previous studies in men treated with ADT have reported 
mixed results in terms of muscle strength when compared to both PCa and healthy 
controls [198]. Consistent with our findings, Joly et al. [26] reported no difference in 
handgrip strength between 57 men treated with ADT (mean age, 73 years) and 51 
healthy age-matched controls. In contrast, another study in 20 men treated with ADT 
(mean age, 74 years) found that handgrip strength was 29% lower compared to 20 age-
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matched healthy controls [27]. Notably, ADT-treated also demonstrated 67% poorer 
hand dexterity and were more likely to self-report compromised hand function when 
compared to healthy controls [27]. As ADT has not been previously associated with 
compromised hand dexterity and function, these differences may indicate that men 
treated with ADT in this previous study had poorer health than ADT-treated men in 
the current study; thus potentially explaining why these men had approximately 10 kg 
lower handgrip strength than those in our study. Galvão et al. [33] showed that 48 men 
treated with ADT (mean age, 70 years) had 15% and 9.1% less chest (chest press 1-
RM) and back (seated row 1-RM) muscle strength, respectively, but similar leg muscle 
strength (leg press 1-RM) when compared to 70 age-matched healthy controls. 
Similarly, another cross-sectional study of 20 men treated with ADT (mean age, 70 
years) demonstrated that they had approximately half the chest muscle strength (bench 
press 1-RM) of 18 age-matched PCa controls, yet no difference in leg muscle strength 
(leg press 1-RM) [314]. Collectively, these results suggest that similar to muscle size, 
non-load bearing sites (e.g. muscles of the upper body) are more likely to be 
compromised by ADT when compared to appropriately selected controls. 
As with muscle mass, there is some evidence that increased body size and/or adiposity 
has been associated with greater muscle strength in healthy older men [319], and thus 
muscle strength is often normalised to body weight (e.g. expressed as strength per 
kilogram of body weight). In our study, when measures of muscle strength were 
expressed relative to weight, we found that men treated with ADT had 13% lower 
chest and 15-18% lower back muscle strength compared to both controls. Moreover, 
ADT-treated men had 21% lower leg muscle strength per kilogram of body weight 
compared to healthy controls, but not PCa controls. However, no significant 
differences were observed in weight-adjusted handgrip strength between the three 
groups. These findings suggest that treatment with ADT may have systemic effects on 
muscle strength when normalised to body weight. While our study is the first to report 
muscle strength per kilogram of body weight in men treated with ADT, similar 
adjustments were applied in a sample of 1,129 men aged 70-79 years after it was 
observed that for every standard deviation increase in fat mass (approximately 7.1 kg), 
leg muscle strength was 3.0-4.7 Nm greater [319]. Additionally, leg muscle strength per 
kilogram of body weight was 0.6-0.9 Nm/kg lower per standard deviation increase in 
fat mass [319]. This suggests that despite having greater absolute leg muscle strength, 
relative to body weight, men with greater body size were weaker. Potential reasons for 
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these observations may include the accumulation of fat around and/or within muscle 
tissue (termed intermuscular or intramuscular fat; see Chapter 5) or potential 
neurological changes associated with ADT-induced hypogonadism. Indeed, in healthy 
older men there is evidence that an increase in skeletal muscle fat infiltration is 
associated with lower muscle strength [177]. The influence of ADT on skeletal muscle 
fat infiltration will be discussed in Chapter 5. It has also been reported that age-related 
losses in muscle strength were only weakly associated with changes in muscle CSA 
[84]. This may be related to various age-related neurological changes, including a 
decrease in the number of functional motor units and the rate in which these can be 
maximally discharged, as well as a reduction in spinal excitability [321]. In our study, 
when muscle strength was expressed per kilogram of lean mass, we found that back 
muscle strength was significantly lower in ADT-treated men compared to controls. 
Whilst there were no between-group differences observed for the other measures of 
muscle strength per kilogram of lean mass, the findings from our study provide some 
evidence to support the notion that ADT induced impairments in muscle strength may 
be independent of changes in lean mass. Previous research has reported that androgens, 
such as testosterone, can enhance neural excitability [322, 323]; thus, hypogonadism may 
impair neural function in men treated with ADT which may influence muscle strength. 
Therefore, despite men with ADT having similar absolute muscle strength values 
compared to PCa and healthy controls, men treated with ADT appear to possess 
compromised muscle strength relative to body size/composition, with these deleterious 
effects likely extending beyond a loss of lean mass and/or muscle CSA alone. 
Effects of androgen deprivation therapy on gait speed 
In addition to muscle mass and strength, functional performance has been identified as 
a key factor associated with an increased risk for incident disability, falls and fractures, 
hospitalisation, cognitive impairment and dementia [132]. In our study, we found that 
men treated with ADT had 5.6-6.9% slower gait speed (0.08-0.10 m/sec) compared to 
both controls. A pooled analysis of seven studies involving 27,220 community-
dwelling older adults aged 65 years or greater reported a 25-32% risk reduction for 
incident disability for every 0.1 m/sec increment in gait speed [324]. Similarly, there is 
evidence that for every 0.1 m/sec increase in gait speed, the risk of mortality is reduced 
by 12% [47]. However, it is important to note that the mean gait speed of the men treated 
with ADT in our study was 1.40 m/sec, which is well above the 0.8-1.0 m/sec threshold 
that has been reported to be associated with incident disability, falls and fractures, 
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hospitalisation and mortality [51, 53]. Thus, despite a significant difference in our study 
between men treated with ADT relative to PCa and healthy controls, the absolute 
values remain within the healthy range, which suggests that such a difference may not 
be clinically relevant. Consistent with our findings, a previous study found that 
although 48 men treated with ADT (mean age, 70 years) had 6.3% slower gait speed 
when compared to 70 age-matched healthy controls, group mean values were 1.25 
m/sec and 1.33 m/sec, respectively [33], which are both also above clinically relevant 
cut-offs. In contrast, no difference was observed between 63 ADT-treated men (mean 
age, 72 years) and 71 age-matched PCa controls, however, similar to our study, both 
groups had a gait speed within the healthy range (both > 1.20 m/sec) [31]. While men 
treated with ADT tend to have compromised gait speed relative to controls, these 
values are likely not of clinical significance, given the lack of adverse outcomes 
associated with speeds greater than 1.00 m/sec. Therefore, exploration of other 
measures of functional capacity are warranted in men treated with ADT to potentially 
detect those at greater risk of long term adverse effects on functional outcomes. 
 
Effects of androgen deprivation therapy on muscle power 
Measures of lower limb muscle power, which represented the ability to produce force 
rapidly, have been suggested to be a better predictor than muscle strength with regard 
to predicting mobility and ambulation impairments, as well as falls, in older adults [151, 
325, 326]. In our study, we examined functional muscle power via the 30-second sit-to-
stand test [130], that has shown good correlation (r=0.6) with the Nottingham power rig 
[131], which is generally considered the gold standard for quantifying muscle power in 
older adults [129]. We found that men treated with ADT had 14% lower 30-second sit-
to-stand performance compared to healthy controls, but not PCa controls. Notably, on 
average men treated with ADT completing two less repetitions during the 30-second 
test when compared to both controls (13 vs 15 repetitions). In a sample of 2,140 adults 
aged 60 years or greater, 13 repetitions was associated with self-reported physical 
independence in men aged 70-74 years (mean age of ADT group in our study, 73 years) 
[327]; thus, differences observed in our study between men treated with ADT and 
controls may not be of clinical relevance. However, within the same study, men aged 
70-74 years who scored less than 15 repetitions were associated with not having the 
ability to retain physical independence [327]. Therefore our findings suggest that when 
compared to PCa and healthy controls, men treated with ADT were likely to currently 
be physically independent, but may be at risk of losing physical independence in the 
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long-term; hence, investigating approaches to preserve this independence is warranted 
in this susceptible population group. These results are in part supported by the only 
other cross-sectional analysis that compared sit-to-stand performance, albeit a time to 
complete five repetitions protocol, in ADT-treated men and both PCa and healthy 
controls [32]. Clay et al. [32] observed that 42 men treated with chronic ADT (mean 
duration, 30.7 months; mean age, 73 years) had 10% (15.2 seconds vs 13.7 seconds) 
poorer functional muscle power when compared to PCa controls (n=25), but not 
healthy controls (n=20), when adjusted for age, comorbidities, BMI and total body 
percent fat mass. Moreover, 13 men treated with acute ADT (mean duration, 3.7 
months; mean age, 74 years) within the same study on average completed the test in 
13.2 seconds and showed no differences compared to either control [32]. Although the 
sample size in this study was small, these findings suggest that the duration of ADT 
may be an important factor when evaluating the effects of ADT on muscle power. 
However, in our study we found no association between duration of ADT use and 30-
second sit-to-stand performance. While it is difficult to directly compare the findings 
across studies due to the dissimilar sit-to-stand protocols used and the variables 
accounted for in the analyses, collectively the findings suggest that ADT may impair 
functional muscle power and suggest that these men are at risk of losing independence 
and/or recurrent falls. However, further studies using more robust measures are need 
to understand the true effects on ADT on muscle power. 
Effects of androgen deprivation therapy on balance and mobility 
It is well established that impairments in static and/or dynamic balance are associated 
with increased falls risk in community-dwelling older adults [328]. Additionally, 
assessments of mobility, particular those of distances/duration capable of inducing 
cardiorespiratory and/or muscular fatigue (e.g. 400 metres), have been shown to 
independently predict mortality in older adults [329]. Within our study, we observed no 
differences in assessments of balance or mobility (timed-up-and-go, four-square step 
test, Berg balance scale and 400 metre walk) between the three groups. Men treated 
with ADT in our study demonstrated mean values of 11.02 seconds, 10.05 seconds, 55 
points and 286 seconds (approximately 4.75 minutes) for timed-up-and-go, four-
square step test, Berg balance scale and 400 metre walk, respectively. These results 
are within healthy ranges based on the previously proposed cut-offs for predicting falls 
risk in community-dwelling older adults for timed-up-and-go (≥ 15 seconds [133]), four-
square step test (≥ 15 seconds [134]) and Berg balance scale (45 points [330]). Moreover, 
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evidence from 948 adults aged 65 years or greater showed that the ability to complete 
the 400 metre walk was associated with three-fold lower risk of mortality when 
compared to those unable to complete the test [329]. Therefore, men treated with ADT 
in our study likely did not possess increased falls and mortality risk associated with 
balance and mobility. Our findings are supported by observations that timed-up-and-
go performance did not differ between 57 men treated with ADT (mean age, 73 years) 
and 51 age-matched healthy controls, with ADT-treated men similarly having had 
mean results (6 seconds) below previously proposed cut-offs for falls risk [26]. Of note, 
the lower time to complete the test in comparison to men treated with ADT in our 
study may stem from our study having used a dual-task version of the timed-up-and-
go, as opposed to the traditional single-task protocol, which has been shown to take 
less time to complete [133]. In contrast to our findings, in the only other known cross-
sectional study that investigated differences in 400 metre walk performance between 
48 ADT-treated men (mean age, 70 years) and 70 age-matched healthy controls, those 
treated with ADT were found to have 6.8% poorer performance [33]. However, this 
difference may be of limited clinical relevance given that the ADT-treated men in this 
study completed the test in approximately 4.5 minutes [33], which would classify them 
in the fastest quartile of community-dwelling older adults [329]. Collectively, it appears 
that men treated with ADT do not have compromised balance and mobility when 
compared to appropriately selected controls and are therefore not at increased risk of 
falls and mortality commonly associated with poorer outcomes in these tests. 
Effects of androgen deprivation therapy on (pre)sarcopenia, obesity and sarcopenic 
obesity 
Globally sarcopenia is now recognised as a clinical condition characterised by varying 
combinations of slow gait speed, impaired muscle strength and low ALM [51-53]. 
Although there remains a lack of consensus internationally with regard to the precise 
clinical cut-points for each of these measures, based on the most widely adopted 
criteria we found that the prevalence of sarcopenia in our cohort of ADT men and 
controls was 0.0% using the IWGS definition and ranged from 1.4% to 5.9% for the 
EWGSOP and 0.0% to 5.7% for the FNIH definitions, respectively. To our knowledge, 
this study is the first to evaluate the prevalence of sarcopenia using these methods in 
men treated with ADT compared to appropriately selected controls. Although 
significant differences were observed when ADT-treated men were compared to both 
controls using the FNIH definition which adjusted ALM for adiposity (BMI), these 
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findings must be interpreted with caution given that only two men treated with ADT 
were found to be sarcopenic (and no controls). Overall, the low prevalence of 
sarcopenia can be largely related to the fact that there was little evidence of impaired 
gait speed (<0.8 or < 1.0 m/s) in any of the groups, with only one participant treated 
with ADT having met this criteria. This limitation, as well as the low prevalence of 
sarcopenia specifically in men treated with ADT, may be partially attributed to the 
recruitment strategies utilised for this cross-sectional analysis. ADT-treated men were 
recruited on the basis of involvement in an ongoing exercise training RCT, thus the 
influence of recruitment bias, both from potential participants (e.g. healthier men may 
have been more likely to seek involvement) and selection criteria (e.g. exclusion of 
men with absolute contraindications to exercise), cannot be discounted and the 
applicability of these findings to the broader ADT patient population group should be 
interpreted with caution. Nevertheless, given the role of adiposity observed in our 
study on various muscle outcomes, these findings further support the concept that for 
men treated with ADT it is important to account for adiposity when evaluating the 
effects of this therapy on muscle. 
Given the low prevalence of sarcopenia in men treated with ADT compared to controls 
in our study, we also examined established cut-offs for pre-sarcopenia (low lean mass 
alone) to assess the ability of these definitions to distinguish risk in this group. We 
found that when adjusted for adiposity (ALMBMI and ALMHFM), rather than height 
(ALMI), 7.2-34% more men treated with ADT were pre-sarcopenic when compared 
to either controls. Similar discrepancies between definitions were shown in a cohort of 
1,435 older men (mean age, 74 years), whereby 8.9% of overweight (BMI, 25-29 
kg/m2) and 0.0% of obese (BMI, ≥ 30 kg/m2) men were diagnosed with sarcopenia 
using the ALMI definition (< 7.23 kg/m2), compared to 15% and 12% of overweight 
and obese men, respectively, when the residual method of ALMHFM was applied [82]. 
This further highlights the need to account for adiposity in populations with increased 
adiposity, such as men treated with ADT for PCa. While yet to be examined in men 
treated with ADT specifically, adiposity-adjusted cut-offs (e.g. ALMBMI < 0.789) have 
been associated with an increased risk of all-cause mortality (OR, 1.47) in a cohort of 
4,449 older adults (age, ≥ 50 years) [331]. Therefore, the adiposity-adjusted definitions 
and cut-offs (i.e. ALMBMI and ALMHFM) for pre-sarcopenia appears to have increased 
sensitivity to detect potentially clinically relevant differences when comparing ALM 
in men treated with ADT compared to appropriately selected controls. 
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Although in their infancy, definitions of sarcopenic obesity may provide unique 
insights into the risk profile of ADT-treated men given the significance of considering 
adiposity when comparing muscle outcomes to appropriately selected controls. 
Sarcopenic obesity has been shown to be associated with a myriad of health issues in 
older men, such as increased cardiometabolic risk and subsequent mortality, beyond 
that of sarcopenia or obesity alone [55]. In our study we observed no cases of sarcopenic 
obesity, but 13% more men treated with ADT presented with pre-sarcopenia and 
obesity concurrently when compared to PCa controls, but similar differences were not 
apparent when compared to healthy controls. Furthermore, differences were only 
detected when using the ALMI cut-off of ≤ 7.26 kg/m2 (EWGSOP [53]) as opposed to 
≤ 7.49 kg/m2 (EWGSOP/IWGS [52, 53] adapted for our study sample). This further 
strengthens the notion that the development of ADT population-specific cut-offs for 
ALM may improve the ability to detect risk in these men when compared to their non-
ADT counterparts and healthy controls. Collectively, these findings should also be 
interpreted with caution given the current lack of a consensus definition of sarcopenic 
obesity and the limited number of cases observed in our study. Nevertheless, our 
findings regarding muscle outcomes relative to adiposity highlight the potential for 
more robust future definitions of sarcopenic obesity to act as a risk assessment tool in 
this susceptible population group.  
4.7 Strengths and limitations 
This study has many strengths, inclusion of both PCa and healthy controls allowed for 
the effects of ADT to be quantified independent of PCa diagnosis, non-hormonal PCa 
treatment and ageing. Additionally, the assessment of each component of the most 
widely used composite definitions of sarcopenia [51-53] allowed for the novel 
application of sarcopenia within this group, which permitted an assessment of risk 
beyond that of individual outcomes alone. Furthermore, a range of potential 
confounding variables were accounted for via a strict list of inclusion/exclusion criteria 
for both PCa and healthy controls, validated assessments of confounders such as 
physical activity (energy expenditure) and diet (energy intake). Moreover, this study 
used robust measures of lean and fat mass via DXA and muscle CSA via pQCT; of 
which the latter provided the first known measurements of the forearm and lower leg 
in men treated with ADT compared to both PCa and healthy controls. Finally, this 
study was adequately powered to detect significant differences between groups for 
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multiple key outcomes, including total body lean mass, total body percent fat mass, 
handgrip strength and gait speed. 
However, several limitations also need to be considered when interpreting results. 
First, volunteer bias may have yielded results which were not representative of the 
broader population. As mentioned in the discussion, men treated with ADT in this 
analysis were involved in a larger RCT in which all agreed to be potentially allocated 
to a 52-week exercise training and nutritional supplementation intervention, which 
may have limited the study sample to only those capable and willing to complete such 
an intervention; therefore these men may have been healthier than the average man 
treated with ADT. Conversely, PCa and healthy controls were recruited for a single 
visit promoted as a ‘free health assessment’, thus potentially increasing the likelihood 
that those with pre-existing medical conditions or concerns would volunteer; hence 
these individuals may have had compromised health when compared to the general 
population. Second, for some measures there was missing data, such as the 3-RM 
protocols, in which 20-25% of the total sample did not complete tests due to an 
unexpectedly high prevalence of relative contraindications (e.g. current 
musculoskeletal injury, hypertension or cardiometabolic disease) for exercise testing 
as defined by the American College of Sports Medicine [24]; thus, further supporting 
that our control groups may have had poorer overall health when compared to the 
broader population. Third, while less crucial in cross-sectional studies when compared 
to those prospectively designed, the majority of outcomes were not obtained by a 
researcher blinded to group allocation; however, DXA and pQCT outcomes were 
assessed blinded to group allocation. Fourth, the potential that reverse casualty was 
observed cannot be excluded (e.g. increased fat mass may have led to PCa progression 
and thus the need for ADT [332]). Fifth, due to the cross-sectional design of this study, 
causality could not be assessed for outcomes of interest. Finally, although applied in 
previous studies to account for the confounding role of adiposity, there are limited 
long-term prospective studies that have established the ability of adiposity- and body 
size-adjusted muscle mass, size and strength outcomes to predict risk in older men, let 
alone in men treated with ADT, and thus the inference of risk associated with these 
outcomes should be made with caution.  
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4.8 Summary and Conclusion 
In summary, our study demonstrated that men treated with ADT did not have 
compromised absolute total body and regional muscle mass and muscle CSA when 
compared to PCa and healthy controls, however ADT-treated men had greater total 
body fat mass. When accounting for these differences via body size- or adiposity-based 
adjustments, men treated with ADT were shown to have lower regional lean mass and 
muscle CSA compared to controls. Similar findings were observed when muscle 
strength outcomes were adjusted for weight. Men treated with ADT were also shown 
to differ in some, but not all, measures of functional capacity when compared to 
controls. Subsequently, men treated with ADT were more likely than both controls to 
present with pre-sarcopenia, sarcopenia, obesity and pre-sarcopenia/obesity 
concurrently.  
 
In conclusion, the absolute differences in total body and regional lean mass between 
men treated with ADT and controls were likely of clinical relevance in terms of risk 
stratification and more noticeably occurred in non-load bearing sites (i.e. upper body), 
suggesting that these sites may be more suitable for monitoring the long-term risk 
associated with ADT. Moreover, considering these differences relative to body 
composition (i.e. ALMBMI and ALMHFM), due to greater amounts of total body fat mass 
associated with ADT, would likely increase the ability to detect those at risk in this 
susceptible population group. Muscle strength outcomes warrant similar 
considerations (i.e. body composition adjustments and monitoring non-load bearing 
sites) if these tests are to be used for risk stratification and/or clinical decision making. 
Based on our observations, assessments of balance and mobility are less likely than 
assessments of functional muscle power to identify men at risk of long-term adverse 
outcomes, such as recurrent falls or losing independence. Collectively, risk 
stratification of ADT-treated men may benefit from the use of body composition-
adjusted cut-offs of pre-sarcopenia (i.e. ALMBMI and ALMHFM), but limited evidence 
was found to support the use of known sarcopenia and/or sarcopenic obesity cut-offs. 
Thus, the development and evaluation of ADT-specific cut-offs for sarcopenia and 
sarcopenic obesity may aid risk stratification in this clinical population group. In the 
following chapter, differences in regional fat, including a novel marker of 
intermuscular fat (pQCT-derived muscle density), will be examined between men 
treated with ADT and controls. 
   119 
Chapter 5 
The effects of androgen deprivation therapy in men with prostate 
cancer on regional depots of fat: results from a cross-sectional study 
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5.1 Declaration statement 
Under the guidance of supervisors, the candidate developed the study concept and 
initiated the project, provided significant input into the development of the protocol, 
implemented the protocol and oversaw the collection of the data, analysed and 
interpreted all data presented.   
5.2 Overview 
This chapter presents the results from a cross-sectional study. The study examined 
whether there were any differences in regional fat mass and cross-sectional area (CSA) 
and muscle density (as a marker of intermuscular fat) in men treated with androgen 
deprivation therapy (ADT) when compared to prostate cancer (PCa) and healthy 
controls. Additionally, this chapter presents within-group correlations between ADT 
use duration and outcomes discussed in men treated with ADT.   
5.3 Introduction 
In developed countries, PCa has been commonly shown to contribute to male cancer-
related morbidity and mortality [1, 2]. Appropriately selected men with PCa have 
benefited from ADT in terms of disease progression and survival [5-9], however, the 
hypogonadism induced by the treatment is often associated with a marked increase in 
total body percent fat mass (6.6-14%) [17-23]. The accumulation of fat mass may in part 
explain why men treated with ADT have been shown to have a 11-20% and 16-44% 
increased risk of cardiovascular disease and type 2 diabetes, respectively, when 
compared to men not treated with this therapy [207, 333, 334]. This is of importance given 
that the most common cause of non-cancer-related mortality in men diagnosed with 
PCa is cardiovascular disease [189, 335]. However, given that the accumulation of fat in 
varying depots may have differing effects in terms of the risk of morbidity and 
mortality in older men [40], the investigation of regional fat depots is warranted.  
Currently, the gold standard for the acquisition of regional fat mass and CSA with high 
accuracy is magnetic resonance imaging (MRI) and computed tomography (CT) [40,
111]. These tools have the advantage of providing a three-dimensional assessment of fat 
CSA or volume [111]. However, the high cost of CT and MRI scan acquisition and data 
processing, complications with claustrophobic and severely obese individuals (body 
mass index [BMI] ≥ 40 kg/m2), and in the case of CT, high exposure to ionising 
radiation [76, 111], may in part explain why these techniques are less commonly used in 
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the research setting. Advancements in the precision and availability of dual-energy x-
ray absorptiometry (DXA) [118, 119] and peripheral quantitative CT (pQCT) [117] for 
quantifying regional fat mass and CSA have led to suggestions that these measures 
may have the potential to be of clinical importance with regard to risk stratification 
and clinical decision making in men treated with ADT [216]. 
Previous research has shown that fat accumulation in subcutaneous depots, such as 
those in the gynoid (hips) region, appear to be negatively associated with 
cardiometabolic risk in healthy older men, whereas the accumulation of fat within 
depots of the abdominal cavity (android region) have been shown to be positively 
associated with this risk [40]. Moreover, differences within these specific regions may 
be of clinical relevance, with findings in healthy men demonstrating that abdominal 
visceral fat, when compared to abdominal subcutaneous fat, tends to be associated with 
an increased risk for hypertension (odds ratio [OR], 1.9 vs 1.5), impaired glucose 
metabolism (OR, 1.8 vs 1.5), diabetes (OR, both 1.6) and metabolic syndrome (OR, 
4.2 vs 2.5) [102]. Similarly, the accumulation and infiltration of fat within muscle, 
leading to decreased muscle density [77], has been associated with many of the above 
cardiometabolic risk factors as well as decreased lower limb muscle strength and 
functional capacity, independent of muscle CSA [177, 178].  
To date, the accumulation of fat within regional depots has received limited attention 
in men treated with ADT compared to appropriately selected controls. To our 
knowledge, only one study has compared DXA-derived arm, leg and trunk fat mass in 
ADT men compared to healthy controls [33]. This study found that only leg fat mass 
was greater (17%; 1.1 kg) in ADT-treated men compared to controls [33]. Only one 
study has also examined muscle density (as a marker of intermuscular fat) in ADT-
treated men (n=39) and showed that 15-20 weeks of therapy resulted in a 19% decrease 
in rectus femoris muscle density [15]. However, this study did not include an 
appropriately selected control group and utilised varying CT scanners due to the multi-
centre design [15]. Two prospective studies have examined regional fat outcomes in 
men treated with ADT, and found that ADT-treated men had an 11-13% increase in 
abdominal subcutaneous fat mass and either a 22% increase or no change in abdominal 
visceral fat mass [17, 199]. However, a limitation of these studies is that they included 
small sample sizes (total n=26-32) and no control group. Therefore, the primary aims 
of this study were to compare total and regional fat mass, fat CSA and muscle density 
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(as a measure of intermuscular fat) in men treated with ADT for PCa when compared 
to non-ADT treated PCa men and healthy controls. A secondary aim was to assess the 
influence of ADT use duration on these outcomes. 
5.4 Methods 
Details on the methodology of this study are discussed in Chapter 3. Briefly, this was 
a cross-sectional study in which comparisons were made between 42 men treated with 
ADT for PCa, 54 men treated with non-hormonal therapies (men currently treated with 
active surveillance were eligible for inclusion in this group) for PCa (PCa controls) 
and 70 men not diagnosed with PCa (healthy controls). Men treated with ADT were 
recruited via clinician referral across various hospitals, private practices and health 
networks, as well as from PCa support groups and advertisements in state/local 
newspapers. PCa and healthy controls were recruited from PCa support groups and 
advertisements in state/local newspapers. 
Total and regional fat mass (arm, legs, android, gynoid, abdominal visceral and 
abdominal subcutaneous) was assessed by DXA. Forearm (66% radius) and lower leg 
(66% tibia) fat CSA and muscle density (as a marker of intermuscular fat) were 
assessed by pQCT [312]. Habitual physical activity and diet were assessed by self-
reported questionnaire and 24-hour food recall, respectively. Demographical, clinical 
and lifestyle information was assessed by questionnaire. Missing data among the three 
groups is presented in Table 5.1. 
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Table 5.1. Missing data in the three groups. 
Added after study 
began Unable to define ROI Movement artefact * 
Pre-existing 
comorbidities Total 
Measure ADT PC HC ADT PC HC ADT PC HC ADT PC HC ADT PC HC 
DXA total body scan - - - 1 0 0 - - - - - - 1 0 0 
pQCT forearm - - - 1 0 0 5 6 8 - - - 6 6 8 
pQCT lower leg - - - 0 0 0 2 4 2 - - - 2 4 2 
Data are: number of participants with missing data. ADT, men treated with androgen deprivation for prostate cancer; DXA, dual energy x-ray absorptiometry; HC, healthy 
control; PC, prostate cancer control; pQCT, peripheral quantitative computed tomography; ROI, region of interest. * Excluded based on scores of four or five on the visual 
inspection rating scale of participant movement proposed by Blew et al. [311]. 
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All analyses were performed using SPSS 24.0 (IBM Corp, Chicago IL, United States 
of America). Initially, all data were screened for outliers and descriptive statistics were 
computed to compare the three groups on known confounding variables of the primary 
outcomes. Equality of variances of all data were assessed using Levene’s test. 
Normality of distribution of all data were assessed using Shapiro-Wilk’s test. Data in 
violation of equality of variance or normal distribution underwent natural log (arm fat 
mass, leg fat mass, forearm fat CSA, forearm percent fat CSA, lower leg fat CSA, 
lower leg percent fat CSA, forearm muscle density and lower leg muscle density) or 
square root (total body fat mass, android fat mass, gynoid fat mass and abdominal 
visceral fat mass) transformation prior to all analyses, but all data presented were 
derived from raw values. Between-group comparisons were assessed by analyses of 
covariance (ANCOVA), with age (years) and physical activity (energy expenditure; 
kilojoules/day) as covariates. The Kruskal-Wallis test was used for data that remained 
non-parametric following transformation (abdominal subcutaneous fat mass). Post-
hoc analyses applied the Bonferroni correction, with the addition of Mann-Whitney 
tests following non-parametric analyses. In the men treated with ADT only, the 
strength and direction of associations between duration of ADT use and all outcomes 
were assessed by Spearman rank-order correlation coefficient. Continuous data were 
reported as mean ± standard deviation, whereas categorical variables were reported as 
frequency and percentage, unless stated otherwise. A significance level of P < 0.05 
was adopted for all statistical tests. 
5.5 Results 
5.5.1 Participant characteristics 
Participant characteristics of the three groups were reported in Chapter 4. In brief, men 
treated with ADT were approximately four years older, more likely to take one 
additional prescription medication and tended to have a 23-30% lower level of habitual 
physical activity (energy expenditure) when compared to both control groups. No 
differences were observed between groups for diet. 
5.5.2 Total and regional fat mass and cross-sectional area 
A significant between-group difference was observed for total body fat mass and 
percent fat mass, but not weight (Table 5.2). Men treated with ADT had 5.0 kg 
(P=0.015) and 4.8% (P=0.005) greater total body fat mass and percent fat mass, 
respectively, when compared to PCa controls, but not healthy controls (both P > 
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0.061). With regard to regional fat mass, there were no significant differences between 
the groups for android or abdominal visceral fat mass. A between-group difference 
was observed for arm, leg and gynoid fat mass and forearm fat CSA and percent fat 
CSA. Post-hoc analyses revealed that when compared to PCa and healthy controls, 
men treated with ADT had 19% greater arm fat mass (P=0.003 and P=0.006, 
respectively), 20-21% greater leg fat mass (P=0.007 and P=0.016, respectively), 15-
18% greater gynoid fat mass (P=0.012 and P=0.032, respectively), 29-36% greater 
forearm fat CSA (P=0.002 and P=0.023, respectively) and 4.8-5.8% greater forearm 
percent fat CSA (P=0.001 and P=0.004, respectively). Men treated with ADT also 
tended to have greater abdominal subcutaneous fat mass (0.2 kg; P=0.067) and lower 
limb fat CSA (18-22%; P=0.070) when compared to controls.   
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Table 5.2. Mean weight, total body and regional fat mass and fat cross-sectional area, and the mean adjusted between-group differences in men 
treated with androgen deprivation therapy (ADT), prostate cancer (PCa) controls and healthy controls. 
Unadjusted mean ± standard derivation 
P-value
Adjusted mean difference (95% CI) 
Men treated 
with ADT 
PCa 
controls 
Healthy 
controls 
Men treated with ADT 
vs PCa controls 
Men treated with ADT 
vs healthy controls 
PCa controls vs 
healthy controls 
Total body 
  Weight (kg) 86.5 ± 18.0 82.8 ± 13.4 85.5 ± 12.6 0.092 6.7 (-0.7, 14.1) 3.6 (-3.4, 10.5) -3.1 (-9.3, 3.0)
  Fat mass (kg)b 29.4 ± 10.7 24.4 ± 8.5 26.1 ± 7.5 0.019 5.8 (1.1, 10.4) * 3.9 (-0.4, 8.2) -1.9 (-5.7, 2.0)
  Fat mass (%) 34.8 ± 7.8 30.0 ± 6.4 31.5 ± 5.4 0.006 4.5 (1.1, 7.9) # 3.1 (-0.1, 6.3) -1.4 (-4.2, 1.4)
Regional fat mass 
  Arm (kg)a 2.9 ± 1.0 2.4 ± 0.7 2.4 ± 0.7 0.002 0.7 (0.2, 1.1) # 0.6 (0.2, 1.0) # 0.0 (-0.4, 0.3) 
  Leg (kg)a 8.4 ± 3.3 6.8 ± 2.3 6.9 ± 2.1 0.005 1.8 (0.5, 3.1) # 1.7 (0.4, 2.9) * -0.1 (-1.2, 1.0)
  Android (kg)b 3.2 ± 1.5 2.6 ± 1.3 2.9 ± 1.1 0.106 0.6 (0.0, 1.3) 0.3 (-0.4, 0.9) -0.3 (-0.9, 0.2)
  Gynoid (kg)b 4.2 ± 1.4 3.5 ± 1.3 3.6 ± 1.1 0.010 0.8 (0.1, 1.4) * 0.7 (0.1, 1.3) * -0.1 (-0.6, 0.4)
  Abdominal visceral (kg)b 2.0 ± 1.3 1.6 ± 1.0 1.9 ± 0.9 0.122 0.4 (-0.2, 0.9) 0.1 (-0.4, 0.6) -0.3 (-0.8, 0.2)
  Abdominal subcutaneous (kg)c 1.2 ± 0.5 1.0 ± 0.5 1.0 ± 0.4 0.067 0.2 (0.0, 0.5) 0.2 (0.0, 0.4) 0.0 (-0.2, 0.2) 
Fat cross-sectional area 
  Forearm (cm2)a 12.0 ± 6.5 8.3 ± 3.4 9.0 ± 3.6 0.003 4.0 (1.5, 6.5) # 3.2 (0.9, 5.5) * -0.8 (-2.9, 1.3)
  Forearm (%)a 20.1 ± 7.9 14.3 ± 4.9 15.3 ± 5.1 0.001 5.7 (2.4, 8.9) # 4.7 (1.6, 7.8) # -0.9 (-3.7, 2.4)
  Lower leg (cm2)a  21.4 ± 12.5 17.8 ± 8.8 17.2 ± 8.1 0.070 4.0 (-1.2, 9.2) 4.5 (-0.3, 9.4) 0.5 (-3.8, 4.9) 
  Lower leg (%)a 20.6 ± 8.3 17.8 ± 7.0 17.0 ± 6.5 0.067 2.4 (-1.5, 6.3) 3.3 (-0.3, 6.9) 0.9 (-2.3, 4.2) 
Muscle density 
  Forearm (mg/cm3)a 77.3 ± 2.3 78.2 ± 1.9 77.7 ± 1.7 0.171 -0.6 (-1.7, 0.4) -0.2 (-1.2, 0.8) 0.5 (-0.4, 1.3) 
  Lower leg (mg/cm3)a 73.5 ± 3.4 74.8 ± 3.3 74.7 ± 3.1 0.069 -0.7 (-2.4, 0.9) -0.6 (-2.2, 0.9) 0.1 (-1.3, 1.5) 
Data are: unadjusted mean ± standard deviation and adjusted mean difference (95% confidence interval). * P < 0.05; # P < 0.01; a analysis used natural log transformed data; b 
analysis used square root transformed data; c Kruskal-Wallis test used for non-parametric data. 
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5.5.3 Muscle density 
Muscle density averages and between-group differences are shown in Table 5.2. No 
significant differences were observed between groups, although men treated with ADT 
trended (P=0.069) towards having poorer lower leg muscle density (indicative of 
increased intermuscular fat) when compared to controls.      
5.5.4 Duration of androgen deprivation therapy use 
The sample of men treated with ADT had undergone an average treatment duration of 
34 months (standard deviation, 45 months). Duration of ADT was shown to correlate 
positively with arm (Spearman’s rho [rs]=0.36), leg (rs=0.39), gynoid (rs=0.34) and 
abdominal subcutaneous fat mass (rs=0.37), and forearm (rs=0.34) and lower leg fat 
CSA (rs=0.44; Table 5.3). Duration of ADT was also negatively correlated with 
forearm muscle density (rs=-0.34). On average, each month of ADT tended to be 
associated with a 0.1-0.2 cm2 greater fat CSA and 0.04 mg/cm3 lower muscle density 
at both the forearm and lower leg (Figure 5.1). 
Table 5.3. Correlations between androgen deprivation therapy (ADT) use duration 
and fat mass, fat cross-sectional area and muscle density outcomes in men with 
prostate cancer treated with ADT. 
Measure ADT duration (month), Spearman’s rho correlations 
Fat mass 
  Arm (kg) 0.36 P=0.020 
  Leg (kg) 0.39 P=0.012 
  Android (kg) 0.13 P=0.433 
  Gynoid (kg) 0.34 P=0.028 
  Abdominal visceral (kg) 0.05 P=0.761 
     Abdominal subcutaneous 
(kg) 
0.37 P=0.021 
Fat cross-sectional area 
  Forearm (cm2) 0.34 P=0.044 
  Lower leg (cm2) 0.44 P=0.005 
Muscle density 
  Forearm (mg/cm3) -0.34 P=0.046 
  Lower leg (mg/cm3) -0.31 P=0.054 
Data are: Spearman’s rho. 
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Figure 5.1. Scatterplot of the relationship between duration of androgen deprivation 
therapy (ADT) and lower leg and forearm fat cross-sectional area (CSA) and muscle 
density in men treated with ADT; Spearman’s rho, rs. 
5.6 Discussion 
To our knowledge, this was the first study to compare regional fat depots in men 
treated with ADT and both PCa and healthy controls simultaneously. The main 
findings were that subcutaneous fat depots, specifically within the arms, legs and 
gynoid region, were 15-36% greater in men treated with ADT when compared to both 
control groups. However, these men did not possess greater abdominal visceral fat and 
only trended towards increased abdominal subcutaneous fat. Similarly, when 
compared to either control, men treated with ADT demonstrated no significant 
differences in appendicular muscle density (as a marker of intermuscular fat), although 
a trend was observed for men on ADT to exhibit an increase in leg intermuscular fat. 
Moreover, all subcutaneous fat depots, with the exception of android region, were 
shown to be positively correlated with ADT duration. Additionally, forearm muscle 
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density was shown to negatively correlate with ADT duration, which indicated the 
presence of greater amounts of intermuscular fat. Collectively, the findings of this 
study suggest that ADT-induced gains in adiposity more commonly affect 
subcutaneous fat depots with fat gains tending to occur throughout treatment with 
ADT.  
Effects of androgen deprivation therapy on android and gynoid fat mass 
Total body adiposity is a known risk factor for cardiometabolic morbidity and 
mortality [55, 171], however, pending regional distribution, the accumulation of fat in 
varying depots may pose differing disease risks [40]. For example, increased abdominal 
(android region) fat mass has been commonly associated with chronic inflammation, 
impaired glucose tolerance, increased blood lipids and decreased mobility [40]. 
Accumulation within subcutaneous depots, such as those within the gluteofemoral 
region, are less often associated with these adverse outcomes [40, 336]. In our study, we 
found that men treated with ADT had greater gynoid fat mass (0.6-0.7 kg; 15-18%), 
but not android fat mass, when compared to either PCa or healthy controls. The only 
known cross-sectional analysis that examined regional fat mass differences between 
48 men treated with ADT (mean age, 70 years) and 70 age-matched healthy controls 
did not measure android or gynoid fat mass, however, trunk fat mass was observed to 
be similar between the two groups [33]. Although a different region of interest, android 
fat mass is encapsulated within the trunk region and thus these observations support 
our findings that men treated with ADT may not have greater abdominal fat mass when 
compared to appropriately selected controls. The clinical significance of an increase 
in gynoid fat mass remains uncertain given the conflicting findings reported in the 
literature. For instance, in a cohort of 175 healthy men (mean age, 45 years), each 
increment of 0.5 kg DXA-derived gynoid fat mass was associated with approximately 
double the risk of impaired glucose metabolism, increased serum triglycerides or 
hypertension [337]. In contrast, in a larger population-based study of 3,818 men (mean 
age, 49 years), each 7.6 cm increase in hip circumference (as a marker of gynoid region 
fat mass), was associated with a decreased risk of impaired glucose metabolism (OR, 
0.55), increased serum triglycerides (OR, 0.58) and hypertension (OR, 0.80) [338]. 
While the latter study relied on a less robust assessment of gynoid fat mass, these 
observations should not be dismissed given similar associations have been reported in 
several other studies examining various measures of gluteofemoral fat depots [40, 336]. 
However, many of these studies have utilised gluteofemoral region outcomes less 
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comparable to DXA-derived gynoid fat mass, such as hip circumference and thigh fat 
CSA [336], therefore limiting comparisons between measures. Moreover, these studies 
tended to neglect the likely increased muscle mass and size associated with increased 
adiposity [319]; thus these negative associations should be interpreted with caution. 
Despite the uncertainty with regard to the risk associated with fat accumulation within 
these depots, our findings suggest that fat accumulation during ADT may more 
commonly occur within subcutaneous depots, such as those in the gynoid region. 
Effects of androgen deprivation therapy on abdominal visceral and subcutaneous fat 
mass 
As discussed already, fat mass within the abdominal cavity (android region) may pose 
differing cardiometabolic risk pending on whether it is stored within subcutaneous or 
visceral depots [40, 336]. When compared to subcutaneous depots within this region, 
visceral fat mass tends to be a better predictor of hypertension, impaired glucose 
metabolism, diabetic status and metabolic syndrome in older men [102, 103]. We found 
that men treated with ADT had similar abdominal visceral fat mass compared to both 
controls, but tended to have 0.2 kg greater abdominal subcutaneous fat mass. There is 
evidence to suggest that a 0.8 kg increment in abdominal subcutaneous fat mass is 
associated with an increased risk of hypertension (OR, 1.45), diabetes (OR, 1.78) and 
metabolic syndrome (OR, 3.57), in a sample of 881 men (mean age, 58 years) [103]. 
Given the absolute difference in abdominal subcutaneous fat mass between ADT-
treated men and controls was four-fold smaller than that of what has been previously 
shown to be associated with adverse health outcomes, this trend is likely not of clinical 
relevance. To date, studies that have examined abdominal subcutaneous and visceral 
fat mass in men treated with ADT have been prospective in nature and shown an 11-
13% increase in subcutaneous fat, yet mixed findings for visceral fat (22% increase or 
no change) [17, 199]. Notably, these studies did not include control groups or account for 
known confounding variables, such as physical activity and diet, thus limiting 
comparisons to our findings. Collectively, our findings indicate that ADT use does not 
appear to have any marked effect on abdominal visceral or subcutaneous fat mass. 
Although, these results must be interpreted with caution given the use of DXA, which 
despite being shown to highly correlate (r=0.83) with CT-derived visceral fat CSA in 
overweight older men (mean age, 66 years; mean BMI, 29.7 kg/m2) [120], only provided 
an estimate of visceral and subcutaneous fat mass within this region of interest.  
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Effects of androgen deprivation therapy on arm and leg fat mass and cross-sectional 
area 
There is limited evidence that the accumulation of fat within subcutaneous depots of 
the arms and legs is associated with adverse health outcomes [336, 339]. Our study found 
that men treated with ADT had greater arm (19%; 1.5-1.6 kg) and leg (20-21%; 0.5 
kg) fat mass when compared to both PCa and healthy controls. These findings were in 
part supported by the observation that leg fat mass was 17% (1.1 kg) greater in 48 men 
treated with ADT (mean age, 70 years) compared to 70 age-matched healthy controls, 
whereas no between-group difference in arm fat mass were shown, although ADT-
treated men had values 8.7% (0.2 kg) greater [33]. Although likely limited with regard 
to predicting risk of adverse outcomes, our findings suggest that the accumulation of 
fat during ADT more commonly occurs in subcutaneous depots within the arms and 
legs.  
DXA-derived total body and regional fat mass has been shown to be highly correlated 
with that of CT-derived outcomes [119], with the latter generally considered the gold 
standard with regard to quantifying these measures [120]. However, limitations may 
arise when examining obese individuals [121], with DXA previously shown to 
underestimate total body fat mass by up to 5.2 kg compared to CT-based protocols 
[119]. Therefore, the use of CT-derived measures of fat may provide increased accuracy 
in men treated with ADT, given the propensity of these men to gain fat mass and size 
during treatment [195]. We found that men treated with ADT had 29-36% greater 
forearm fat CSA when compared to both controls, and a trend for 18-22% greater 
lower leg CSA. Similarly, when expressed as a percent of total limb area, men treated 
with ADT had 4.8-5.8% greater forearm percent fat CSA compared to both controls. 
To our knowledge, this study is the first to examine pQCT-derived fat CSA in men 
treated with ADT when compared to appropriately selected controls. The similar 
magnitude of difference we observed between ADT-treated men and controls at these 
sites (both 3-4 cm2) further supports the notion that ADT likely systematically affects 
subcutaneous fat depots. Subsequently, the difference in forearm fat CSA and trend in 
lower leg fat CSA we observed between men treated with ADT and controls may not 
be of clinical relevance in terms of predicting increased risk of mortality. However, 
the accuracy associated with pQCT-derived fat outcomes strengthen the notion that 
these subcutaneous depots store greater amounts of fat in these men compared to men 
not treated with this therapy.  
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Effects of androgen deprivation therapy on forearm and lower leg muscle density 
Greater amounts of intermuscular fat are represented by a decreased muscle density 
measured pQCT; thus, muscle density is often used as a marker of intermuscular fat 
[77]. Previous research has shown that the accumulation of fat within these ectopic 
depots may impact muscle performance, and has been suggested as one potential 
mechanism to help explain the non-parallel decrements of lean mass and muscle 
strength/power associated with ageing [40]. Furthermore, decreased muscle density was 
independently associated with both increased cardiovascular and all-cause mortality 
in a sample of 1,063 community-dwelling older men (mean age, 77 years) [181]. 
Therefore, the assessment of intermuscular fat via the quantification of muscle density 
appears to be a strong predictor of risk in population groups susceptible to its 
accumulation. Our study demonstrated that men treated with ADT had similar forearm 
muscle density when compared to PCa and healthy controls. However, we observed a 
trend towards ADT-treated men having lesser lower leg muscle density when 
compared to both controls (1.2-1.3 mg/cm3). The influence of ADT on intermuscular 
fat has received limited attention to date. The only study to date having quantified 
prospective changes in CT-derived intermuscular fat following 15-20 weeks of 
treatment observed a mean reduction of 19% [15]. In the aforementioned cohort of 1,063 
healthy older men, each decrement of 3.5 mg/cm3 in muscle density of the lower leg 
was associated with an 18-39% increase in all-cause mortality, 34-66% increase in 
cardiovascular disease mortality and 14-29% increase in non-cardiovascular disease 
mortality [181]. Thus, the trend for a difference we observed may be of limited clinical 
relevance with regard to disease risk. Regardless, our study was the first to compare 
muscle density (as a marker of intermuscular fat) in men treated with ADT to 
appropriately selected controls, with our findings suggesting that ADT may not result 
in greater amounts of fat accumulation in intermuscular depots.     
Duration of androgen deprivation therapy use 
Recent advancements in the treatment of PCa have led to the incorporation of 
intermittent ADT protocols in usual care [4], with this approach aiming to reduce to 
time spent in a hypogonadal state due to the long-term adverse effects associated with 
continuous ADT [65]. There is evidence to suggest that duration of ADT use is 
associated with greater amounts of total body fat mass [18, 315], however, associations 
between ADT use duration and regional depots have not been previously examined. 
We found that duration of ADT use was positively correlated with all subcutaneous 
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regions of fat mass and CSA, bar android region. Moreover, duration of ADT use was 
negatively correlated with forearm muscle density with a negative trend observed for 
lower leg muscle density (P=0.054). These findings suggest that fat likely continues 
to accumulate in subcutaneous and intermuscular depots, but not within visceral 
regions, throughout treatment with ADT. These observations are of significance given 
that ADT may lead to the accumulation of fat mass beyond the plateau or gradual 
decrease in adiposity commonly reported in men following the seventh decade of life 
[142]. Notably, the correlations we observed may have been influenced by the few men 
treated with ADT for greater than five years; thus suggesting that these results should 
be interpreted with caution. Despite this limitation, these correlations should be 
considered during risk stratification and clinical decision making in men treated with 
ADT to ensure both the patient and clinician are aware of the long-term impact of this 
treatment on fat mass and CSA, and subsequent morbidity and mortality.  
Mechanisms of fat accumulation during androgen deprivation therapy 
Given the limited cross-sectional and prospective research to date that examined 
regional fat depots in men treated with ADT, the precise mechanisms behind the 
differences we observed are unknown. However, evidence from the androgen-receptor 
knockout mouse model indicated that hypogonadism decreased overall lipolysis and 
led to obesity [340] whereas, testosterone treatment increased lipolysis [341]. 
Hypogonadism has been suggested to increase adipocyte size and number through 
facilitating triglyceride uptake via increased lipoprotein lipase activity, as well as by 
stimulating pluripotent stem cells to mature into adipocytes [342]. However, the 
translation of these observations to humans is unclear, with the in vitro evidence to 
date having shown that testosterone treatment reduced lipolysis in subcutaneous, but 
not visceral fat depots [343]. This observation in part supports our findings that ADT-
induced hypogonadism appeared to influence subcutaneous, rather than visceral or 
intermuscular fat depots. Whilst the understanding of these mechanisms remain in their 
infancy, current hypotheses propose a cycle in which the accumulation of fat due to 
hypogonadism leads to the inability of the hypothalamic-pituitary-testicular axis to 
respond to decreased androgens [342]; thus potentially explaining why men treated with 
ADT may continue to be hypogonadal following the cessation of ADT [194].  
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5.7 Strengths and limitations 
The strengths of this study were discussed in Chapter 4. Furthermore, the 
quantification of region specific subcutaneous, visceral and intermuscular fat depots 
provided novel insight into potential complications associated with ADT-induced 
hypogonadism. Of these regional fat depots, this study was the first that examined 
forearm (66% radius) and lower leg (66% tibia) fat CSA and muscle density (as a 
marker of intermuscular fat) in men treated with ADT. Moreover, this study was the 
first to have examined a wide range of fat depots in men treated with ADT when 
compared to appropriately selected controls.  
In addition to those outlined in Chapter 4, there are limitations associated with the data 
presented in this chapter which warrant caution when interpreting results. Due to 
DXA-estimated measurement of abdominal subcutaneous and visceral fat mass in this 
study, comparisons to CT- and MRI-derived outcomes may be limited. Additionally, 
muscle density was used as a marker of intermuscular fat due to noted limitations with 
current soft tissue analyses when assessing intermuscular fat directly [117]; therefore, 
these results were only an estimate of true intermuscular fat differences between 
groups.  
5.8 Conclusion 
In summary, the findings from this study found that men treated with ADT had greater 
amounts of fat stored in subcutaneous depots, but not within the visceral region of the 
abdominal cavity, when compared to PCa and healthy controls. Moreover, ADT-
treated men did not possess compromised intermuscular fat compared to either control. 
Finally, we found that ADT use duration correlated with the majority of subcutaneous 
and intermuscular depots, indicating that the accumulation of fat mass at these sites 
likely continues throughout ADT. Collectively, the findings from this study indicate 
that ADT use has regional specific effects of fat depots, largely resulting in an increase 
in subcutaneous fat deposits.  
In conclusion, differences in regional fat mass observed between men treated with 
ADT and controls tended to be within subcutaneous depots, rather than visceral or 
intermuscular depots, and thus may be of limited clinical relevance with regard to risk 
of adverse health outcomes. Given these observations, quantifying visceral and 
intermuscular fat in ADT-treated men may be of less importance in the clinical setting, 
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and these men may benefit from DXA-based monitoring of fat mass during therapy, 
similar to current recommendations with regard to bone mineral density [195]. 
Monitoring these changes are of increased clinical importance given the correlations 
observed in this study, which indicated that men treated with ADT do not experience 
the plateau/decline in various depots of fat mass commonly observed in healthy older 
men following the seventh decade of life. Therefore, interventions are required to 
manage this continued increase in fat mass during ADT to mitigate subsequent risk of 
adverse health outcomes. In the following chapter, the effects of a novel multi-
component exercise program and nutritional supplementation intervention in men 
treated with ADT for PCa compared to usual care will be presented. 
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The feasibility of combined exercise training and nutritional 
supplementation compared to usual care in men treated with 
androgen deprivation therapy for prostate cancer: a randomised 
controlled trial 
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6.1 Declaration statement 
Under the guidance of supervisors, the candidate developed the study concept and 
initiated the project, provided significant input into the development of the protocol, 
implemented the protocol and oversaw the collection of the data, analysed and 
interpreted all data presented, and drafted, revised and approved the published protocol 
manuscript.   
6.2 Overview 
This chapter was initially planned to present the results of a 52-week randomised 
controlled trial (RCT) that examined the efficacy of a multi-component exercise 
program combined with protein, calcium and vitamin D supplementation 
(Ex+ProCaD) compared to usual care in men treated with androgen deprivation 
therapy (ADT) for prostate cancer (PCa; Appendix A). However, delays in the 
recruitment of this clinical population group beyond the control of the PhD candidate 
and the supervision team resulted in an extended study timeline, with recruitment still 
remaining active as of the submission of this thesis. Subsequently, this chapter presents 
the feasibility of conducting the first 26-weeks of the RCT from 2014 to 2017 with 
regard to recruitment, attrition, adherence, data collection and safety.  
Additionally, baseline and follow-up descriptive data from the first 28 men who 
completed the 26-week intervention during this timeframe are presented in this 
chapter. Baseline data from the 42 ADT-treated men recruited in total are presented in 
Chapter 4 and Chapter 5. Notably, within- and between-group statistics are not 
presented based on the following reasons: 1) trial results may change with follow-up 
of the complete cohort of participants (n=70 target); 2) the reporting of preliminary 
results may introduce biases that jeopardise the eventual outcomes; and 3) the lack of 
adequate statistical power may increase the probably of a type II error [302].  
6.3 Introduction 
In Australia, as in other developed countries, PCa is the most commonly diagnosed 
male cancer [1]. Approximately 1.1 million new cases of PCa are diagnosed worldwide 
each year [1]. It was estimated that approximately 13% of Australian male cancer-
related deaths were attributed to PCa, which ranks second to lung cancer as the most 
common cause of male cancer-related death [63]. Due to medical advancements in both 
the screening and treatment of PCa, 5-year relative survival rates are now approaching 
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100% internationally [344], and thus these patients are living longer, but susceptible to 
potential age-related and treatment-related declines in health. Therefore, the clinical 
paradigm is shifting to an increased focus on survivorship and improving the quality 
of years lived.   
Various modalities of ADT, including those administered neoadjuvant or adjuvant 
with other treatments, are commonly used to treat PCa as it improves overall survival, 
particularly in men with advanced PCa [5, 6, 8, 9]. However, the evidence that ADT 
prolongs survival in men with localised PCa remains limited and therefore debated [68,
69]. Despite this lack of evidence, the use of ADT continues to increase for all stages 
and grades of PCa [345]. It was estimated that approximately 23,500 Australian men 
received pharmacological ADT via gonadotropin-releasing hormone (GnRH) agonists 
in 2008-09 [56]. After repeating this analysis for 2013-14, we estimated that 
approximately 25,500 men are currently receiving ADT via GnRH agonists [71]. Thus 
ADT remains the most common cause for severe male hypogonadism in Australia. 
Despite benefits in overall survival, the hypogonadism induced via ADT has been 
associated with numerous adverse effects, such as those negatively influencing 
muscle, fat and performance outcomes. It has been reported that within the first three 
to 12 months of ADT, men experience losses in lean mass and muscle strength of up 
to 5% [21, 194, 346, 347] and 11% [25, 28, 29], respectively, which may partially contribute to 
the observed 23-65% increased fracture risk in this group [202, 214, 348]. There is also a 
profound gain (up to 15%) in fat mass which likely contributes to the 10-45% reported 
increased risk of diabetes, coronary heart disease, myocardial infarction and sudden 
cardiac death [207, 220, 333, 346, 349, 350]. Thus, there is a need to develop safe and effective 
interventions to manage the multiple treatment-induced adverse effects of ADT in men 
with PCa. 
Exercise training has been recommended as a viable intervention to ameliorate many 
of the adverse effects of ADT [60, 231, 351]. Previous studies in men treated with ADT 
have shown that interventions including aerobic training, progressive resistance 
training (PRT) or the combination of both over periods of 12-52 weeks may improve 
total body (0.7 kg) [227, 246] and appendicular lean mass (ALM; 0.5 kg) [227, 238], lower 
total body (-0.6 kg) [234] and trunk fat mass (-0.5 kg) [234], increase upper body (up to 
26%) [227, 232, 234, 238, 243, 246] and lower body muscle strength (up to 37%) [227, 232, 234, 238,
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243, 246], improve upper (47%) [227] and lower body muscle endurance (69%) [227] and 
improve gait speed (6.4%) [227], when compared to usual care control groups. However, 
emerging evidence in healthy older men without PCa has suggested that the use of 
multi-nutrient supplementation, such as vitamin D and protein, may optimise the 
benefits of exercise training on certain muscle outcomes, including lean mass and 
muscle strength [195, 351].  
Current nutritional guidelines for individuals with or at risk of sarcopenia have 
emphasised the importance of vitamin D and dietary protein [352]. Studies in healthy 
older adults have shown that 700-2,000 IU/day of vitamin D can improve muscle 
strength and functional capacity and reduce falls risk, however, these results were most 
commonly observed in individuals with the lowest serum 25-hydroxyvitamin D (< 30-
60 nmol/L) [279, 353, 354]. While data on the vitamin D status of men with PCa is limited, 
in a small sample of 49 older men treated with ADT for PCa (mean age, 73 years) from 
Spain, it was reported that the average serum 25-hydroxyvitamin D was 21 ng/ml (52 
nmol/L), with only 22% of men having levels > 30 nmol/L, whereas 30% and 48% 
were reported to have very low levels of < 15 nmol/L and levels between 15-30 
nmol/L, respectively [249]. Therefore, supplementation with vitamin D in this 
susceptible population group should also be considered. With regard to protein 
supplementation, there is some evidence in healthy older adults that higher protein 
intakes (> 1.2 g/kg/d) may help to enhance weight loss, offset muscle loss, improve 
lipid profiles and insulin sensitivity [274]. While this is not a universal finding, this could 
be explained by the basal levels of protein intake prior to supplementation, the modest 
level of protein intake achieved in some studies and/or the type (quality) of protein 
consumed. To date, the efficacy of these nutritional supplementation protocols have 
not been investigated in men treated with ADT. It is well known that PRT stimulates 
muscle protein synthesis, but in a fasted state it also accelerates muscle protein 
breakdown [292]. Ingestion of a high quality, rapidly digested protein-rich source such 
as whey-protein, post-exercise can attenuate the increase in muscle protein breakdown 
and stimulate muscle protein synthesis to enhance the anabolic benefits of PRT [292]. 
Additionally, PRT prior to protein intake may facilitate greater use of protein-derived 
amino acids from the ingested protein [292]. Thus, combining PRT with whey-protein 
ingestion may represent an optimal strategy to enhance muscle hypertrophy. While 
questions still remain in terms of the optimal dose of protein needed to elicit a 
synergistic response with PRT, emerging evidence indicates that 20-40 g of high 
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quality protein be consumed early after a bout of PRT to enhance lean mass and/or 
muscle strength [292]. However, a critical but as yet unanswered question is whether 
ingestion of a whey-protein with PRT can improve these outcomes in ADT-treated 
men.  
Previous studies that have examined the efficacy of exercise training and multi-
nutrient supplementation in healthy older adults have shown mixed results with regard 
to muscle, fat and performance outcomes [355, 356]. Following an 18-month factorial 
design RCT in 180 healthy older men (age range, 50-79 years), the addition of a low-
fat fortified milk product which provided approximately 13.2 g protein, 1,000 mg 
calcium and 800 IU vitamin D did not further augment the improvements observed 
following a multi-modal exercise program including PRT alone on dual-energy x-ray 
absorptiometry (DXA)-derived lean mass (0.6 kg), computed tomography (CT)-
derived muscle cross-sectional area (CSA; 1.8%), muscle strength (20-52%) and gait 
speed (11%) [355]. The authors suggested that the lack of additional benefit of the multi-
nutrient supplement likely stemmed from the adequate levels of serum 25-
hydroxyvitamin D (mean, 86 nmol/L) in participants at baseline, as well as these 
participants having reported daily dietary protein and calcium intakes above or 
equivalent to current Australian daily recommendations (0.85 g/kg and 1,000 mg, 
respectively) [357]. In contrast, a 9-month RCT in 96 vitamin D deficient (serum 25-
hydroxyvitamin D ≤ 16 ng/ml) adults aged 70 years or greater demonstrated that a 
multi-nutrient supplement (400 IU vitamin D and 800 mg calcium) and PRT 
intervention relative to a calcium-only supplement (800 mg) and PRT intervention 
resulted in greater improvements in functional capacity assessed via the timed-up-and-
go (net difference, 3.9%), yet no within group changes or between group differences 
were observed for the change of DXA-derived lean or fat mass [356]. Emerging 
evidence has shown that in 130 older adults (mean age, 80 years) with pre-sarcopenia 
via low ALM adjusted for height (ALMI; men, < 7.26 kg/m2; women, < 5.5 kg/m2), a 
12-week progressive exercise program combined with a daily multi-nutrient 
supplement (whey protein, 22 g; vitamin D, 100 IU) increased DXA-derived fat-free 
mass relative to a 12-week PRT program combined with a placebo supplement (net 
difference, 1.7 kg) [358]. These findings support the initial values principle of exercise 
training, in which those with the lowest physiological values have the greatest capacity 
to obtain improvements. Collectively, these findings suggest that multi-nutrient 
supplements may augment the effects of exercise training in those who are deficient 
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in the included nutrients and present with lower initial values, however, this notion is 
yet to be examined within men treated with ADT. 
Given the demonstrated efficacy of previously mentioned exercise training and 
emerging evidence in support of nutritional supplementation to potentially counteract 
the range of treatment-induced adverse effects in men undergoing ADT, it is therefore 
plausible that the combination of these interventions may optimise benefits in these 
men [195]. There are currently no established guidelines for specifically managing the 
large range of adverse effects observed in men treated with ADT [231]. In terms of 
muscle, fat and performance, the guidelines are less evidence-based within this 
specific clinical population group [56, 59], and commonly recommend more generic 
exercise training guidelines for cancer survivors [221, 359-361], with no mention of 
nutrition and/or diet [195]. Therefore, well-designed long-term trials are needed to 
inform ADT-specific exercise training and nutritional guidelines for managing the 
myriad of adverse effects associated with ADT. However, whether these interventions 
are feasible in this clinical population group is unknown.  
Potential feasibility issues in men treated with ADT for PCa primarily stem from the 
myriad of treatment-induced adverse effects often reported [11-14]. Whilst a recent 
pooled analysis of 1,366 cancer survivors (mean age, 75 years; PCa, 46%) concluded 
that average retention rates for exercise and diet-based lifestyle interventions were 
91% [363], the potential influence of ADT-induced adverse effects is unknown. 
Similarly, whether these complications impede adherence and pose concerns to 
participant safety warrants investigation. In a study of 62 men treated with ADT (mean 
age, 68 years), 40% were precluded from muscle strength tests involving a handheld 
dynamometer due to pre-existing comorbidities [28]; thus the feasibility of collecting 
data should also be considered in this clinical population group. Moreover, it has been 
estimated that only 55% of funded clinical trials in the United Kingdom recruited their 
intended total sample [370]. Whilst these findings are not specific to ADT-treated men, 
the aforementioned concerns associated with treatment-induced adverse effects, as 
well as that poor physical and mental health has been shown to limit participation in 
physical activity in older adults [364, 365] highlight the need to determine the most 
effective pathways for recruiting and enrolling ADT-treated men into lifestyle 
interventions.  
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While the overall aim of this study was to examine the efficacy of Ex+ProCaD when 
compared to usual care in men treated with ADT for PCa, the specific aim of this 
chapter was to describe the feasibility of conducting the first 26-weeks of the RCT 
with regard to recruitment, attrition, adherence, data collection and safety. Secondary 
aims included the presentation of descriptive data from the 28 men who completed the 
26-week intervention at the time of write up for this chapter. 
6.4 Methods 
Details on the methodology of this study are discussed in Chapter 3 and Appendix A. 
In brief, the study presented in this chapter was a single-blinded, parallel two-arm 26-
week RCT in which men with PCa treated with ADT were randomly assigned to either 
Ex+ProCaD or a usual care control. The aspects presented in this chapter were 
undertaken within the Institute for Physical Activity and Nutrition, Deakin University, 
Australia from 2014 to 2017. The study was approved by the human research ethic 
committees at Deakin University (HREC 2013-184) and Alfred Health (Project No: 
455/15) and was registered with the Australian and New Zealand Clinical Trials 
Registry (ACTRN12614000317695). 
Participants were mainly recruited via clinician referral from Alfred Health 
(Melbourne, Australia) and six private practices (all within Victoria, Australia), as well 
as from 32 PCa support groups and advertisements in one state and 38 local 
newspapers. In addition, a state news report was aired on state television, 
advertisements were placed on Deakin University’s website and in Deakin 
University’s Clinical Exercise Learning Centre and mailing lists of the Prostate Cancer 
Foundation of Australia and Advanced Prostate Cancer Group were emailed. Eligible 
participants were men aged 50-85 years who were currently treated with 
pharmacological ADT for histologically diagnosed PCa for greater than 12 weeks at 
enrolment. Participants were excluded if they did not have the ability to complete 
surveys in the English language, had any disorder known to affect bone, calcium or 
vitamin D metabolism (other than hypogonadism), were currently receiving 
pharmacological intervention known to affect bone metabolism (other than ADT), had 
supplemented with protein, calcium (> 600 mg/day) or vitamin D (> 1,000 IU/day) in 
the past three months, had undertaken PRT (> 1 session/week) or regular weight-
bearing impact exercise (> 150 min/week) in the past three months, were current 
smokers, had a weight greater than 159 kg, had plans to travel for greater than six 
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weeks continuously within the following 52 weeks, or had any absolute 
contraindications to exercise training (e.g. musculoskeletal, cardiovascular or 
neurological) according to the American College of Sports Medicine guidelines [24]. 
All eligible participants were required to provide informed consent before 
participating in the study and were required to obtain medical approval from their 
physician. Randomisation was at the level of the individual participant following 
baseline testing, stratified by age (< 65 or ≥ 65 years) and body mass index (BMI; < 
30 or ≥ 30 kg/m2), using a computer-generated random number sequence and opaque 
envelopes to ensure allocation concealment by an independent researcher not affiliated 
with the study.  
Participants randomised to the intervention group received Ex+ProCaD. The exercise 
program consisted of two gym-based supervised training sessions per week under the 
guidance of an Accredited Exercise Physiologist (tertiary trained exercise 
professional), as well as one unsupervised home-based training session. The exercise 
program followed key training principles of specificity, progressive overload and 
periodisation and was individually tailored to the health and functional status of each 
participant. Each supervised session (approximately 60 minutes) consisted of a warm-
up and cool-down and a combination of aerobic, resistance, weight-bearing impact and 
challenging balance/functional exercises. Home-based sessions followed a similar 
format to supervised sessions, but were modified to be completed within the home-
based setting. The nutritional supplementation consistent of a daily whey protein, 
calcium and vitamin D enriched drink (sachet) combined with a single 1,000 IU 
vitamin D tablet. Together, these provided 25 g protein (21 g whey protein), 1,200 mg 
calcium carbonate (480 mg elemental calcium) and 2,000 IU vitamin D per day. On 
exercise training days, participants were encouraged to consume the sachet within 1-2 
hours of completing their exercise session and on the non-training days, participants 
were asked to take one sachet every morning before breakfast. This was designed to 
try and ensure a more even protein intake throughout the day. Participants allocated to 
usual care received ongoing care from their physician/specialist, but no additional 
access to the intervention. Due to current practice guidelines, all men randomised to 
usual care received 1,000 IU vitamin D per day in the form of a single tablet. 
All data were collected at baseline and 26 weeks. Information with regard to feasibility 
outcomes are presented in Table 6.1, and include those pertaining to recruitment, 
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attrition, adherence, data collection and safety. Height and weight were assessed using 
standard techniques. BMI was calculated as weight (kg) divided by height (m) squared. 
Habitual physical activity and diet (excluding nutritional supplementation provide in 
the study) were assessed by self-reported questionnaire and 24-hour food recall, 
respectively. Demographical, clinical and lifestyle information was assessed by 
questionnaire. Total body and regional lean mass and total body fat mass and 
percentage fat mass were assessed by DXA. Specifically, DXA-derived abdominal 
subcutaneous and visceral fat were measured using CoreScan software. ALM was 
calculated as arm lean mass (kg) plus leg lean mass (kg) [77]. Muscle, subcutaneous fat 
and limb CSA and muscle density of the forearm (66% radius) and lower leg (66% 
tibia) was assessed by peripheral quantitative computed tomography (pQCT) [311, 312]. 
Percent muscle and subcutaneous fat CSA was calculated as muscle or fat CSA (cm2) 
divided by total limb CSA (cm2). Muscle strength was assessed by various three-
repetition maximum (3-RM) protocols and handgrip dynamometry. Functional muscle 
power was assessed by the 30-second sit to stand. Functional capacity was assessed by 
a battery of common valid and reliable tests: timed-up-and-go with a secondary 
cognitive task (a measure of dual-task agility), four-square step test (a measure of 
dynamic mobility), Berg balance scale (a measure of static and dynamic balance), four 
metre usual walk (a measure of gait speed) and 400 metre walk (a measure of mobility 
limitations). Prostate-specific antigen (PSA; a measure of PCa activity) was assessed 
by immunoassay. Compliance was assessed by attendance record, self-reported diaries 
and counting all returned supplement. Adverse events potentially or confirmed to be 
associated with the study were monitored and documented by the exercise trainers at 
each exercise training sessions for the intervention group participants and via monthly 
phone calls by the research staff to the control group participants. 
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Table 6.1. Feasibility outcomes examined in the randomised controlled trial. 
Outcome Measures 
Recruitment Enrolled participants compared to total screened potential participants 
Reasons for ineligibility or declined participation  
Enrolment timeline 
Efficacy of recruitment pathways 
Attrition Number of participants available for follow-up 
Reasons for loss to follow-up 
Adherence Supervised, home-based and total exercise training sessions completed 
Sachet supplement consumed  
Vitamin D tablet supplement consumed (both groups) 
Data collection Collected data compared to missing data 
Safety Number, severity and relatedness to the study of adverse events 
Prostate specific antigen 
All data were collated using STATA statistical software (STATA, College Station TX, 
United States of America). After data were screened for outliers, descriptive statistics 
were computed. Where possible, endpoint measures were obtained from any 
participant lost to follow-up and all randomised men who had completed 26-week 
follow-up by the time of data analysis for this chapter were included in descriptive 
statistics. Baseline measures and changes in outcome variables were computed as 
means ± standard deviation or 95% confidence intervals. Net differences were 
calculated by subtracting within-group changes for the control group from within-
group changes for the intervention group.  
6.5 Results 
6.5.1 Recruitment 
A total of 149 participants (expressions of interest) were assessed for eligibility (Table 
6.2; Figure 6.1), from which 42 (28%) were included in the study. A total of 75 (50%) 
men did not meet specific inclusion criteria and 21 (14%) subsequently declined to 
participate, despite having met all inclusion criteria. At the time of write up for this 
chapter, an additional 11 potential participants were deemed ‘pending’ as they were 
still being assessed for eligibility and yet to complete baseline testing. The most 
common reasons for failing to meet inclusion criteria were not currently being treated 
with ADT (n=36; 24% of all potential participants) and vitamin D supplementation 
greater than 1,000 IU per day (n=12; 8.1% of all potential participants). For those 
participants who declined to participant, no reason (n=10, 6.7% of all potential 
participants) was the most frequent response.    
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Table 6.2. Reasons participants were excluded from the trial. 
Failed inclusion criteria Declined to participate 
Reason Total, n (%) Reason Total, n (%) 
Not currently on ADT 36 (48.0%) No reason 10 (47.6%) 
Vitamin D > 1,000 IU/day 12 (16.0%) No time 4 (19.0%) 
PRT > 1 session/week 6 (8.0%) Disease progression 2 (9.5%) 
Use of antiresorptive therapy 5 (6.7%) Geographical location 2 (9.5%) 
Located interstate 5 (6.7%) Pain due to metastases 1 (4.8%) 
Current smoker 5 (6.7%) No clinician support 1 (4.8%) 
No prostate cancer 2 (2.7%) Not willing to be control 1 (4.8%) 
Age > 85 years 1 (1.3%) - - 
Calcium > 600 mg/day 1 (1.3%) - - 
Lost to follow-up 1 (1.3%) - - 
Orchiectomy 1 (1.3%) - - 
Total 75 (100.0%) Total 21 (100.0%) 
Data are: number of participants and percentage of participants who failed inclusion criteria or declined 
to participate. 
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Figure 6.1. Flowchart of participants through the study.* Participants who had 
completed the 26-week follow-up period by write up of this chapter. ADT, androgen 
deprivation therapy; PRT, progressive resistance training. 
A summary of recruitment pathway outcomes are presented in Table 6.3. Overall 
clinician referral (n=42; 28% of total screened), followed by PCa support groups and 
local newspaper advertisement (both, n=31; both, 21% of total screened) and then a 
State television news report (n=23; 15.4% of total screened) resulted in the highest 
number of participants screened. In terms of eligible participants who were included 
in the intervention, clinician referral (n=18; 43% of total screened from recruitment 
pathway) and PCa support groups (n=12; 39% of total screened from the recruitment 
pathway) were the most successful.  
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Table 6.3. Outcomes of all recruitment pathways. 
Outcome Total 
screened Recruitment pathway Included Excluded Pending 
Clinician referral 18 (43%) 18 (43%) 6 (14%) 42 
Prostate cancer support group 12 (39%) 18 (58%) 1 (3%) 31 
Local newspaper advertisement 4 (13%) 27 (87%) 0 (0%) 31 
State news television report 3 (13%) 18 (78%) 2 (9%) 23 
Word of mouth 2 (29%) 4 (57%) 1 (14%) 7 
Deakin University website 2 (67%) 1 (33%) 0 (0%) 3 
State newspaper advertisement 1 (20%) 3 (60%) 1 (20%) 5 
Advanced PCa Group Australia email 0 (0%) 3 (100%) 0 (0%) 3 
PCa Foundation of Australia email 0 (0%) 2 (100%) 0 (0%) 2 
Flyer in university exercise centre 0 (0%) 2 (100%) 0 (0%) 2 
Total 42 96 11 149 
Data are: number of participants and percentage of total screened from specific recruitment pathway. 
PCa, prostate cancer. 
A timeline of participant recruitment is presented in Figure 6.2; notably, four clusters 
of enrolment occurred. The first cluster of enrolled participants (n=12) was 
predominantly attributed to the commencement of recruitment via PCa support groups 
and newspaper advertisement. The second cluster of enrolled participants (n=9) largely 
stemmed from contact with private urology practices and subsequent clinician 
referrals. The third cluster of enrolled participants (n=14) mainly resulted from 
clinician referrals from Alfred Health. The final cluster of enrolled participants (n=7) 
followed the state news television report that featured the trial.  
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Figure 6.2. Participants recruited throughout the randomised controlled trial. 
Recruitment (ongoing) 
Prostate cancer support groups and newspaper advertisement 
Clinician referrals 
News report 
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6.5.2 Attrition 
For this analysis, a total of 28 men with PCa on ADT were randomised to the exercise 
intervention (n=16) or usual care control group (n=12). Participant retention from 
baseline to 26-week follow up was 96% (27 of 28 men). One participant who was 
allocated to the Ex+ProCaD group was lost to follow-up due to complications 
associated with PCa progression.  
6.5.3 Adherence 
On average, participants within the Ex+ProCaD group completed 60% (range, 10-
90%) of all training sessions (68% supervised gym-based [range, 12-90%]; 50% 
unsupervised home-based [range, 15-88%]; Figure 6.3). Notably, one participant (lost 
to follow-up) discontinued the intervention after completing 10% of total sessions due 
to complications associated with PCa progression. Compliance with the protein, 
calcium and vitamin D sachet and vitamin D tablet within the Ex+ProCaD group was 
92% (range, 60-100%) and 93% (range, 55-100%), respectively (Figure 6.3). Due to 
gastrointestinal upset (constipation), one participant discontinued the sachet 
supplement and finished with a compliance of 60%. Participants allocated to the 
control consumed 94% (range, 64-100%) of the daily vitamin D tablets.  
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Figure 6.3. Histograms of the 26-week compliance for participants in the 
intervention group for the vitamin D tablet, multi-nutrient sachet and exercise training 
(all and supervised).  
6.5.4 Data collection 
Missing data at baseline and follow-up in men who completed the 26-week 
intervention period are presented in Table 6.4. All outcomes include some missing 
data at baseline and/or follow-up (range, 3.6-50%). Four outcomes only had missing 
data for the one participant who was lost to follow-up. Missing data for dietary intake 
(n=8), handgrip muscle strength (n=6), chest muscle strength (n=6) and gait speed 
(n=6) was due to the addition of secondary aims, outcome measures and confounding 
variables pertaining to sarcopenia and sarcopenic obesity after the initial 
commencement of the study. Global obesity prevented the acquisition of DXA total 
body scan outcomes for one participant, while central obesity limited the acquisition 
of DXA CoreScan outcomes for two participants. Upper arm obesity restricted the 
ability to obtain pQCT forearm outcomes for one participant. One participant refused 
radiological scans at follow-up due to concerns regarding radiation exposure, whereas 
one participant refused the PSA blood test at follow-up due to the self-reported 
inconvenience associated with providing a fasting blood sample. Six pQCT scans 
(forearm, n=5; lower leg, n=1) were excluded based on scoring four or five on the 
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visual inspection rating scale of participant movement (i.e. erroneous data due to 
movement artefact) proposed by Blew et al. [311]. The ethical approval granted for the 
study did not include the option for repeat scans due to the radiological nature of scan 
acquisition. Safety concerns associated with various pre-existing comorbidities 
prevented the collection of the following outcomes: chest muscle strength (n=3, 
shoulder injury; n=2, acute hypertension; n=1, inguinal hernia; n=1, bone metastases 
at shoulder; n=1, atrial fibrillation; n=1, fatigue), leg muscle strength (n=3, acute 
hypertension; n=2, knee injury; n=1, inguinal hernia; n=1, atrial fibrillation; n=1, 
fatigue), back muscle strength (n=2, acute hypertension; n=2, neck injury; n=1, 
inguinal hernia; n=1, atrial fibrillation; n=1, fatigue; n=1, recent cervical spine 
surgery), 400 metre walk (n=1, fatigue) and Berg balance scale (n=1, postural 
hypotension). Finally, due to the complete case approach adopted for the descriptive 
statistics of absolute and percent changes presented in this chapter, when analysable 
data was not collected at baseline, these participants were omitted from analyses 
(range, 0-46%). 
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Table 6.4. Missing data at baseline and 26 weeks in the Ex+ProCaD (INT; n=16) and control (CON; n=12) groups. 
Added after 
study began 
Missing at 
baseline 
Unable to 
define ROI 
Lost to 
follow-up 
Participant 
refused 
Movement 
artefact * 
Pre-existing 
comorbidities Total 
Measure INT CON INT CON INT CON INT CON INT CON INT CON INT CON INT CON 
Dietary intake 
  Baseline 4 4 - - - - 0 0 0 0 - - - - 4 4 
  26 weeks - - 4 4 - - 0 0 0 0 - - - - 4 4 
Weight 
  Baseline - - - - - - 0 0 0 0 - - - - 0 0 
  26 weeks - - 0 0 - - 1 0 0 0 - - - - 1 0 
DXA total body scan 
  Baseline - - - - 1 0 0 0 0 0 - - - - 1 - 
  26 weeks - - 1 0 0 0 1 0 0 1 - - - - 2 1 
DXA CoreScan 
  Baseline - - - - 1 1 0 0 0 0 - - - - 1 1 
  26 weeks - - 1 1 0 0 1 0 0 1 - - - - 2 2 
pQCT forearm 
  Baseline - - - - 1 0 0 0 0 0 1 4 - - 2 4 
  26 weeks - - 2 4 0 0 0 0 0 0 0 0 - - 2 4 
pQCT lower leg 
  Baseline - - - - 0 0 0 0 0 0 0 1 - - 0 1 
  26 weeks - - 0 1 0 0 1 0 0 1 0 0 - - 1 2 
Handgrip muscle strength 
  Baseline 3 3 - - - - 0 0 0 0 - - 0 0 3 3 
  26 weeks - - 3 3 - - 0 0 0 0 - - 0 0 3 3 
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Chest muscle strength 
  Baseline - - - - - - 0 0 0 0 - - 2 6 2 6 
  26 weeks - - 2 6 - - 1 0 0 0 - - 1 0 4 6 
Leg muscle strength 
  Baseline - - - - - - 0 0 0 0 - - 2 4 2 4 
  26 weeks - - 2 4 - - 1 0 0 0 - - 1 1 4 5 
Back muscle strength 
  Baseline 3 3 - - - - 0 0 0 0 - - 2 5 5 8 
  26 weeks - - 5 8 - - 0 0 0 0 - - 0 1 5 9 
Timed-up-and-go 
  Baseline - - - - - - 0 0 0 0 - - 0 0 0 0 
  26 weeks - - 0 0 - - 1 0 0 0 - - 0 0 1 0 
Four-square step test 
  Baseline - - - - - - 0 0 0 0 - - 0 0 0 0 
  26 weeks - - 0 0 - - 1 0 0 0 - - 0 0 1 0 
30-second sit-to-stand
  Baseline - - - - - - 0 0 0 0 - - 0 0 0 0 
  26 weeks - - 0 0 - - 1 0 0 0 - - 0 0 1 0 
Gait speed 
  Baseline 3 3 - - - - 0 0 0 0 - - 0 0 3 3 
  26 weeks - - 3 3 - - 0 0 0 0 - - 0 0 3 3 
400 metre walk 
  Baseline - - - - - - 0 0 0 0 - - 0 1 0 1 
  26 weeks - - 0 1 - - 1 0 0 0 - - 0 0 1 1 
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Berg balance scale 
  Baseline - - - - - - 0 0 0 0 - - 1 0 1 0 
  26 weeks - - 1 0 - - 1 0 0 0 - - 0 0 2 0 
Prostate specific antigen 
  Baseline - - - - - - 0 0 0 0 - - 0 0 0 0 
  26 weeks - - 0 0 - - 1 0 1 0 - - 0 0 2 0 
Data are: number of participants with missing data. DXA, dual energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography; ROI, region of interest. * 
Excluded based on scores of four or five on the visual inspection rating scale of participant movement proposed by Blew et al. [311]. 
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6.5.5 Safety 
Absolute changes in PSA over the 26-week follow-up are shown in Figure 6.4. On 
average, men allocated to Ex+ProCaD decreased PSA by 1.4 ng/mL (range, -8.2 to 
15.2 ng/mL), whereas the control group increased by 1.0 ng/mL (range, -42.0 to 49.7 
ng/mL).  
Figure 6.4. Individual absolute changes in prostate specific antigen in the 
Ex+ProCaD and control groups from baseline to 26-week follow-up. 
Overall, there were 37 adverse events reported in 13 participants (46% of total sample; 
all within the intervention group; 81% of intervention group) documented throughout 
the study (Table 6.5). Five participants reported one adverse event, three reported two, 
two reported four, one reported five, one reported six and one reported seven. On 
average, men who reported an adverse event experienced three. No adverse events 
were reported from the controls during monthly phone calls to them. Only one adverse 
event (2.7%) was deemed serious, in which a participant in the intervention group was 
hospitalised due to hyperglycaemia and was subsequently diagnosed with type 2 
diabetes; however, this event was determined to be unrelated to the study. All other 
adverse events were either mild (n=22; 59%) or moderate (n=14; 38%) in terms of 
severity, which meant they caused limited inconvenience when completing activities 
of daily living. Collectively, six of 37 events (16%) were confirmed to be related to 
the study, two (5.4%) were deemed probable and six (16%) were deemed possible in 
terms of being study-related. No events resulted in a permanent discontinuation of the 
intervention, however, one participant discontinued the sachet supplement due to 
gastrointestinal upset (constipation). Moreover, two adverse events reported by the 
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same participant resulted in two and three sessions missed, respectively. The exercise 
program was also temporarily or permanently modified following 19 (51%) and 5 
(14%) adverse events, respectively. The majority of temporary modification lasted one 
session (89%), whilst one event led to the cessation of the home-based training 
component for one week and another resulted in the removal of the bench press 
exercise indefinitely. Permanent modification of the exercise program tended to 
pertain to safety and resulted in increased emphasis on posture (n=1), support rails for 
balance (n=1), education and specific exercises (n=1) and monitoring of blood glucose 
levels (n=1) or blood pressure (n=1). 
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Table 6.5. Details of all recorded adverse events from baseline to 26-week follow-up. 
ID Adverse event Severity Study-related Action taken with intervention Outcome of adverse event Expected Serious 
001 
Acute illness  
(flu-like symptoms) Mild No None Resolved No No 
001 
Acute illness 
(diverticulitis flare-up) Mild No None Resolved No No 
001 Muscle/Joint(lower leg muscle strain) Mild No 
Temporarily modified 
(lower leg exercises removed for 
1 session) 
Resolved No No 
001 
Muscle/Joint 
(chest muscle strain) Moderate Probable 
Temporarily modified 
(seated row modified for 1 
session) 
Resolved No No 
002 Acute illness(gastroenteritis) Mild No None Resolved No No 
003 Gastrointestinal upset(constipation) Moderate Definite 
Permanently modified 
(sachet discontinued) Resolved No No 
004 Muscle/Joint
(shoulder muscle strain) 
Mild Definite 
Temporarily modified 
(upper limb exercise intensity 
reduced for 1 session)  
Resolved No No 
005 
Gastrointestinal upset 
(constipation) Mild Possible None Resolved No No 
006 Blood pressure
(acute hypotension) 
Mild No None Still present, treatment 
(general practitioner)  
No No 
006 
Blood pressure 
(postural hypotension) Mild No None 
Still present, treatment 
(general practitioner)  No No 
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006 Fall(during lunge; no injury) Mild Definite 
Permanently modified 
(emphasised support rails) Resolved No No 
006 
Fall 
(vasovagal; bruises) Mild No None 
Residual effects, no 
treatment No No 
006 
Muscle/Joint 
(foot pain; synovitis) Mild No None Resolved No No 
007 Blood pressure(acute hypertension) Mild No 
Permanently modified 
(emphasised monitoring of 
blood pressure) 
Still present, treatment 
(general practitioner)  No No 
007 
Muscle/Joint 
(back muscle strain) Moderate Possible 
Temporarily modified 
(home-based exercises not 
completed for 1 week) 
Resolved No No 
008 
Metabolic 
(hyperglycaemia; diagnosed 
with type 2 diabetes) 
Severe No 
Permanently modified 
(emphasised monitoring of 
blood glucose levels) 
Still present, treatment 
(general practitioner)  No Yes 
008 
Muscle/Joint 
(radiating leg pain from pre-
existing disc bulge) 
Moderate Probable 
Permanently modified 
(specific exercises and education 
provided) 
Still present, treatment 
(exercises) 
No No 
008 Muscle/Joint(shoulder muscle strain) Mild Possible 
Temporarily modified 
(upper limb exercise intensity 
reduced for 1 session) 
Resolved No No 
008 
Muscle/Joint 
(lower limb muscle strain) Mild Definite 
Temporarily modified 
(lower limb exercise intensity 
reduced for 1 session) 
Resolved No No 
009 Acute illness
(flu-like symptoms) 
Moderate No 
Temporarily modified 
(1 session missed; reduced 
intensity for 1 session) 
Resolved No No 
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009 Blood pressure(acute hypertension) Moderate No 
Temporarily modified 
(reduced intensity for 1 session) Resolved No No 
009 Muscle/Joint
(chest muscle strain) 
Moderate No 
Temporarily modified 
(upper limb exercise intensity 
reduced for 1 session) 
Resolved No No 
009 
Muscle/Joint 
(fatigue) Moderate No 
Temporarily modified 
(reduced intensity for 1 session) Resolved No No 
009 Muscle/Joint
(fatigue) 
Moderate No Temporarily modified 
(reduced intensity for 1 session) 
Resolved No No 
009 
Muscle/Joint 
(knee pain) Mild Possible 
Temporarily modified 
(lower limb exercise intensity 
reduced for 1 session) 
Resolved No No 
009 
Muscle/Joint 
(ankle sprain) Moderate Definite 
Temporarily modified 
(lower limb exercise intensity 
reduced for 1 session) 
Resolved No No 
010 Muscle/Joint
(lower leg muscle strain) 
Mild Possible 
Temporarily modified 
(lower limb exercise intensity 
reduced for 1 session) 
Resolved No No 
011 Muscle/Joint(ankle sprain) Moderate No 
Temporarily modified 
(lower limb exercise intensity 
reduced for 1 session) 
Residual effects, treatment 
(general practitioner) No No 
011 
Muscle/Joint 
(chest muscle strain) Mild Definite 
Temporarily modified 
(upper limb exercise intensity 
reduced for 1 session) 
Resolved No No 
012 
Metabolic 
(hyperglycaemic day prior to 
training session) 
Mild No None Still present, no treatment No No 
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012 
Muscle/Joint 
(back pain during seated 
row) 
Mild Possible 
Permanently modified 
(emphasised monitoring correct 
posture)  
Resolved No No 
012 
Sleep disturbance 
(restlessness) Mild No 
Temporarily modified 
(intensity reduced for 1 session) Resolved No No 
012 
Respiratory 
(asthma flare-up) Moderate No 
Intervention stopped temporarily 
(2 sessions missed) 
Still present, treatment 
(general practitioner)  No No 
012 Respiratory
(asthma flare-up) 
Moderate No Intervention stopped temporarily 
(3 sessions missed) 
Still present, treatment 
(general practitioner)  
No No 
012 Respiratory
(asthma flare-up) 
Mild No None Resolved No No 
013 Blood pressure
(vasovagal) 
Mild No Temporarily modified 
(intensity reduced for 1 session) 
Residual effects, no 
treatment 
No No 
013 Muscle/Joint
(wrist pain) 
Moderate No Temporarily modified 
(bench press removed) 
Still present, treatment 
(orthopaedic surgeon)  
No No 
Identifiers (ID) generated for use in this table only. Severity: mild, awareness of signs or symptoms, but easily tolerated and are of minor irritant type causing no loss of time 
from normal activities, symptoms do not require therapy or a medical evaluation; moderate, events introduce a low level of inconvenience or concern to the participant and 
may interfere with daily activities, but are usually improved by simple therapeutic measures, may cause some interference with functioning; severe, events interrupt the 
participant’s normal daily activities and generally require systemic drug therapy or other treatment, they are usually incapacitating. 
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6.5.6 Participant characteristics 
Participant characteristics at baseline of the 28 men who had completed the 26-week 
intervention at the time of write up for this chapter are shown in Table 6.6. The mean 
age of the men in the Ex+ProCaD and control group was 72 and 75 years, respectively. 
More than half of the men in the Ex+ProCaD and control group had completed 
university or tertiary level education (56% and 58%, respectively) and most were 
retired from employment (81% and 83%, respectively) and of Caucasian decent (94% 
and 92%, respectively). Overall, 75% of the men within each of the two groups were 
classified as overweight or obese and the majority of all participants (83-94%) reported 
three comorbidities. Among men in the Ex+ProCaD and control group aware of the 
stage of their PCa, there was a similar distribution of localised (53% and 50%, 
respectively) and advanced disease (47% and 50%, respectively). Half of the total 
cohort had undergone a previous prostatectomy, whereas approximately two thirds 
(68%) had completed prior radiotherapy. Additionally, one participant from the 
intervention group had completed a course of chemotherapy. When compared to the 
control group, men within the Ex+ProCaD group were, on average, living with PCa 
for approximately five years less, treated with ADT for two years less, prescribed three 
less non-ADT medications, were 6.9 kg heavier and 37% more physically active. From 
baseline to follow-up, the average difference in the number of non-ADT prescription 
medications between groups remained the same (Ex+ProCaD, n=3; control, n=6). 
Both groups were administered a similar number of ADT doses on average throughout 
the 26-week period (Ex+ProCaD, n=3; control, n=2). 
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Table 6.6. Baseline characteristics of the 28 participants randomised to the 
Ex+ProCaD and control groups who completed the 26-week intervention. 
Ex+ProCaD Control 
n 16 12 
Age (years) 72 ± 6 75 ± 6 
Height (cm) 175.9 ± 6.2 171.4 ± 7.9 
Weight (kg) 88.5 ± 21.8 81.6 ± 14.7 
Body mass index (BMI; kg/m2) 28.4 ± 5.3 27.8 ± 5.0 
  Overweight (BMI ≥ 25 to < 30), n 
(%) 
7 (43.8) 7 (58.3) 
 Obese (BMI ≥ 30), n (%) 5 (31.3) 2 (16.7) 
Highest level of education, n (%) 
  Primary or some high school 2 (12.5) 0 (0.0) 
  Completed high school 3 (18.8) 4 (33.3) 
  Technical/trade certificate 2 (12.5) 1 (8.3) 
  University or tertiary level 9 (56.3) 7 (58.3) 
Current work status, n (%) 
  Full-time 2 (12.5) 0 (0.0) 
  Part-time 1 (8.3) 2 (16.7) 
  Retired 13 (81.3) 10 (83.3) 
Ethnicity, n (%) 
  Caucasian 15 (93.8) 11 (91.7) 
  Asian 0 (0.0) 1 (8.3) 
  African 1 (6.3) 0 (0.0) 
Comorbidities*, n (%) 15 (93.8) 10 (83.3) 
  If yes, total (n) 3 ± 0 3 ± 0 
Prescription medication, n (%) 12 (75.0) 8 (66.7) 
  If yes, total (n) 3 ± 2 6 ± 2 
Energy expenditure (kJ/d) 2673 ± 1638 1846 ± 1299 
Time since PCa diagnosis (months) 52 ± 17 113 ± 20 
Stage of PCa, n (%) 
  Localised 8 (50.0) 5 (41.7) 
  Advanced 7 (43.8) 5 (41.7) 
  Unknown 1 (6.3) 2 (16.7) 
Duration of ADT (months) 18 ± 30 46 ± 53 
Previous prostatectomy, n (%) 8 (50.0) 6 (50.0) 
Previous radiotherapy, n (%) 11 (68.8) 8 (66.7) 
Previous chemotherapy, n (%) 1 (6.3) 0 (0.0) 
Data are: mean ± standard deviation unless stated otherwise. * Comorbidities included 
asthma/respiratory problems, chronic bronchitis, muscle/ligament problems, back pain, 
angina/stroke/heart condition, diabetes, hypertension and hypercholesteromaemia. 
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6.5.7 Dietary intake 
Dietary intakes (excluding the nutritional supplement) of the two groups at baseline 
are presented in Table 6.7. Baseline and 26-week total protein and energy intake 
(including the nutritional supplement; calculated by adding supplemental daily protein 
[25 g] or energy [439 kJ] multiplied by individual compliance; 28 g and 417 kJ, 
respectively) are presented in Figure 6.5. When including the nutritional supplement, 
men allocated to Ex+ProCaD increased their total protein and energy intake, on 
average, by 28% (24 g/d) and 7.9% (722 kJ/d) between baseline and follow-up, 
respectively, whereas the control group decreased 9.8% (9 g/d) and 2.8% (224 kJ/d), 
respectively. Using current consensus criteria in terms of the recommended dietary 
protein intake for older adults [313], the proportion of men with a protein intake ≤ 1.2 
g/kg/d at baseline was similar between the intervention (67%) and control group 
(63%). However, when a protein intake of ≤ 1.0 g/kg/d was considered at baseline, 
greater variation between the groups was observed (intervention, 33%; control, 50%). 
Based on Australian guidelines for acceptable macronutrient distribution ranges 
associated with reduced risk of chronic disease (20-35% from fat, 45-65% from 
carbohydrate and 15-25% from protein) [362], men within the two groups at baseline, 
on average, were within these ranges for total daily energy intake from fat (29-32%) 
and protein (19-20%), but not carbohydrate (42-44%). Average daily calcium intakes 
at baseline in both groups were 13-25% below Australian recommended daily intakes 
for adults aged 50 years or greater (1,000 mg) [362]. 
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Table 6.7. Mean baseline dietary intake, within-group changes relative to baseline and between-group net differences for the change after 26 
weeks in the Ex+ProCaD and control groups.  
Baseline values and within-group changes 
Ex+ProCaD Control Between-group changes 
n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) Net difference (95% CI) 
Energy (kJ/d) 
  Baseline 12 9194 ± 1811 8 8084 ± 2470 
529 (-1117, 2174)   ∆ 26-week 12 305 (-343, 953) 8 -224 (-1988, 1541)
Protein (g/d) 
  Baseline 12 99 ± 29 8 92 ± 25 
14 (-13, 40)   ∆ 26-week 12 4 (-13, 21) 8 -9 (-29, 10)
Protein (g/kg/d) 
  Baseline 12 1.13 ± 0.32 8 1.13 ± 0.35 
0.11 (-0.19, 0.41)   ∆ 26-week 12 0.00 (-0.19, 0.19) 8 -0.11 (-0.35, 0.13)
Protein (% of energy/d) 
  Baseline 12 19 ± 6 8 20 ± 4 
1 (-4, 5)   ∆ 26-week 12 -1 (-4, 2) 8 -2 (-5, 2)
Carbohydrate (g/d) 
  Baseline 12 256 ± 78 8 204 ± 67 
-17 (-61, 27)  ∆ 26-week 12 -18 (-45, 9) 8 -1 (-36, 35)
Carbohydrate (% of energy/d) 
  Baseline 12 44 ± 7 8 42 ± 14 
0 (-9, 9)   ∆ 26-week 12 -1 (-7, 4) 8 -1 (-8, 5)
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Fat (g/d) 
  Baseline 12 72 ± 25 8 74 ± 49 
21 (-10, 53)   ∆ 26-week 12 17 (5, 30) 8 -4 (-37, 29)
Fat (% of energy/d) 
  Baseline 12 29 ± 8 8 32 ± 14 
2 (-8, 12)   ∆ 26-week 12 4 (-1, 9) 8 2 (-7, 11) 
Saturated fat (g/d) 
  Baseline 12 29 ± 11 8 26 ± 18 
3 (-8, 15)   ∆ 26-week 12 4 (-2, 11) 8 1 (-10, 12) 
Saturated fat (% of energy/d) 
  Baseline 12 12 ± 4 8 11 ± 6 
2 (-4, 9)   ∆ 26-week 12 4 (-1, 9) 8 2 (-1, 4) 
Calcium (mg/d) 
  Baseline 12 882 ± 337 8 777 ± 235 
114 (-143, 369)   ∆ 26-week 12 30 (-199, 178) 8 -84 (-304, 136)
Data are: baseline mean ± standard deviation (SD); within-group absolute changes with 95% confidence interval (CI); net difference (95% CI) were calculated by subtracting 
within-group absolute change for the control group from that of the Ex+ProCaD group. Dietary data for the Ex+ProCaD group does not include the supplement. 
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Figure 6.5. Total dietary protein and energy intakes (dietary plus daily supplemental 
adjusted for average compliance [shaded]) in the Ex+ProCaD (black) and control 
groups (white) at baseline and 26 weeks; data are: mean and standard deviation.  
6.5.8 Body composition 
Weight 
Baseline and follow-up weight is reported in Table 6.8. On average, men allocated to 
Ex+ProCaD increased weight by 1.6 kg (1.8%), whereas the control group increased 
by 1.0 kg (1.2%; Figure 6.6).  
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Table 6.8. Mean baseline total body weight and lean mass and regional lean mass and muscle cross-sectional area (CSA), within-group changes 
relative to baseline and between-group net differences for the change after 26 weeks in the Ex+ProCaD and control groups.    
Baseline values and within-group changes 
Ex+ProCaD Control Between-group changes 
n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) Net difference (95% CI) 
Weight (kg) 
  Baseline 16 88.5 ± 21.8 12 81.6 ± 14.7 
0.6 (-1.1, 2.3)   ∆ 26-week 15 1.6 (0.4, 2.9) 12 1.0 (-0.1, 2.2) 
Total body lean mass (kg) 
  Baseline 15 52.6 ± 7.5 12 51.1 ± 7.3 
1.4 (0.1, 2.4)   ∆ 26-week 14 1.1 (0.4, 1.9) 11 -0.3 (-1.0, 0.3)
Arm lean mass (kg) 
  Baseline 15 6.1 ± 1.3 12 5.8 ± 1.2 
0.2 (-0.1, 0.4)   ∆ 26-week 14 0.1 (-0.1, 0.2) 11 -0.1 (-0.2, 0.1)
Leg lean mass (kg) 
  Baseline 15 17.6 ± 2.7 12 17.4 ± 3.0 
0.8 (0.2, 1.3)   ∆ 26-week 14 0.9 (0.4, 1.3) 11 0.1 (-0.2, 0.3) 
Appendicular lean mass (kg) 
  Baseline 15 23.7 ± 3.8 12 23.2 ± 4.2 
1.0 (0.4, 1.6)   ∆ 26-week 14 1.0 (0.5, 1.5) 11 0.0 (-0.2, 0.2) 
Forearm muscle CSA (cm2) 
  Baseline 14 38.6 ± 5.6 8 38.4 ± 6.4 
-0.6 (-2.0, 0.7)  ∆ 26-week 14 0.7 (-0.2, 1.5) 8 1.3 (0.3, 2.3) 
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Lower leg muscle CSA (cm2) 
  Baseline 16 73.4 ± 12.1 11 68.3 ± 14.3 
-0.5 (-3.3, 2.4)  ∆ 26-week 15 -0.3 (2.1, 1.6) 10 0.2 (-1.9, 2.3) 
Data are: baseline mean ± standard deviation (SD); within-group absolute changes with 95% confidence interval (CI); net difference (95% CI) were calculated by subtracting 
within-group absolute change for the control group from that of the Ex+ProCaD group. 
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Figure 6.6. Individual absolute changes in weight in men treated with androgen 
deprivation therapy for prostate cancer in the Ex+ProCaD and control groups from 
baseline to 26-week follow-up. 
Lean mass and muscle cross-sectional area 
Baseline values, within-group changes and between-group changes in lean mass and 
muscle CSA are presented in Table 6.8. A high proportion of men treated with ADT 
responded positively (increase greater than zero) to the Ex+ProCaD with regard to 
total body lean mass (64%), ALM (87%) and forearm (64%) and lower leg muscle 
CSA (67%; Figure 6.7). On average, men allocated to the control group decreased total 
body lean mass (0.3 kg), but maintained ALM and increased forearm (1.3 cm2) and 
lower leg muscle CSA (0.2 cm2). 
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Figure 6.7. Individual absolute changes in total body and appendicular lean mass and 
forearm and lower leg muscle cross-sectional area (CSA) in men treated with androgen 
deprivation therapy for prostate cancer in the Ex+ProCaD and control groups from 
baseline to 26-week follow-up. 
Fat mass and cross-sectional area 
Baseline, within- and between-group values and changes in fat mass and CSA are 
shown in Table 6.9. Following Ex+ProCaD, participants tended to increase total body 
(mean, 0.8 kg) and regional fat mass (mean, 0.1-0.5 kg) and forearm and lower leg 
subcutaneous fat CSA (mean, 1.1-1.9 cm2), despite no change in total body percent fat 
mass (Figure 6.8). The majority of participants allocated to the control group gained 
total body and total body percent fat mass (both, 82% of group) and forearm (75% of 
group) and lower leg subcutaneous fat CSA (60% of group). 
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Table 6.9. Mean baseline total body fat mass and regional fat mass, subcutaneous fat cross-sectional area (CSA) and muscle density, 
within-group changes relative to baseline and between-group net differences for the change after 26 weeks in the Ex+ProCaD and control 
groups.    
Baseline values and within-group changes 
Ex+ProCaD Control Between-group changes 
n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) Net difference (95% CI) 
Total body fat mass (kg) 
  Baseline 15 28.9 ± 10.9 12 27.7 ± 10.5 
-0.9 (-2.5, 0.5)  ∆ 26-week 14 0.8 (-0.1, 1.7) 11 1.7 (0.5, 3.0) 
Total body fat mass (%) 
  Baseline 15 34.5 ± 8.9 12 34.2 ± 7.7 
-1.4 (-2.6, -0.1)  ∆ 26-week 14 0.0 (-0.8, 0.9) 11 1.4 (0.5, 2.3) 
Arm fat mass (kg) 
  Baseline 15 2.9 ± 1.2 12 2.7 ± 1.0 
0.0 (-0.2, 0.2)   ∆ 26-week 14 0.0 (-0.1, 0.2) 11 0.0 (-0.1, 0.2) 
Leg fat mass (kg) 
  Baseline 15 7.8 ± 2.6 12 8.9 ± 4.6 
-0.1 (-0.7, 0.5)  ∆ 26-week 14 0.5 (0.1, 0.9) 11 0.6 (0.1, 1.1) 
Android fat mass (kg) 
  Baseline 15 3.2 ± 1.6 12 2.7 ± 1.2 
-0.2 (-0.4, 0.0)  ∆ 26-week 14 0.1 (-0.1, 0.2) 11 0.3 (0.1, 0.4) 
Gynoid fat mass (kg) 
  Baseline 15 4.1 ± 1.4 12 4.2 ± 1.5 
-0.1 (-0.3, 0.2)  ∆ 26-week 14 0.2 (0.0, 0.4) 11 0.3 (0.0, 0.5) 
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Abdominal visceral fat mass (kg) 
  Baseline 15 2.0 ± 1.4 11 1.5 ± 0.8 
-0.1 (-0.4, 0.1)  ∆ 26-week 14 0.1 (-0.1, 0.2) 10 0.2 (0.0, 0.4) 
Abdominal subcutaneous fat mass (kg) 
  Baseline 15 1.2 ± 0.5 11 1.1 ± 0.5 
0.0 (-0.1, 0.2)   ∆ 26-week 14 0.0 (-0.1, 0.1) 10 0.0 (-0.1, 0.1) 
Forearm subcutaneous fat CSA (cm2) 
  Baseline 14 10.6 ± 4.8 8 13.2 ± 10.0 
0.4 (-0.7, 1.7)   ∆ 26-week 14 1.1 (0.4, 1.8) 8 0.7 (-0.4, 1.7) 
Lower leg subcutaneous fat CSA (cm2) 
  Baseline 16 17.9 ± 6.9 11 26.0 ± 18.6 
1.3 (0.2, 3.0)   ∆ 26-week 15 1.9 (0.7, 3.1) 10 0.6 (-0.3, 1.4) 
Forearm muscle density (mg/cm3) 
  Baseline 14 78.3 ± 1.3 8 76.9 ± 3.5 
0.4 (-0.9, 1.5)   ∆ 26-week 14 -0.3 (-1.0, 0.3) 8 -0.7 (-1.8, 0.5)
Lower leg muscle density (mg/cm3) 
  Baseline 16 74.8 ± 2.7 11 73.3 ± 3.2 
-0.2 (-1.3, 0.9)  ∆ 26-week 15 0.2 (-0.6, 1.0) 10 0.4 (-0.4, 1.1) 
Data are: baseline mean ± standard deviation (SD); within-group absolute changes with 95% confidence interval (CI); net difference (95% CI) were calculated by subtracting 
within-group absolute change for the control group from that of the Ex+ProCaD group.  
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Figure 6.8. Individual absolute changes in total body and total body percent fat mass 
and forearm and lower leg subcutaneous fat cross-sectional area (SFCSA) in men 
treated with androgen deprivation therapy for prostate cancer in the Ex+ProCaD and 
control groups from baseline to 26-week follow-up. 
Muscle density 
Descriptive statistics for muscle density are presented in Table 6.9. Forearm muscle 
density tended to decrease in both groups by an average of 0.3-0.7 mg/cm3, whereas 
lower leg muscle density appeared to increase following Ex+ProCaD (0.2 mg/cm3) or 
usual care (0.4 mg/cm3; Figure 6.9).  
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Figure 6.9. Individual absolute changes in forearm and lower leg muscle density in 
men treated with androgen deprivation therapy for prostate cancer in the Ex+ProCaD 
and control groups from baseline to 26-week follow-up. 
6.5.9 Muscle strength and functional capacity 
Muscle strength 
Muscle strength outcomes at baseline and follow-up are shown in Table 6.10. Men in 
the Ex+ProCaD group tended to improve chest (mean, 16%), leg (mean, 31%) and 
back muscle strength (mean, 18%), but not handgrip muscle strength (mean, -0.7%; 
Figure 6.10). Of those allocated to the control group, one third decreased chest muscle 
strength and approximately two thirds (67%) decreased handgrip muscle strength, 
however, no controls decreased back or leg muscle strength.  
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Table 6.10. Mean baseline muscle strength variables, within-group changes relative to baseline and between-group net differences for the 
change after 26 weeks in the Ex+ProCaD and control groups.   
Baseline values and within-group changes 
Ex+ProCaD Control Between-group changes 
Muscle Strength n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) Net difference (95% CI) 
Handgrip 
  Baseline (kg) 13 36.7 ± 7.0 9 37.4 ± 8.1 
-3.5 (-13.6, 6.6)  ∆ 26-week (%) 13 -0.7 (-5.9, 4.4) 9 2.8 (-8.2, 13.7) 
Chest 
  Baseline (kg) 14 38.7 ± 12.8 6 33.7 ± 6.8 
18.6 (-7.9, 45.1)   ∆ 26-week (%) 12 16.0 (-2.8, 34.9) 6 -2.6 (-10.7, 5.5)
Leg 
  Baseline (kg) 14 131.1 ± 42.9 8 94.4 ± 40.1 
12.5 (15.6, 36.5)   ∆ 26-week (%) 12 30.7 (15.5, 45.8) 7 18.2 (3.7, 32.8) 
Back 
  Baseline (kg) 11 49.2 ± 17.7 4 43.9 ± 11.6 
8.0 (-37.7, 53.8)   ∆ 26-week (%) 11 17.9 (-5.6, 41.4) 3 9.9 (-14.5, 34.2) 
Data are: baseline mean ± standard deviation (SD); within-group percent changes with 95% confidence interval (CI); net difference (95% CI) were calculated by subtracting 
within-group percent change for the control group from that of the Ex+ProCaD group. 
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Figure 6.10. Individual percent changes in handgrip, chest, leg and back 
muscle strength in men treated with androgen deprivation therapy for prostate 
cancer in the Ex+ProCaD and control groups from baseline to 26-week follow-up. 
Functional capacity 
Baseline values and percent within- and between-group differences for various 
outcomes of functional capacity are presented in Table 6.11. Men treated with ADT in 
the Ex+ProCaD group more commonly improved timed-up-and-go (53% of group) 
and four-square step test performance (80% of group), but not 30-second sit-to-stand, 
gait speed, 400 metre walk and Berg balance scale (all < 40% of group; Figure 6.11). 
Half of the participants allocated to the control group decreased 30-second sit-to-stand 
and four-square step test performance, whereas the majority decreased timed-up-and-
go performance (58%; increase) and gait speed (67%; decrease), but not 400 metre 
walk (36%; decrease) and Berg balance scale (25%; decrease).  
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Table 6.11. Mean baseline functional capacity variables, within-group changes relative to baseline and between-group net differences for 
the change after 26 weeks in the Ex+ProCaD and control groups.    
Baseline values and within-group changes 
Ex+ProCaD Control Between-group changes 
n 
Mean ± SD 
Mean (95% CI) n 
Mean ± SD 
Mean (95% CI) Net difference (95% CI) 
Timed-up-and-go 
  Baseline (sec) 16 11.11 ± 3.26 12 11.76 ± 5.71 
-12.2 (-46.8, 22.4)  ∆ 26-week (%) 15 6.7 (-13.3, 26.7) 12 18.9 (-13.6, 51.4) 
Four-square step test 
  Baseline (sec) 16 10.54 ± 2.20 12 10.83 ± 2.66 
-13.6 (-25.9, -1.3)  ∆ 26-week (%) 15 -12.1 (-20.6, -3.6) 12 1.5 (-8.4, 11.5) 
30-second sit-to-stand
  Baseline (sec) 16 13 ± 4 12 12 ± 4 
8.6 (-15.2, 32,2)   ∆ 26-week (%) 15 7.7 (-11.5, 26.8) 12 -0.9 (-14.9, 13.1)
Gait speed 
  Baseline (m/s) 13 1.39 ± 0.16 9 1.36 ± 0.29 
-0.6 (-7.4, 6.0)  ∆ 26-week (%) 13 -0.4 (-4.6, 3.8) 9 0.2 (-5.9, 6.4) 
400 metre walk 
  Baseline (sec) 16 278 ± 37 11 299 ± 47 
6.1 (-8.0, 20.2)   ∆ 26-week (%) 15 8.5 (-3.1, 20.1) 11 2.4 (-5.5, 10.4) 
Berg balance scale 
  Baseline (n) 15 55 ± 1 12 54 ± 3 
-0.6 (-4.1, 2.9)  ∆ 26-week (%) 14 -0.9 (-2.5, 0.7) 12 -0.3 (-3.9, 3.3)
Data are: baseline mean ± standard deviation (SD); within-group percent changes with 95% confidence interval (CI); net difference (95% CI) were calculated by subtracting 
within-group percent change for the control group from that of the Ex+ProCaD group.  
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Figure 6.11. Individual percent changes in the performance of timed-up-and-go, 
four-square step test, 30-second sit-to-stand, gait speed, 400 metre walk and Berg 
balance scale in men treated with androgen deprivation therapy for prostate 
cancer in the Ex+ProCaD and control groups from baseline to 26-week follow-up. 
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6.6 Discussion 
The main findings from the preliminary analysis of this RCT that examined the 
feasibility of implementing a community-based multi-component exercise program 
combined with protein, calcium and vitamin D supplementation intervention in men 
treated with ADT for PCa were that participant retention rates (96%) and adherence to 
the supplement (mean, 92-93%) were high, but adherence to the exercise program was 
modest (mean, 60%). Furthermore, a relatively high proportion (81%) of participants 
in the intervention group reported an adverse event during the 26-week intervention, 
although only 16% were confirmed to be related to the intervention and the vast 
majority (97%) were determined by research staff to be mild (“Awareness of signs or 
symptoms, but easily tolerated and are of minor irritant type causing no loss of time 
from normal activities. Symptoms do not require therapy or a medical evaluation; signs 
and symptoms are transient”) or moderate (“Events introduce a low level of 
inconvenience or concern to the participant and may interfere with daily activities, but 
are usually improved by simple therapeutic measures; moderate experiences may 
cause some interference with functioning”) in terms of severity. 
Numerous issues pertaining to recruitment and data collection in this clinical 
population group were observed, which unforeseeably elongated the study timeline 
and prevented the collection of various outcome measures, respectively. Throughout 
the study, 10 separate recruitment pathways were considered, with clinician referral 
(43%) and PCa support groups (29%) yielding the greatest proportion of enrolled 
participants. Collectively, a total of 149 potential participants were screened for the 
RCT, which resulted in 42 participants at the time of write up for this thesis. The main 
reason for exclusion (n=75) was a lack of current ADT use (48%) and the men who 
declined to participate (n=21) most commonly cited no specific reason (48%). Among 
the first 28 participants to complete the 26-week intervention, there was a notable 
inability to completed all measures, in particular muscle strength assessed by 3-RM 
(21-50% were unable to complete these tests), which primarily stemmed from safety 
concerns with regard to previous comorbidities. Data from the initial 28 participants 
who completed the study tended to respond positively to the Ex+ProCaD intervention 
compared to usual care with regard to net differences in lean mass (0.2-1.4 kg), fat 
mass (-0.1 to -0.9 kg), muscle strength (8.0-19%), functional muscle power (8.6%) and 
functional capacity (12-14%). Together, these findings support the feasibility of 
implementing a multifaceted exercise and nutrition intervention in ADT-treated men, 
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but highlight the potential limitations associated with recruitment, safety and elements 
of data collection.   
Attrition and adherence 
Given the myriad of adverse effects associated with ADT [11-14], as well as the tendency 
for this treatment to be used for advanced PCa which may eventually progress and lead 
to additional comorbidities [3, 4], there is a need to consider retention rates and 
adherence when designing and implementing lifestyle interventions. In this study, only 
one participant of the first 28 men to complete the intervention was lost to follow-up; 
thus, the retention rate of our study at the time of write up of this chapter was 96%. On 
average, previous exercise-only RCTs of 12 weeks or greater have reported retention 
rates ranging from 66-96% [225, 227-229, 234, 238, 244, 246]. Notably, a recent study that pooled 
1,366 cancer survivors (mean age, 75 years; PCa, 46%) from three diet and exercise-
based lifestyle interventions found that overall retention (91%) was not influenced by 
factors that commonly reduce willingness to participate and adherence, such as sex, 
age, race, time since cancer diagnosis or cancer type [363]. These findings suggest that 
once ADT-treated men are enrolled in the study, the attention of researchers should 
shift towards ensuring adequate adherence to the prescribed intervention.  
In terms of adherence, participants allocated to Ex+ProCaD completed 60% of all 
exercise training sessions (68% supervised gym-based; 50% unsupervised home-
based) and consumed 92-93% of the nutritional supplement over the 26-week period. 
Similar compliance was observed for the vitamin D supplement in the control group 
(94%). On average, previous trials that have examined exercise training interventions 
of 12 weeks or greater in men treated with ADT have reported an adherence for 
supervised sessions ranging from 69-96%. It is difficult to explain the lower rates of 
adherence to supervised exercise training in our study, however, given the modest 
sample size (n=16) and the subsequent influence of outliers on mean adherence, the 
median adherence of 85% should be considered when interpreting the initial findings 
from our study. Compliance rates of unsupervised home-based exercise training tend 
to be omitted when RCT outcomes are reported, with only one study of 51 ADT-
treated men (mean age, 70 years) having reported a 43% adherence to a once weekly 
session over a 52-week intervention; notably, unsupervised session compliance was 
approximately half of that of supervised sessions (84%) [244]. The authors suggested 
that the lower rates of compliance with unsupervised sessions may have stemmed from 
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training individually, whereas the supervised sessions were performed in a group-
based setting [244]. Social support is a known facilitator to exercise training in older 
adults [364, 365] and may in part explain the compromised compliance of unsupervised 
sessions when compared to supervised sessions in our study.  
To date, the feasibility of consuming a multi-nutrient supplement high in protein, 
calcium and vitamin D has not been examined in ADT-treated men, however, a 
previous multi-factorial RCT of 120 men treated for ADT (median age, 69 years) 
showed that a similar supplement delivery method (i.e. sachet of powder [soy 
isoflavones or placebo] and single tablet [venlafaxine or placebo]) had a compliance 
rate of 92% [366]. While this trial aimed to ameliorate ADT-induced hot flushes, the 
high compliance observed supports our findings that a powder sachet and single tablet 
appears to be a feasible approach for administering a multi-nutrient supplement in 
these men. Overall, our findings indicate that implementing a multifaceted lifestyle 
intervention incorporating supervised and home-based exercise with a multi-nutrient 
supplement is feasible in men treated with ADT in terms of retention and adherence 
over the initial 26-week follow-up. However, determining whether these rates are 
continued over the subsequent 26-week period in the larger RCT is warranted in order 
to assess the long-term likelihood of this clinical population group adopting such a 
lifestyle intervention.  
Safety 
To date, the safety of lifestyle interventions in men treated with ADT for PCa has 
predominately focused on the impact of these interventions on the efficacy of ADT 
itself, as measured by changes in PSA or testosterone, rather than potential adverse 
events associated with the intervention (e.g. exercise or nutritional factors) [60]. 
Moreover, given the novelty of the multi-nutrient supplementation examined in our 
study, its safety is currently unknown. In our study, the absence of robust statistical 
analyses limits the inference of safety associated with fluctuations in PSA, however, 
men randomised to Ex+ProCaD showed an average reduction of 1.4 ng/mL, whereas 
the control group increased by 1.0 ng/mL. Whilst these responses appear to support 
the safety of a multi-component exercise program combined with protein, calcium and 
vitamin D supplementation in terms of PSA, analyses of the complete dataset from the 
larger RCT are required before definitive conclusions may be drawn. With regards to 
the exercise training and nutritional supplements in our study, we observed no study-
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related adverse events that led to permanent discontinuation of the complete 
intervention, however, one participant discontinued the sachet supplement due to 
gastrointestinal upset. Whilst the age-related changes in the gastrointestinal tract may 
impede the ability to digest protein and lead to gastrointestinal upset in some adults 
[367], protein supplementation has generally been shown to be well tolerated and 
accompanied by no serious adverse events in older adults [269, 270]. Previous RCTs that 
examined the efficacy of exercise programs in men treated with ADT have also 
reported the absence of intervention-based adverse events that resulted in permanent 
discontinuation [227, 229, 234, 238, 244, 246]. Of the reported adverse events in our trial that 
were study-related (n=6) or potentially study-related (n=8); the majority were 
muscle/joint-based from previously documented comorbidities and were resolved with 
temporary modification to the exercise program within a single training session. The 
presence of various comorbidities in older men, as well as in those treated with ADT 
for PCa, is well established [11-14], thus the prescription of exercise in these population 
group should be individually tailored and overseen by an appropriately qualified 
exercise trainers (e.g. a tertiary trained Accredited Exercise Physiologist in Australia). 
Collectively, the findings from our study support the safety of a multi-component 
exercise program combined with protein, calcium and vitamin D supplementation, yet 
highlight the potential for non-severe adverse events, primarily due to pre-existing 
comorbidities. Importantly, analyses of potential changes in PSA at the completion of 
the larger RCT are warranted before conclusions pertaining to the impact on the 
efficacy of ADT itself may be established.  
 
Recruitment  
There are a wide range of barriers to the recruitment of older adults with cancer into 
clinical trials, which often stem from trial design, clinician support and patient 
characteristics [368, 369]. In addition, poor physical and mental health has been shown to 
limit physical activity participation in older adults [364, 365]. Interestingly, a recent 
review of funded clinical trials conducted in the United Kingdom concluded that 45% 
of trials required an extended timeline due to recruitment-based delays and only 55% 
of trials eventually recruited their intended total sample, whereas 78% ultimately 
recruited 80% of their target sample size [370]. Despite these challenges, it has been 
noted that many clinical trials that recruited cancer patients did not include adequate 
details of the recruitment process in order to inform future research [371]. In our study, 
a total of 149 potential participants were screened from 2014 to 2017, with clinician 
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referral (n=42), PCa support groups (n=31), local newspaper advertisement (n=31) and 
state news television report (n=23) accounting for the majority of recruitment. Of these 
pathways, clinician referral and PCa support groups provided 43% and 29% of the 
total enrolled sample (n=42), respectively. A multi-pathway approach similar to our 
study (i.e. state cancer registry, clinician referral, support groups, community events 
and study advertisement) was utilised during the 2-year recruitment of men treated 
with ADT to a year-long exercise training RCT and resulted in 467 men screened and 
51 randomised to the intervention [244]. Notably, the efficacy of each specific pathway 
was not reported and thus direct comparisons to the pathways utilised in our study are 
limited. Regardless, this previous approach screened greater than 300 more potential 
participants when compared to our trial [244], which may in part stem from our lack of 
utilisation of a cancer registry, which has previously been shown to be a successful 
recruitment pathway in cancer patients [372, 373]. Furthermore, two previous trials that 
adopted 14-16 month single pathway approaches that relied on clinician referral were 
only able to screen 97 [227] and 126 [234] men treated with ADT for inclusion in exercise-
based RCTs, successfully enrolling 59% (n=57) and 50% (n=63) of potential 
participants, respectively. The greater efficacy of these approaches, when compared to 
our study, is difficult to explain and whilst counterintuitive may stem from the greater 
focus of resources on a singular recruitment pathway as opposed to several. Moreover, 
previous research has supported the importance of a clinician referral to an exercise 
program, with 80% of 47 men who recently received active treatment for PCa having 
cited that clinician involvement influenced their decision to participate in 12-week 
intervention [374]. Notably, these observations supported our findings that clinician 
referral led to a greater proportion of eligible participants, compared to those screened 
from other recruitment pathways. Collectively, our findings highlight the difficulty of 
recruiting ADT-treated men to a lifestyle intervention, and suggest that future trials 
should consider the development of a thoroughly designed recruitment plan that 
includes the clinical referral pathway to ensure predetermined sample sizes can be 
achieved.  
The design of a clinical trial may also have significant implications on participant 
recruitment, especially when considering the strict inclusion/exclusion criteria often 
imposed to account for known confounding variables [369]. Approximately half (52%) 
of excluded participants were not eligible for our trial due to a lack of current 
pharmacological ADT for PCa and the remainder were precluded from involvement 
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due to various exclusion criteria designed to account for known confounding variables 
related to the main outcomes of the larger RCT (bone health). This was similar to a 
previous RCT that recruited men to a 52-week exercise training intervention, whereby 
the majority of exclusions were based on a lack of current ADT use [243]. Of ADT-
treated men excluded in our study, vitamin D supplementation greater than 1,000 
IU/day (16%) and PRT greater than one session/week (8.0%) were the most common 
reasons. Comparisons between our exclusion criteria and that of previous trials is 
difficult given the omission [225, 228, 241] or lack of detail [234, 238, 244, 246] when reporting 
these reasons, as well as the differences in primary outcomes. Exclusions based on 
current vitamin D supplementation and PRT align with current lifestyle guidelines for 
men treated with ADT for PCa that suggest these interventions to overcome the myriad 
of treatment-induced adverse effects [195]. Furthermore, in a survey of urologists and 
radiation oncologists, 47% recommended vitamin D supplementation for this 
susceptible population group [283]. The proportion of men treated with ADT who were 
precluded from our trial after expressing interest further highlights the importance of 
determining effective recruitment pathways.   
Data collection 
It is well established that men treated with ADT for PCa frequently present with 
additional comorbidities [11-14], which may in turn limit the ability to obtain certain 
outcome measures in research studies involving these men. In our study, men who 
presented with a current comorbidity reported three on average. These pre-existing 
comorbidities, which were most commonly musculoskeletal and haemodynamic in 
nature, predominantly impacted the acquisition of muscle strength measures of the 
three 3-RM protocols implemented (21-50% of data missing). Additionally, global and 
regional obesity limited the collection of some radiological scan outcomes due to an 
inability to define regions of interest (17-50% of data missing). To our knowledge, the 
majority of previous trials that have examined similar outcomes in studies that have 
examined lifestyle interventions in ADT-treated men have not reported these 
observations, which may in part stem from volunteer or reporting biases. In support of 
our limitations when muscle strength was assessed, 40% of men in a cohort of 62 men 
commencing ADT (mean age, 68 years) were unable to complete at least one of three 
assessment of handgrip strength over a 12-month follow-up [28]. Moreover, given the 
average annual gain of total body fat mass exceeds 11% in ADT-treated men [198] and 
the known limitations of DXA scan acquisition in those with obesity [76], the missing 
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data in our study appears to be in line with current limitations of these tools. However, 
our findings suggest that researchers should consider the feasibility of data collection 
when designing trials with clinical populations groups with multiple comorbidities, 
such as men treated with ADT for PCa.  
Intervention responses to Ex+ProCaD versus usual care 
Given that this chapter only reported descriptive statistics of the first 28 men to 
complete the intervention, responses to Ex+ProCaD and usual care (i.e. 1000 IU/day 
vitamin D) in these men should be interpreted with caution. Moreover, these 
observations may change following the analysis of the complete dataset of the larger 
RCT. Nonetheless, the following section presents the preliminary efficacy of 
Ex+ProCaD compared to usual care in men treated with ADT for PCa. Notably, due 
to the lack of previous studies in ADT-treated men that have examined the efficacy of 
multifaceted exercise and nutrition interventions similar to that of Ex+ProCaD in our 
study, comparisons will be primarily made with exercise-only trials in these men.  
Men allocated to Ex+ProCaD demonstrated a 1.4 kg average net gain in total body 
lean mass compared to controls, which was primarily due to an improvement in ALM 
(net difference, 1.0 kg), particularly leg lean mass (net difference, 0.8 kg). Consistent 
with these findings, a previous 26-week RCT in 97 men treated with ADT (mean age, 
69 years) that examined the efficacy of supervised PRT combined with aerobic 
exercise training reported an average net gain of 0.8 kg in DXA-derived total body 
lean mass compared to usual care; however, region-specific outcomes were not 
reported [246]. Moreover, following 12 weeks of PRT in a sample of 57 ADT-treated 
men (mean age, 70 years), total body lean mass increased compared to controls 
(adjusted net difference, 0.8 kg), which was due to gains in ALM (adjusted net 
difference, 0.8 kg), specifically leg lean mass (adjusted net difference, 0.5 kg). An 
explanation for these greater gains in leg lean mass when compared to that of the arms 
may in part stem from the exercise training principle of initial values, in which 
physiological outcomes with poorer results have the greatest capacity for improvement 
[24]. Indeed, multiple studies have observed age-related losses of muscle of the lower 
limb occur at more than double the rate of the upper limb [139-141]. However, the net 
effects of Ex+ProCaD on and lower leg muscle CSA (-0.5 cm2) appeared to contrast 
these observations and favoured usual care. Whilst difficult to explain, these findings 
potentially suggest that Ex+ProCaD led to gains in upper, rather than lower, leg lean 
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mass. Given the design of the PRT program in our study (e.g. targeting muscles with 
attachments to the hip and spine), muscles located within the upper leg likely received 
greater attention than those of the lower leg. To further investigate this notion, future 
studies should consider upper leg pQCT measures, such as those at the 25% or 50% 
femur [77]. Collectively, these findings support the use of lifestyle interventions that 
combine exercise training and nutritional supplementation to ameliorate the loss of 
lean mass often observed during ADT [195]. 
When compared to the control group, Ex+ProCaD resulted in a mean net loss of 0.9 
kg in total body fat mass which corresponded with a reduction in total body percent 
fat mass (net difference, -1.4%). These changes in fat mass following Ex+ProCaD 
tended to span across multiple regions (i.e. leg, android, gynoid, abdominal visceral; 
net difference, -0.1 to -0.2 kg). Similarly, following a 52-week exercise program that 
combined PRT and impact exercise training, a sample of 51 men treated with ADT 
(mean age, 70-71 years) demonstrated net losses in total body fat mass (2.0 kg) and 
total body percent fat mass (1.3%) compared to stretching-only control group [242]. In 
contrast, multiple RCTs that examined the efficacy of lifestyle interventions including 
exercise training on adiposity showed no change compared to controls [227, 228, 238, 375]. 
For example, when compared to controls, no change in total body fat mass or total 
body percent fat mass was observed following 12 weeks of PRT in 57 ADT-treated 
men (mean age, 70 years) [227]. Many factors pertaining to the design of these exercise 
training programs (e.g. intensity, sets, repetitions and number of exercises) may in part 
explain these discrepancies. Particularly, it is possible that the trials that differed to our 
results and observed no change in adiposity achieved a training load below current 
recommendations (i.e. 150-250 minutes per week of moderate-intensity exercise) for 
weight loss and subsequent reductions in fat mass [376]. Interestingly, the loss of leg fat 
mass in men allocated to Ex+ProCaD compared to usual care was conflicted by the 
net gain in lower leg subcutaneous fat CSA (1.3 cm2). Similar to aforementioned 
discrepancies in leg lean mass and muscle CSA, these findings may further support 
that Ex+ProCaD resulted in decreased fat mass within the upper, but not lower leg, 
and further strengthens our recommendations for the incorporation of upper leg pQCT 
measures. Another factor may have been the difference in ADT duration between 
groups, with controls having reported two more years of treatment on average. A 
previous 6-month prospective study showed that 30 men treated with ADT for an 
average of three months gained 7.7% total body percent fat mass, whereas those treated 
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for an average of 33 months (n=50) showed no change [18]. Thus, there is a need to 
consider duration of ADT as a confounding variable in future analyses. Contrasting 
net differences were also observed in forearm (0.4 mg/cm3) and lower leg muscle 
density (-0.2 mg/cm3), which suggests effect of Ex+ProCaD on intermuscular fat may 
have been region-specific. To date, no other studies have examined muscle density in 
this clinical population group, however, given the small magnitude of change in 
comparison to decrements of 3.5 mg/cm3 previously shown to be associated with 
mortality in a cohort of 1,063 healthy older men (mean age, 77 years), it is unlikely 
that these changes in muscle density are of clinical relevance with regard to mortality 
risk [181]. Therefore, these findings provide novel insight into the role of combining 
exercise training and nutritional supplementation to address the known gains in fat 
mass during ADT [195]. 
On average, participants randomised to Ex+ProCaD showed net increases of 8-19% in 
all measures of muscle strength, bar handgrip, when compared to controls. Previous 
exercise training studies of 12-52 weeks in men treated with ADT have shown 
improvements in various assessments of upper (4.0-26%) and lower body muscle 
strength (17-37%) when compared to controls [227, 232, 234, 238, 243]. Specifically, in a 
cohort of 58 ADT-treated men, 16 weeks of PRT resulted in a similar magnitude of 
improvement in leg, chest and shoulder muscle strength (10-26%) when compared to 
controls [238]. These improvements in muscle strength following Ex+ProCaD are 
important given that muscle strength tends to be a better independent predictor of 
adverse health outcomes when compared to lean mass alone [42, 44, 49, 182]. Among a 
sample of 5,995 older men (mean age, 74 years), men within the three highest quartiles 
of muscle strength had a reduced risk of falls when compared to those within the lowest 
quartile (relative risk, 0.74-0.84) [42]. Reducing the risk of falls in men treated with 
ADT is of clinical relevance given the established increased prevalence [201] and 
subsequent fractures [202-204]. Moreover, Ex+ProCaD resulted in mean net 
improvements in measures of functional muscle power (8.6%) compared to usual care. 
The only other known RCT that examined the effects of a lifestyle intervention on 
functional muscle power in 50 men treated with ADT (mean age, 72 years) 
demonstrated that a 12-week aerobic and PRT program combined with dietary advice 
improved 30-second sit-to-stand performance relative to the controls (net difference, 
35% [four repetitions]) [375]. When compared to our absolute findings (net difference, 
one repetition), the variation in magnitude of improvement between intervention and 
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control participants likely stems from the lower initial values in the previous study (11 
repetitions) compared to ours (13 repetitions).  
Whilst Ex+ProCaD led to improvements in 30-second sit-to-stand performance in our 
study, an average baseline result of 13 repetitions was previously shown to be 
associated with physical independence in a sample of 2,140 older adults; thus the 
improvements observed in our study may be of limited clinical relevance. Similar to 
the improvements in Ex+ProCaD compared to usual care in our study with regard to 
functional capacity (net difference, 12-14%), various exercise training interventions in 
this clinical population group have also been shown to improve functional capacity, 
albeit variations in tests utilised limit the comparability between trials [227, 238, 375]. 
Regardless, the changes in functional capacity following Ex+ProCaD in our study are 
likely of limited clinical relevance given that average baseline results for outcomes 
such as timed-up-and-go (11.11 second), gait speed (1.39 m/s) and four-square step 
test (10.54 second) were within healthy ranges when compared to established cut-offs 
for predicting risk of adverse outcomes (i.e. timed-up-and-go ≥ 15 second, gait speed 
< 1.00 m/s and four-square step test ≥ 15 second). Overall, these findings demonstrate 
the potential role of lifestyle interventions that incorporate both exercise training and 
nutritional supplementation in mitigating the loss of muscle strength, functional 
muscle power and functional capacity that commonly accompany treatment-induced 
decrements in body composition [195].  
6.7 Strengths and limitations 
The strengths of this study were discussed in Chapters 4 and 5. More specific to the 
RCT however, this is the first study that examined a wide range of feasibility outcomes 
of a combined multi-component exercise program and multi-nutrient supplement in 
men treated with ADT for PCa. Similarly, the 26-week duration of the trial was longer 
than the majority of previously conducted lifestyle intervention studies in ADT-treated 
men. However, several limitations should be noted when interpreting the results from 
this study. First, due to the feasibility issues outlined in this chapter and the subsequent 
lack of a completed dataset, the descriptive statistics presented should be interpreted 
with caution given the modest sample size. Second, as with any study involving 
exercise training, those of greater functional capacity and/or a penchant for health and 
fitness, may have been more likely to participate. Third, the strict exclusion criteria, 
albeit a strength of our trial in terms of accounting for a range of confounding 
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variables, may have excluded men with characteristics that represent a large proportion 
of men treated with ADT, such as those with absolute contraindications to exercise 
training. Fourth, the assessment of safety was restricted to recorded adverse events and 
PSA, whereas testosterone and its precursors were not measured to assess whether the 
intervention impacted the intended therapeutic effects of ADT. Finally, apart from the 
analyses of radiological images, neither the participant nor the researchers were 
blinded to treatment allocation.  
 
6.8 Summary and conclusion 
In summary, our study showed that the implementation of Ex+ProCaD when 
compared to usual care in men treated with ADT for PCa was feasible in terms of 
participant retention, adherence to the intervention and safe with regard to changes in 
PSA. However, issues stemming from recruitment and data collection unforeseeably 
extended the study timeline and limited the ability to collect a complete dataset, 
respectively. Whilst various recruitment pathways were used to recruit participants, 
only clinician referral and PCa support groups resulted in meaningful numbers of 
enrolled participants. Of those included, data collection, particularly outcomes of 
muscle strength, were at times hindered by safety concerns associated with pre-
existing comorbidities. Beyond these limitations, among the first 28 ADT-treated men 
to complete the 26-week follow-up, those allocated to Ex+ProCaD tended to improve 
various outcomes of muscle, fat and performance when compared to usual care. 
 
In conclusion, our findings provide novel insight into the feasibility of implementing 
a multifaceted community-based exercise and nutrition intervention in men treated 
with ADT for PCa. Importantly, our observations support the notion that trials aiming 
to recruit these men should consider clinician referral and PCa support groups to 
ensure sample size targets are met in a timely manner. Moreover, the pre-existing 
comorbidities commonly observed in ADT-treated men should be considered when 
designing future trials to ensure realistically obtained outcome measures are utilised. 
Furthermore, these comorbidities may predispose these men to adverse events 
associated with lifestyle interventions, particularly exercise training, and therefore 
strategies to modify these exercise programs when required should be completed in 
advance. Finally, the safety in terms of PSA, adherence and retention associated with 
Ex+ProCaD, as well as the apparent positive responses among the initial participants 
suggest that this lifestyle intervention may be suitable for ameliorating the wide range 
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of ADT-induced adverse effects in this susceptible population group. However, 
outcomes of the large 52-week RCT should be considered before definitive 
conclusions are drawn with regard to the efficacy of multi-component exercise 
program combined with protein, calcium and vitamin D supplementation interventions 
in ADT-treated men. In the following chapter, the key themes and findings of this 
study, along with suggestions for future research, will be presented.   
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Conclusions and future direction 
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7.1 Overview 
This chapter presents concluding remarks pertaining to the key findings from the cross-
sectional study and randomised controlled trial (RCT) reported within this thesis. 
Moreover, this chapter discusses the strengths and limitations of these studies and 
provides suggestions that should be considered for future research.  
7.2 Summary 
Worldwide, prostate cancer (PCa) continues to be one of the most frequently 
diagnosed male cancers and accounts for a substantial proportion of male cancer-
related deaths [1]. However, as the five-year relative survival rate approaches 100% 
internationally [2], men diagnosed with PCa are now living longer and at risk of age- 
and treatment-related complications. PCa is commonly managed via androgen 
deprivation therapy (ADT) in both metastatic [3] and non-metastatic PCa survivors [4] 
and has been shown to increase survival in appropriately selected patients [5-9]. The 
treatment-induced hypogonadism is often accompanied by a range of adverse effects 
[11-14], including those that negatively impact lean mass and muscle cross-sectional area 
(CSA) [15-21], fat mass and CSA [17-23] and performance (e.g. muscle strength, muscle 
power and functional capacity) [25-34]. To date, the true extent in which these outcomes 
are affected by ADT is limited due to methodological limitations and inconsistencies 
in prior studies [15-23, 25-34, 36-38]. Moreover, the regional accumulation of fat in varying 
subcutaneous, visceral and intermuscular depots has received limited attention in this 
susceptible population group [15, 17-23]. A greater understanding of these ADT-induced 
adverse effects to muscle, fat and performance outcomes are of clinical importance 
given the propensity for these men to develop musculoskeletal, cardiometabolic and 
functional comorbidities [41-49]. Additionally, the application of pre-defined 
syndromes, such as sarcopenia [51-53] and sarcopenic obesity [54, 55], may assist in 
quantifying the risk of these comorbidities in ADT-treated men, although, these 
concepts are yet to be applied in these men. Emerging evidence has supported the use 
of lifestyle interventions, such as exercise training and to a lesser extent nutritional 
supplementation, to improve or maintain muscle, fat and performance outcomes in 
men treated with ADT [14, 56-59]. However, the majority of these interventions have been 
limited to singular modalities (e.g. exercise training only) and thus may not represent 
the most feasible approach to addressing the wide range of adverse effects associated 
with ADT. Therefore, the overall aim of this thesis was to quantify outcomes of 
muscle, fat and performance in men treated with ADT when compared to PCa and 
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healthy controls, and assess the feasibility of a multi-component exercise program 
combined with protein, calcium and vitamin D supplementation (Ex+ProCaD) when 
compared to usual care in ADT-treated men.  
The specific aims of this thesis were the following: 
1. To compare lean mass (total body, appendicular, arm and leg; dual-energy x-
ray absorptiometry [DXA]) and muscle CSA (forearm [66% radius] and lower
leg [66% tibia]); peripheral quantitative computer tomography [pQCT]) in men
treated with ADT to PCa and healthy controls (Chapter 4).
2. To compare fat mass (total body, arm, leg, android, gynoid, abdominal visceral
and abdominal subcutaneous; DXA) and fat CSA (forearm [66% radius] and
lower leg [66% tibia]; pQCT) in men treated with ADT to PCa and healthy
controls (Chapter 4 and Chapter 5).
3. To compare muscle strength (handgrip strength and three-repetition maximum
leg press, chest press and seated row), functional muscle power (30-second sit-
to-stand) and functional capacity (timed up-and-go, four-square step test, four
metre walk and Berg balance scale) in men treated with ADT to PCa and
healthy controls (Chapter 4).
4. To compare the prevalence of pre-sarcopenia, sarcopenia, obesity and
sarcopenic obesity in men treated with ADT to PCa and healthy controls
(Chapter 4).
5. To compare muscle density (forearm [66% radius] and lower leg [66% tibia];
pQCT) as a marker of intermuscular fat in men treated with ADT to PCa and
healthy controls (Chapter 5).
6. To assess the influence of ADT use duration on lean mass, muscle CSA, fat
mass and CSA, muscle density, muscle strength, functional muscle power and
functional capacity in men treated with ADT (Chapter 4 and Chapter 5).
7. To assess the feasibility (recruitment, attrition, adherence, data collection and
safety) of Ex+ProCaD when compared to usual care in men treated with ADT
(Chapter 6).
7.3 Key findings, limitations and future direction 
The key findings from this thesis were the following:  
1. Men treated with ADT did not have compromised absolute total body and
regional muscle mass and muscle CSA when compared to PCa and healthy
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controls, however ADT-treated men had greater total body fat mass. When 
accounting for these differences via body size- or adiposity-based adjustments, 
men treated with ADT were shown to have significantly lower regional lean 
mass and muscle CSA compared to controls. Similar findings were observed 
when muscle strength outcomes were adjusted for weight. Men treated with 
ADT were also shown to differ in some, but not all, measures of functional 
capacity when compared to controls. Subsequently, men treated with ADT 
were more likely than both controls to present with pre-sarcopenia, sarcopenia, 
obesity and pre-sarcopenia/obesity concurrently. 
2. Men treated with ADT had greater amounts of fat stored in subcutaneous
depots, but not within the visceral region of the abdominal cavity, when
compared to PCa and healthy controls. Moreover, ADT-treated men did not
possess compromised muscle density (as a marker of intermuscular fat)
compared to either control. However, duration of ADT use correlated with the
majority of subcutaneous and intermuscular depots, indicating that the
accumulation of fat mass at these sites likely continues throughout ADT.
3. The implementation of Ex+ProCaD when compared to usual care in men
treated with ADT for PCa was feasible in terms of participant retention,
adherence to the intervention and safe with regard to adverse events and
changes in PSA. However, issues stemming from recruitment and data
collection unforeseeably elongated the study timeline and limited the ability to
collect a complete dataset, respectively. Whilst various recruitment pathways
led to contact with potential participants, only clinician referral and PCa
support groups resulted in meaningful numbers of enrolled participants. Of
those included, the collection of data, particularly outcomes of muscle strength,
were at times hindered by safety concerns associated with pre-existing
comorbidities. Beyond these limitations, among the first 28 ADT-treated men
to complete the 26-week follow-up, those allocated to Ex+ProCaD tended to
respond positively in terms of improvement in lean and fat mass, muscle
strength, functional muscle power and functional capacity.
7.3.1 Measures of muscle health should be considered relative to body size or 
adiposity in men treated with androgen deprivation therapy for prostate cancer 
In Chapter 4, the effects of ADT on total body lean and fat mass, regional lean mass 
and muscle CSA and muscle strength were examined. The accelerated accumulation 
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of total body fat during ADT, when compared to normal ageing, is well established in 
men with PCa [195] and was supported by our findings that these men had 3.3-5.0 kg 
greater DXA-derived fat mass than controls. Despite this notion, the application of 
methods for adjusting muscle-based outcomes for body size and adiposity have not 
been explored in ADT-treated men when compared to appropriately selected controls. 
We found that despite a lack of difference in absolute (unadjusted) measures of lean 
mass and muscle CSA, men treated with ADT tended to have compromised 
appendicular lean mass (ALM) adjusted for body mass index (BMI; ALMBMI; 10-
12%), forearm muscle percent CSA (5.4-6.1%) and muscle strength expressed per 
kilogram of body weight (13-21%), when compared to controls. Reasons for the 
confounding influence of fat may stem from additional muscle contractile work 
required during locomotion and activities of daily living whilst carrying additional fat 
[320], as well as the infiltration of fat around and/or within muscle tissue [177]. 
Accounting for these adjustments rather than relying on absolute values is of clinical 
relevance given the potential to overlook men with compromised lean mass, muscle 
CSA or muscle strength that may predispose them to the adverse health outcomes more 
commonly reported in this susceptible population group than their non-ADT 
counterparts, such as falls, fractures, cardiometabolic disease and functional 
impairment [41-49].  
Strengths and limitations 
These observations were strengthened by the inclusion of both a PCa and healthy 
control group, which allowed for the effects of ADT to be assessed independent of the 
ageing process and the diagnosis and non-hormonal treatment of PCa. Similarly, to 
our knowledge, this was the first study to compare pQCT-derived muscle CSA of the 
forearm and lower leg in men treated with ADT compared to both PCa and healthy 
controls. However, various limitations pertaining to the collection of outcome 
measures should be noted when interpreting these results. For example, DXA-derived 
outcomes of body composition may be confounded by the presence of excessive fat 
mass (e.g. global or regional obesity) [121], whereas BMI may erroneously predict 
adiposity when compared to more robust radiological measures of body composition 
[101]. Additionally, due to the cross-sectional design of this study, rationale for the 
confounding role of adiposity on muscle-based outcomes remains speculative, rather 
than causative in nature. Finally, there is a current lack of prospective trials that have 
assessed the risk of adverse health outcomes associated with compromised body size- 
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and adiposity-adjusted muscle outcomes in healthy older adults, let alone those 
undergoing ADT; thus, the true risk associated with compromised lean mass relative 
to body size or adiposity in men treated with ADT for PCa is unknown.  
Future direction 
Future studies should consider reporting body size and adiposity adjustments of 
muscle-based outcomes in men treated with ADT for PCa when compared to 
appropriately selected controls, to avoid potential erroneous conclusions pertaining to 
the effect of ADT on these outcomes. A time- and cost-effective way to further address 
this question is via retrospective analyses of previously collected datasets and 
researchers should consider performing and publishing these analyses or making their 
datasets available to other researchers. Moreover, the quantification of the risk of 
adverse health outcomes associated with differences in these adjusted outcomes is 
warranted in both healthy older men and this specific clinical population group, 
particularly in prospective cohorts in which a wide range of risk factors and adverse 
events are reliably documented.  
7.3.2 Current definitions of sarcopenia and sarcopenic obesity are limited in 
men treated with androgen deprivation therapy for prostate cancer 
In Chapter 4, various definitions of sarcopenia and sarcopenic obesity were examined 
in men treated with ADT and appropriately selected controls. While there is no 
international consensus definition of sarcopenia in terms of clinical cut-offs, recently 
proposed definitions tend to include low lean mass and compromised muscle strength 
or functional capacity, most commonly measured via DXA, handgrip dynamometry 
and gait speed, respectively [51, 53]. Despite a worldwide prevalence of approximately 
8.0% in older men [158], our study only observed two cases (< 6.0%) in men treated 
with ADT for PCa, a cohort that has been previously shown to lose lean mass at an 
accelerated rate when compared to natural ageing (2.0-3.6% vs 0.5-1.0% per year) [195]. 
Notably, the low prevalence of sarcopenia was largely related to the limited evidence 
of impaired gait speed (< 0.8 or < 1.0 m/s) in these men, with only one case observed. 
Additionally, the lack of ability for current definitions of sarcopenia to detect cases in 
our sample of men treated with ADT may have stemmed from the aforementioned 
confounding role of fat on muscle-based outcomes. This concept was supported when 
we examined pre-sarcopenia (low lean mass only) and observed that when adjusted 
for adiposity (ALMBMI and ALM adjusted for height and fat mass; ALMHFM), 7.2-34% 
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more ADT-treated men were pre-sarcopenic when compared to either control. These 
findings were not evident when considering ALM adjusted for height alone (ALMI), 
thus supporting the notion that adiposity, rather than body size, likely played a role in 
these observations. Given the influence of adiposity, we also examined the prevalence 
of sarcopenic obesity, yet observed no cases among men treated with ADT. However, 
there was some evidence in our study that ADT-treated men were more likely to have 
pre-sarcopenic obesity. Collectively, these findings suggest that current definitions of 
sarcopenia and sarcopenic obesity are limited in their ability to detect men treated with 
ADT at risk of adverse health outcomes. Alternatively, our observations may suggest 
that ADT does not lead to sarcopenia or sarcopenic obesity, albeit this notion appears 
counterintuitive given the high prevalence of musculoskeletal, cardiometabolic and 
functional comorbidities in men treated with ADT for PCa [41-49]. Therefore, our 
findings highlight the potential use of adiposity-adjusted pre-sarcopenia and pre-
sarcopenic obesity given these consider the role of fat accumulation associated with 
ADT.  
 
Strengths and limitations 
To our knowledge, this was the first study to consider composite definitions of 
sarcopenia and sarcopenic obesity in men treated with ADT. Additionally, our findings 
were strengthened by the use of various established criteria for these syndromes, rather 
than reliance on a single set of criteria. Although, these findings are not without notable 
limitations. Firstly, given that men treated with ADT included in our cross-sectional 
study were enrolled in a lifestyle intervention RCT, volunteer bias may have resulted 
in a cohort less representative of the broader population of these men in terms of 
overall health and fitness. Moreover, as the definitions of sarcopenia and sarcopenic 
obesity investigated in our study were initially developed and validated in larger 
cohorts, our results may be limited by the comparatively modest sample size.  
 
Future direction 
As various definitions of sarcopenia and sarcopenic obesity have been shown to predict 
greater risk of falls [81, 88, 89], fractures [48, 88, 90], functional impairment [88, 91-94] and 
mortality [88, 91, 95, 96] in healthy older men, men treated with ADT may benefit from the 
development of population-specific cut-offs. Whilst amassing a cohort large enough 
to represent the broader population of men and allow for robust conclusions to be 
drawn may pose logistical difficulties, pooled data may be pertinent to the feasibility 
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of this approach. This may be facilitated by the pooling of retrospective cohorts in 
which these measures were collected and/or the integration of these measures into 
current clinical practice, which would allow for prospective data to be collected. 
 
7.3.3 The accumulation of fat associated with androgen deprivation therapy for 
prostate cancer more commonly occurred in subcutaneous depots and 
superseded expected age-related plateaus/declines 
In Chapter 5, the effects of ADT on regional fat depots were examined. The risk of 
adverse health outcomes associated with the accumulation of fat differs pending 
regional distribution [40, 102, 177, 178]. For example, the accumulation in visceral and 
intermuscular depots tends to be associated with greater risk than fat stored in 
subcutaneous depots [40, 102, 177, 178]. In our study, men treated with ADT tended to have 
15-36% greater subcutaneous fat, but similar visceral and intermuscular fat, when 
compared to controls. Our findings suggest that the accelerated fat accumulation 
previously shown in men treated with ADT [195] predominantly affects subcutaneous 
depots, which suggests that these effects of ADT may be of limited importance in 
terms of risk of adverse health outcomes. From a clinical practice perspective, our 
findings proposes that the quantification of visceral (DXA CoreScan) and 
intermuscular fat (pQCT) in ADT-treated men may be of less importance when 
compared to traditional measures of fat mass via DXA. The monitoring of DXA-
derived fat mass in men treated with ADT is further supported by our findings that 
duration of ADT use tended to correlate with the increase storage of fat in 
subcutaneous and intermuscular depots, which appeared to supersede the age-related 
plateau or gradual decrease of fat storage at these sites commonly observed in men 
following the seventh decade of life [142].  
 
Strengths and limitations 
Our findings were strengthened by the use of robust radiological measures (i.e. DXA 
and pQCT), as well as the quantification of various depots of fat accumulation (i.e. 
subcutaneous, visceral and intermuscular). Although, these findings are primarily 
limited by the cross-sectional design of our study and subsequent lack of ability to 
infer causality and discount reverse causality (e.g. increased fat may have led to PCa 
progression and thus the need for ADT [332]). Moreover, the associations between ADT 
use duration and various outcomes may have been influenced by a few participants 
who had been treated for greater than five years. Finally, it should be noted that 
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abdominal subcutaneous and visceral fat mass were estimated via DXA CoreScan 
software and pQCT-derived muscle density was used as a marker of intermuscular fat, 
rather than quantified by more robust measures such as those involving computed 
tomography (CT) and magnetic resonance imaging (MRI).  
Future direction 
Further research is required to elucidate the risk of adverse health outcomes associated 
with the regional accumulation of fat during ADT for PCa. These studies would benefit 
from the use of radiological scanning protocols, ideally CT or MRI-based [40, 77, 111, 112], 
and should be prospective in design. A valuable study design would involve an 
assessment immediately prior to the commencement of ADT, assessments at several 
intervals throughout treatment and then several assessments at similar intervals 
following the cessation of therapy, coupled with a comprehensive and ongoing health 
and medical assessment. These observations would allow for a greater understanding 
of the long-term impact of ADT on the accumulation of fat in regional depot and 
inform clinical decision-making for men suitable for commencing or stopping this 
treatment.  
7.3.4 The recruitment of men treated with androgen deprivation therapy for 
prostate cancer into a lifestyle intervention was challenging 
In Chapter 6, the efficacy of various recruitment pathways utilised while conducting 
an RCT examining the efficacy of Ex+ProCaD compared to usual care in men treated 
with ADT for PCa was described. Clinical trials are often hindered by recruitment-
based issues and it has been previously estimated that 45% of trials require an extended 
timeline due to these issues and only 55% eventually recruit their intended sample size 
[370]. In our study, 149 potential participants were screened, which resulted in 42 
enrolled participants; thus, our initial target sample size for adequate statistical power 
was not met by the time of thesis write up. Clinician referral emerged as the most 
successful recruitment pathway in terms of the greatest number of participants 
screened (n=42; 28%) and enrolled (n=18; 43%). Notable success was also attained 
via PCa support groups, with 31 screened (21%) and 12 enrolled (29%) participants. 
Collectively, the seven other recruitment pathways resulted in only 12 enrolled (29%) 
participants. These findings suggest that clinician referral and PCa support groups 
should be utilised to increase the likelihood of attaining intended sample sizes in a 
timely manner.  
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The inclusion and exclusion criteria of a clinical trial has been shown to have 
significant implications on participant recruitment [369]. Among potential participants 
who were screened for inclusion in our study, the majority of excluded participants 
were deemed illegible due to a lack of pharmacological ADT for PCa (52%), whereas 
the remainder were excluded based on criteria designed to account for known 
confounding variables (e.g. vitamin D supplementation > 1,000 IU/day and 
progressive resistance training [PRT] > one session/week) of the main outcomes in the 
larger trial (bone health). The proportion of men treated with ADT who were precluded 
from our trial after expressing interest further highlights the importance of establishing 
effective recruitment pathways.  
Strengths and limitations 
This study provided novel insights into a wide range of feasibility outcomes of a 
combined multi-component exercise program and multi-nutrient supplement in men 
treated with ADT for PCa. These findings were strengthened by the 26-week duration 
of the trial, which was longer than most previously conducted lifestyle interventions 
in these men. However, our reporting of recruitment pathway efficacy was primarily 
limited by the retrospective nature of analysis. Data on the number of potential 
participants who were not interested in pursuing participation after face-to-face 
discussion or receiving a letter from their clinician was not recorded. Similarly, the 
total number of men who attended PCa support group presentations, received mailing 
list emails and viewed the trial information on the university website is unknown. 
Moreover, it is difficult to determine how many potential participants saw study-
related flyers or the state news television report and received information via word of 
mouth and opted not seek involvement. Furthermore, a large proportion (48%) of men 
who declined to participant provided ‘no reason’, which may have been further 
explored if an anonymous feedback process was implemented. Finally, the 52-week 
study duration of the larger RCT may have deterred some men from expressing 
interest.  
Future direction 
Future research examining lifestyle interventions in men treated with ADT for PCa 
should report further details pertaining to the efficacy of recruitment pathway. 
Additionally, a larger clinical trial could include cost-effective analyses which would 
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provide valuable data on the potential cost-benefit of a combined exercise training and 
nutritional supplementation intervention on health outcomes and potential reductions 
in emergency department presentations or unplanned hospital admissions due to 
comorbidities associated with ADT. Qualitative research studies may also lead to a 
better understanding of the barriers and facilitators for ADT-treated men pursuing 
involvement in lifestyle interventions and research projects.  
7.3.5 Men treated with androgen deprivation therapy for prostate cancer 
tended to respond positively to a multi-modal exercise training combined with 
multi-nutrient supplementation 
Exercise training continues to gain traction as a viable intervention to ameliorate a 
wide range of ADT-induced adverse effects [60, 231, 351] and evidence in healthy older 
men without PCa highlights the many benefits which may be augmented by multi-
nutrient supplements, such as those high in protein, calcium and vitamin D [195]. 
Despite these benefits, to our knowledge, our study was the first RCT to compare 
Ex+ProCaD to usual care in men treated with ADT for PCa. Data from the first 28 
men to complete the 26-week follow-up indicated that men randomised to Ex+ProCaD 
tended to respond positively when compared to usual care with regard to net 
differences in lean mass (0.2-1.4 kg), fat mass (-0.1 to -0.9 kg), muscle strength (8.0-
19%), functional muscle power (8.6%) and functional capacity (12-14%). These 
findings are promising and support our recent recommendations [195] that ADT-treated 
men should be prescribed exercise training and nutritional supplementation under the 
guidance of their clinical care team.   
Strengths and limitations 
Strengths associated with these outcomes included the novelty of the lifestyle 
intervention investigated with regard to this clinical population group, as well as the 
use of robust and valid measures of muscle, fat and performance. Although, multiple 
limitations associated with these findings warrant caution during interpretation. 
Primarily, the incomplete dataset and subsequent lack of preliminary within- and 
between-group analyses resulted in the presentation of descriptive statistics only. 
Subsequently, some responses deemed positive may be limited in terms of clinical 
significance. Additionally, potential volunteer bias of those capable and interested in 
exercise training may limit the generalisability of these findings. Similarly, the strict 
inclusion and exclusion criteria implemented to participant safety may have precluded 
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men with comorbidities commonly present in the broader ADT-treated population. 
Moreover, during the collection of data, neither participants nor researchers were 
blinded to treatment allocation.  
Future direction 
In light of the aforementioned limitations, there is a need to consider the outcomes of 
the larger 52-week RCT before definitive conclusions may be drawn with regard to 
the efficacy of Ex+ProCaD in men treated with ADT for PCa. Assuming our 
observations persist following the completion of the RCT, a factorial RCT should be 
considered to elucidate the individual and comparatively synergistic effects of the 
multi-modal exercise program and multi-nutrient supplement. Similarly, examining 
the feasibility of integrating Ex+ProCaD into clinical practice or a community-based 
setting is warranted.  
7.4 Conclusion 
This thesis provided new information on muscle, fat and performance in men treated 
with ADT for PCa when compared to PCa and healthy controls, and assessed the 
feasibility of implementing a lifestyle intervention designed to address these 
differences when compared to usual care. The main findings were that men treated 
with ADT had greater stores of subcutaneous fat when compared to controls, which 
tended to impair the quantification of muscle-based outcomes; thus, the consideration 
of muscle-based outcomes relative to body size or adiposity is warranted. Moreover, 
the recruitment of ADT-treated men into an Ex+ProCaD intervention was challenging, 
yet men randomised to Ex+ProCaD tended to respond positively in terms of 
improvement in lean and fat mass, muscle strength, functional muscle power and 
functional capacity.  
The following key themes emerged from this thesis and may be used (in context with 
the aforementioned strengths and limitations) to guide clinical practice guidelines and 
future research along with the proposed recommendations for managing the adverse 
effects of ADT on muscle, fat and performance outcomes in Table 7.1: 
1. Men treated with ADT for PCa had greater amounts of fat when compared to
non-ADT counterparts; therefore, muscle-based outcomes should be
considered relative to body size or adiposity in these men
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2. Current definitions of sarcopenia and sarcopenic obesity were limited in men
treated with ADT for PCa; thus, the development of additional risk
stratification tools specific to this clinical population group are warranted
3. The greater amounts of fat observed in men treated with ADT for PCa tended
to be stored in subcutaneous depots and supersede age-related plateaus/losses;
hence, the long-term risk associated with this pattern of fat accumulation
should be explored in these men
4. The recruitment of men treated with ADT for PCa into a lifestyle intervention
was challenging; therefore, future trials should consider clinician referral and
PCa support groups to increase the likelihood of attaining intended sample
sizes in a timely manner.
5. Men treated with ADT for PCa tended to respond positively to a multi-modal
exercise training combined with multi-nutrient supplementation; thus, the
incorporation of similar interventions into usual care for this susceptible
population group should be considered pending results of the larger 52-week
RCT.
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Table 7.1. Recommendations for managing adverse effects of androgen deprivation 
therapy (ADT) in men with prostate cancer on muscle, fat and performance. 
Densitometry 
• Prior to commencing ADT, men should undergo a DXA total body scan for the
assessment of total and regional lean and fat mass. These measures should be
repeated yearly (or even 6-monthly) until the cessation of ADT.
Exercise Training 
• It is recommended that clinicians discuss and refer men to an individualised,
multi-component exercise program incorporating the elements below:
• Progressive resistance training: at least twice per week, 8-10 exercises (targeting
major muscle groups, specifically the muscle attached too or near the hip and
spine), 2-3 sets of 8-10 repetitions at moderate to high-intensity (70-85% of 1-RM
or 5-8 ‘hard to very hard’ on the 10-point Borg RPE scale).
• Weight bearing impact exercises (jumping, bounding, hopping, skipping, bench
stepping): at least 4 days per week, 2-4 impact exercises varying in magnitude and
direction, progress to 50-100 jumps per session divided into 2-3 sets of 10-20
repetitions. *progressive resistance training is recommended first for those with
low muscle strength and/or poor muscle function prior to commencing some
impact activities.
• Aerobic exercises: 5-7 days per week, 30 minutes of continuous, 55-75% of
predicted heart rate maximum, modalities including cycling, walking, rowing or
sports such as tennis. Aerobic training can be divided into shorter bouts if required
(three by 10 minutes sessions).
• The concept of specificity and progressive overload should be applied to all
exercises and when possible, programs should initially be performed under the
supervision of a tertiary trained exercise professional (e.g. an Accredited Exercise
Physiologist in Australia).
Vitamin D 
• Prior to commencing ADT, men should have their serum 25-hydroxyvitamin D
assessed and those with levels > 50 nmol/L (> 20 ng/ml) should consider a daily
supplement of 800 IU. Men with < 50 nmol/L should supplement with 3,000-
5,000 IU/day for at least 6-12 weeks under the guidance of a clinician.
Calcium 
• Include 3-4 serves of dairy food each day and if daily calcium intake is below the
recommended dietary intake of 1,000-1,300 mg/day, supplement with 600
mg/day.
Protein 
• Daily protein intake of at least 1.2 grams per kilogram body weight per day.
• Consume 25-30 g of high quality protein with each meal and on exercise training
days, within the first few hours post-exercise.
Tobacco and alcohol 
• Smoking cessation should be considered.
• Alcohol consumption should be limited to < 2 standard drinks per day.
DXA, dual-energy x-ray absorptiometry; RM, repetition maximum; RPE, rating of perceived exertion. 
Adapted from Owen et al. [195]. 
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